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ABSTRACT

HK-2 CELLS AS A HUMAN MODEL OF
GLUCURONIDE TRANSPORT
by Eliza E. Robertson

Glucuronidation is primarily a pathway of detoxification in most species, but many glucuronide
conjugates are associated with toxicity. Numerous drugs are excreted in the urine as glucuronide
conjugates. Being organic anions, it is likely that glucuronides are secreted into the urine by
organic anion transporters found in renal proximal tubule cells (PTCs). Some drugs that are
metabolized by glucuronidation have been shown to cause renal toxicity, yet little is known about
the renal handling of glucuronide conjugates. It is hypothesized that glucuronides are transported
into renal PTCs by an organic anion transporter (OAT) on the basolateral membrane of the cell.
A potential human model for examining renal organic anion transport is the HK-2 cell line, an
immortalized adult human male proximal tubule cell line. Little evidence exists that this model is
capable of transporting organic anions. Therefore, the purpose of this study was to determine
which OATs (1-3) exist in this cell line, if the OATs are functional, and finally, the nature of
glucuronide transport. HK-2 cells were grown in keratinocyte serum-free media supplemented
with 2% fetal bovine serum. Western blot analysis of membrane fractions of HK-2 cells grown for
5-7 days in T-75 flasks revealed the presence of OAT1 and OAT3, but not OAT2 in the cell
membranes. In separate studies, HK-2 cells grown on microporous membranes for 4-9 days
transported fluorescein (FL) and p-aminohippurate (PAH), prototypical substrates for OAT1 and
OAT3 and estrone sulfate (ES), the prototypical substrate for OAT3. Transport of acetaminophen
glucuronide (AG) by HK-2 cells demonstrated time-, temperature- and concentration-dependent
uptake suggestive of protein-mediated transport. Transport characteristics of AG in the HK-2
model, such as biphasic concentration-dependent transport and lack of inhibition of transepithelial
transport by probenecid are consistent with in vivo transport as found in the literature. These
results suggest that HK-2 cells possess functional OATs and demonstrate transport of a model
glucuronide compound such that HK-2 cells may be useful as a model to study the renal handling
of organic anions, including glucuronide conjugates.
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CHAPTER I. Introduction
Introduction

Glucuronides
Glucuronidation is a major route of metabolism of both endogenous and
exogenous compounds including many classes of drugs. Primarily, glucuronide
conjugates are formed via an enzyme-catalyzed reaction in the liver, creating
metabolites that are more water-soluble and more readily excreted in the urine or
the feces. Although glucuronidation is considered a detoxification pathway, some
glucuronide metabolites have been shown to bind irreversibly to protein and are
associated with toxicity.

Indeed, many glucuronides have been shown to be

associated with nephrotoxicity in humans, yet little is known about how
glucuronides accumulate in the human kidney.
Organic Anion Transport
Since glucuronide conjugates are organic anions, it is possible that they are
substrates of the renal organic anion transporters. Organic anion transporters are
responsible for the uptake of numerous endogenous and xenobiotic organic anions
into renal proximal tubule epithelial cells along their basolateral membranes
(BLMs). Subsequent secretion of these anions into the glomerular filtrate occurs
via carriers in the apical membrane. Hence, transepithelial flux of organic anions
is a two-step, protein-mediated process of uptake at the BLM and efflux across the
apical, brush-border membrane (BBM). The resultant secretion of these organic
anions, including many associated with toxicity, fulfills an important function of the
kidney. It is the uptake of these compounds by organic anion transporters that
may lead to accumulation and toxic effects in the proximal tubule.
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Hypothesis
It is hypothesized that glucuronides are transported into renal proximal tubule
cells by an organic anion transporter on the basolateral membrane of the cells.
Model Development
Most studies of renal organic anion transport have been conducted with nonhuman models. Recent cloning of human organic anion transporters, substrate
specificity studies, immunolocalization and gene expression levels have indicated
that there are considerable differences in human and animal models which may
explain their differing pharmacokinetic profiles for many drugs. Consequently, to
study the hypothesis, a human renal model of organic anion transport was chosen.
Difficulties in procurement of human tissue often make studies with primary culture
or freshly isolated human proximal tubules improbable.

A functional human

proximal tubule cell line expressing the transporters was a desirable alternative.
Dr. Lawrence H. Lash recommended the HK-2 cell line as a likely candidate.
The HK-2 cell line was developed by Dr. Richard Zager, The Fred Hutchinson
Cancer Research Center, University of Washington, via transfection of an adult
human male proximal tubule cell with the human papilloma virus (HPV 16) E6/E7
genes. Studies indicated that this cell line retains both phenotypical and functional
characteristics of a well differentiated proximal tubule cell. Little evidence exists as
to the ability of the HK-2 cells to perform active transport of organic anions. A
major part of the work described herein is in the development and characterization
of the HK-2 cell line relative to organic anion transport.
Studies of the uptake of glucuronide conjugates into HK-2 monolayers
proceeded using acetaminophen glucuronide (AG) as the model glucuronide. AG
was chosen because evidence in the literature supports renal secretion of AG
(Prescott, 1980; Duggin and Mudge, 1975) and because radiolabeled AG was
available for purchase. Unlabeled AG as well as other glucuronides were used to
study the effect on radiolabeled AG uptake and transepithelial transport.
2

Throughout this document, BBM and BLM will refer to brush-border and
basolateral membranes, respectively, of a renal proximal tubule cell (PTC). The
abbreviations BL (basolateral) and A (apical) will refer to the respective
membranes of nonproximal tubule cells, such as transfectant models, or to the
respective fluid compartments of the porous support membranes upon which the
cells are grown.
By convention, the results of transport experiments have been referred to as
either uptake or clearance. However, the term uptake describes a single process
and is therefore not accurate.

Rather, more appropriate terminology is net

intracellular accumulation implying the amount of substrate remaining in the cells
after uptake and efflux have terminated. The terms, uptake and net accumulation,
are used interchangeably in this document.
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CHAPTER II. Review of Literature
Review of Literature

Glucuronides

Role of Glucuronidation in Metabolism and Disposition
Glucuronidation is a Phase II biotransformation reaction responsible for the
elimination of numerous biologically active or potentially toxic substances via
conjugation with glucuronic acid. Substrates for this reaction must be lipophilic,
and include endogenous compounds, such as steroids, bile acids and hormones,
as well as many xenobiotics, including many therapeutic agents and environmental
toxicants.

Substrates may directly undergo glucuronidation or may first be

oxidized in a Phase I reaction, forming an acceptor group for glucuronic acid.
Glucuronide formation requires the co-substrate UDP-glucuronic acid (UGA) and is
catalyzed by a multi-gene family of enzymes, the UDP-glucuronysyl-transferases
(UDPGTs). The reaction takes place in the smooth endoplasmic reticulum and is
referred to as a microsomal reaction.

Substrates for glucuronidation include

compounds with a wide range of acceptor groups, such as alcohols, phenols,
carboxylic acids, aliphatic amines and acidic carbon atoms (Miners et al., 1991).
Formation of the glucuronide conjugate results in a more hydrophilic compound
that typically has the dual effect of inactivating the parent compound and
partitioning it to the extracellular compartment, from which it can be more readily
excreted in the bile or the urine. Glucuronide formation is depicted in Figure 2.1
(Mulder GJ, 1992; Lohr et al., 1998; Tukey and Strassburg, 2000).
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Figure 2.1. Formation of Acetaminophen Glucuronide and Diclofenac Glucuronide.
Formation, Hepatic vs. Renal
The largest concentration of the UDPGTs resides in the liver.

However,

evidence of UDPGT activity in the kidney has been reported (Tukey and
Strassburg, 2000). Although the concentration of UGA in human kidney is less
than 10% of that of the liver (Cappiello et al., 1991), immunocytochemical studies
in rat and human demonstrate the highest concentration of the renal UDPGTs is
present in the proximal tubule (Lock and Reed, 1998). Figure 2.2 depicts the
biotransformation and secretion of a lipophilic compound in both the liver and the
kidney. The contribution of renal vs. hepatic glucuronidation varies for different
species and substrates. For example, Morris and Levy (1984) suggested that
human renal synthesis of acetaminophen glucuronide (AG) is negligible because
elimination of acetaminophen by conjugation is not impaired in anephric patients.
In isolated perfused rat kidneys, Newton et al. (1982) found that AG is synthesized
from acetaminophen and secreted into the urine at a very low rate. Clearance of
indomethacin, however, occurs predominantly by renal glucuronidation in humans
(Moolenaar et al., 1992). Evidence also suggests that estradiol is conjugated with
glucuronic acid in the kidney forming β−estradiol 17β-D-glucuronide (E217βG) with
subsequent tubular secretion (Kanai et al., 1996).
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Figure 2.2. General Scheme for Hepatic and Renal Biotransformation and Secretion.

Substances may diffuse or be transported into the hepatocyte across the
sinusoidal membrane. If they are sufficiently lipophilic, they may enter the smooth
endoplasmic reticulum and undergo Phase I and/or Phase II biotransformations
such as oxidation by cytochrome P450 enzymes and conjugation with glucuronic
acid. Higher molecular weight conjugates (MW > 400) may then be secreted at
the canalicular membrane into the bile (represented as a starburst) but may be
secreted back into the sinusoid and delivered to the circulation. Lower molecular
weight conjugates typically are secreted into the circulation. The conjugate will be
more water soluble and may be actively taken up by the renal proximal tubule from
the blood delivered to the kidney. Additionally, the parent compound may enter
the proximal tubule by diffusion or by carrier-mediated transport and undergo
biotransformations in the kidney as in the liver, but to a lesser extent. The
conjugates are then secreted into the glomerular filtrate.
6

Renal Handling of Glucuronide Conjugates
It is well established that glucuronides are efficiently excreted by the kidney
(O'Neill et al., 1981; Pantuck et al., 1991; Moolenaar et al., 1992). Numerous
drugs are eliminated in the urine as their glucuronide conjugates and have rates of
excretion greater than that of creatinine, indicating a secretory process (Prescott et
al., 1980, Spahn-Langguth et al., 1996). Most of the information on the renal
handling of glucuronides has been attained in the study of the endogenous steroid
conjugate, estradiol-17β-glucuronide (E217βG), which is a high-affinity substrate
for basolateral and apical carriers.

An extensive review of transport-specific

information for glucuronides is covered in the Transport section of this document.
Toxicity Associated with Glucuronides
Several compounds that form glucuronides have been associated with hepatic
and renal toxicity (Spahn-Langguth and Benet, 1992; Smith and Liu, 1995; Bailey
et al., 2003). Carboxylic acids are the main class of compounds that form labile
glucuronides. These conjugates, known as acyl glucuronides, are formed by an
ester-linkage of the parent compound with glucuronic acid (see Figure 2.1,
diclofenac glucuronide synthesis).

Acyl glucuronides, which are stable at low

temperature and low pH, are reactive at physiologic temperature and pH (SpahnLangguth and Benet, 1992). Indeed, acyl glucuronides are known to undergo
hydrolysis, intramolecular rearrangement via acyl migration, and formation of
protein adducts by intermolecular covalent binding under physiologic conditions.
Protein adduct formation is believed to be the mechanism of toxicity (SpahnLangguth and Benet, 1992). Adverse drug reactions associated with drugs that
are metabolized to acyl glucuronides may occur by functional inactivation of target
proteins or by hapten formation, resulting in an immune response against the drugprotein adduct (Bailey et al., 2003). Renal proximal tubules are thought to be
highly susceptible to the toxic effects of acyl glucuronides due to the ability of the
tubules to concentrate the glucuronides (Smith and Liu, 1995).

7

Renal Excretion of Organic Anions
The Process of Urinary Excretion
More substances are eliminated from the body by renal excretion than by any
other route (Klaassen CD, 2001).

Renal excretion occurs through three

processes: glomerular filtration and tubular excretion by both passive diffusion and
active secretion. Glomerular filtration equals about 20% of the renal blood flow.
Passive diffusion is thought to be only a minor process in comparison. Proteinbound compounds are typically too large to be filtered and do not diffuse easily,
but are readily transferred from plasma proteins at the tubule membrane and
secreted by transport-mediated processes in the tubule. Tubular secretion can
occur as a facilitated transport mechanism down an electrochemical gradient or as
an active process (or dependent upon an active process) requiring energy to move
chemicals against an electrochemical gradient.

Tubular secretion of organic

anions is a very efficient process which occurs in the proximal tubule of the
nephron.
Tubular Secretion of Organic Anions
Tubular secretion involves protein-mediated uptake of substrate at the BLM and
protein-mediated efflux at the BBM. The transport proteins in the membranes
affect the apparent permeability of the membrane to organic anions in a substratespecific manner. During the secretory process, as studied in perfused tubules
(mammalian and non-mammalian), the steadystate concentration of organic anion inside the
cells is greater than in the tubule lumen

Cb

Ci

Cu

(glomerular filtrate), which is greater than in the
peritubular fluid/bathing medium (i.e., Ci>Cu>Cb;
i = intracellular, u = urinary, b = blood; Figure 2.3;
Dantzler, 2002).

This process can only occur

Blood

Intracellular

Urine

Figure 2.3. Concentration Gradient
for Fluorescein at Steady-State in
the Isolated Perfused Tubule.
Ci > Cu > Cb

because the BBM is more permeable to the substrate than is the BLM, a condition
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that has been demonstrated in numerous species and is requisite of uptake at the
BLM being the rate limiting step in transepithelial transport (Dantzler, 2002). This
condition, however, does not hold true for all organic anions. Terlouw et al. (2003)
states that in general, the efflux mechanism at the luminal membrane is less
efficient than basolateral uptake, resulting in accumulation of organic anions. This
condition has been demonstrated for many of the antiviral drugs for which efflux at
the BBM is rate limiting, resulting in intracellular accumulation (Russel et al., 2002).
Uptake of substrate at the BLM is often measured as the net accumulation
within the cell. Since both cellular energetics (available counter-ions or ATP) and
apical efflux will affect net accumulation, uptake is assessed at the initial rate of
uptake, during the linear phase for the purpose of kinetic analysis (Sugiyama et al.,
2001). Thus, a time course study is conducted to determine the linear phase of
uptake.
Transepithelial

transport

is

evaluated

by

determining

the

substrate

concentrations in both compartments (BL and A) at the end of an incubation period
and calculating the substrate clearance. Clearance is the volume of fluid totally
cleared of substrate over a period of time (Groves et al., 1999a):

Clearance

=

[ substrate ] A * Volume A
= [ µ l / cm
[ substrate ] BL * SA * time

2

/ min]

where A = apical, BL = basolateral and SA = surface area.
Transport Kinetics
The epithelium of the nephron is formed from a single layer of cells known as a
monolayer. The kinetics of transport of substrates across a monolayer follows the
laws that govern chemical interactions. Kinetic studies are performed during the
linear phase of transport (initial velocity) (Sugiyama et al., 2002). By performing a
concentration dependent study during the linear phase of transport, the rate of
9

transport can be evaluated with a rectangular hyperbolic function, namely, the
Michaelis-Menten equation:

V=

Vmax * [ S ]
+d
K m + [S ]

where V = rate of transport, Vmax = maximum rate of transport, [S] is the substrate
concentration, Km = the substrate concentration which produces 1/2 Vmax, and d is
a nonspecific term to account for nonspecific binding (Groves et al., 1994). A Vmax
is predictive of any interaction that is saturable and correlates with the capacity of
the transporter for the substrate, such that a high Vmax corresponds to a high
capacity of transport.

The Km relates to the affinity of the substrate for the

transporter, such that the higher the affinity, the lower the Km.
The Berteloot equation offers an alternative method of analysis for
concentration-dependent studies.

Data used to analyze transport using this

regression is more reflective of the measurements that are made for transport.
The data entered for Berteloot regression analysis are the tracer concentration, the
concentration of unlabeled substrate and the transport of tracer rather than the
total concentration and transport of total substrate as for the Michaelis-Menten
analysis. The Berteloot Equation is of the form:

V =

Vmax * [T ]
K m + [T ] + [ S ]

where V = rate of transport, Vmax = maximum rate of transport, [T] is the tracer
concentration, [S] is the substrate concentration and Km = the substrate
concentration which produces 1/2 Vmax (Malo and Berteloot, 1991).
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Efficiency of transport is defined as the ratio of Vmax to Km (Cihlar and Ho,
2000; Gerk et al., 2002).
Efficiency =

Vmax
Km

This is an appropriate tool to evaluate relative efficiencies of BLM vs. BBM
transport and relative transport of one substrate vs. another.

For example,

E217βG has a higher affinity (lower Km) than does taurocholate (TC) for the rOatp2
transporter, but because rOatp2 has a greater capacity (higher Vmax) for TC, it is
much more efficiently transported by rOatp2 than is E217βG (Sugiyama et al.,
2002).
The permeability of the apical membrane can be evaluated by calculating the
permeability-surface area product (PSa):

PS a =

Apical Efflux
Intracellular Accumulation

PSa is useful in understanding effects at the apical membrane in transepithelial
studies using models expressing transporters in BL and A membranes (Sasaki et
al., 2002).
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Organic Anion Transporters
The OAT Family
The OAT family is a group of transmembrane proteins which function in the
transport of organic anions and are associated by a high degree of homology.
These transporters belong to the amphiphilic solute transporter family 22a
(Slc22a), a subset of the major facilitator superfamily (Sweet et al., 2002). The
classical OAT system which was long referred to as the PAH (paraaminohippurate) transporter (Lu et al., 1999) is now known as OAT1 (Sekine et al.,
2000; Burckhardt et al.,2000; Sun et al., 2001; Sweet et al., 2001). There are
currently 5 known members of the family, named OAT1 to OAT5 (Sun et al.,
2001). With advances in technology, the genes encoding transporters OAT1-4
have been characterized, expressed in various cell models and studied to gain a
better understanding of their localization and functionality (mechanism, regulation
and substrate specificity).
Molecular Studies
Recent molecular cloning of the transporters in several species and
immunolocalization studies have dramatically advanced the study of organic anion
transport. In 1996, the gene encoding a renal organic anion transporter in mouse,
termed NKT (novel kidney transporter), was identified and cloned (Lopez-Nieto et
al., 1997). This gene was subsequently identified as the mouse equivalent of
OAT1. The following year, two groups of scientists cloned the rat OAT1 (rOAT1)
gene (Sekine et al., 1997; Sweet et al., 1997). There have been 4 laboratories that
have since reported cloning the human orthologue, hOAT1 (Reid et al., 1998;
Hosoyamada et al, 1999; Lu et al., 1999; and Race et al., 1999). Soon after the
characterization began of OAT1, followed the discovery of other members of the
multispecific organic anion transporters with high homology to OAT1. The cloning
of a novel liver transporter (NLT) in rat (Simonson et al., 1994) was later
discovered to share a 46% homology to OAT1. NLT was thus termed OAT2
(Sekine et al., 1998). Cloning of yet a third OA transporter from rat, termed OAT3,
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was reported in 1999 (Kusuhara et al.) and shares a 49% homology with rOAT1.
Human OAT3 (hOAT3) was cloned and reported to share a 51% homology to
hOAT1 (Cha et al., 2001). Cloning of human OAT4 by Cha et al. (2000) was soon
followed by a report of isolation of a family of OATs, hOAT1 to hOAT5 from the
human liver and kidney (Sun et al., 2001).

Human OATs, hOAT1-3, are

orthologues to rat OATs, rOAT1-3, whereas hOAT4 and hOAT5 had not been
identified in species other than human (Sun et al., 2001). The hOAT4 transporter
cloned by Sun et al., is not the same transporter as that cloned earlier by Cha and
coworkers (2000) and has been identified as structurally nonhomologous to the
OAT family. Consequently, hOAT4 refers to the transporter cloned by Cha et al.
(2000).

Recently rOAT5 which shares only a 55% homology to hOAT5 was

isolated from a rat kidney cDNA library and is thought not to represent an
orthologue of hOAT5 (Koepsell and Endou, 2003). Thus, there are 3 members of
the rat OAT family, and they are orthologous to hOATs 1-3.
A composite of the characteristics reported by the above investigators reveals a
family of proteins with a range of 541-568 amino acid residues (aa), 12 putative
membrane spanning domains (11 in mouse) and 5 (hOAT1), 4 (hOAT3) and 5
(hOAT4) potential N-glycosylation sites. Isoforms, thought to be splice variants of
the individual members, have also been identified. There are 4 isoforms of hOAT1
(563, 550, 506 and 519 aa; Bahn et al., 2000); 2 isoforms of hOAT2 (546 and
538 aa) and 2 of hOAT3 (543 and 568 aa).

Although it is unclear as to the

purpose of the various isoforms, not all isoforms of a particular transporter have
identical substrate specificity and some do not function in transport.
Tables 1-3 are a compilation of the isoforms of hOAT1 and hOAT3 that have
been submitted to the sequence databases maintained by the members of the
international collaboration of sequence databases: the NIH National Center for
Biotechnology Information (NCBI) GenBank, the European Molecular Biology
Laboratory (EMBL), and the DNA Database of Japan (DDBJ).

The Protein

database contains sequence data from the translated coding regions from DNA
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sequences in GenBank, EMBL and DDBJ as well as protein sequences submitted
to Protein Information Resource (PIR), SWISSPROT, Protein Research
Foundation (PRF), and Protein Data Bank (PDB) (sequences from solved
structures) (source: National Center for Biotechnology Information, Entrez).
Using the Bioinformatics Harvester, http://harvester.embl.de, a search of the
EMBL GenBank DDBJ databases for human organic anion transporters yielded 4
entries for hOAT1 from human kidney and 3 entries for hOAT3. The number of
amino acids (aa) recorded for the hOAT1 entries are in agreement with those
reported by Bahn et al. (2000) and are those submitted by the individual
laboratories and reported in the journal articles (Reid et al., 1998; Hosoyamada et
al., 1999; Lu et al., 1999; Race et al., 1999; Cihlar et al., 1999; and Bahn et al.,
2000). The EMBL entries for hOAT3 are those submitted by the laboratories and
reported by Race et al. (1999), Cha et al. (2000), and one direct submission to the
database by Strausberg R in 2002. The GenBank entry for hOAT3 submitted by
Cha et al., 2000, lists a 542 aa protein vs. a 543 aa protein as reported by Cha et
al. (2000). The third hOAT3 EMBL entry, submitted by Strausberg et al. in 2002
(direct submission, no publication), is a computer derived hypothetical protein and
represents a single aa substitution at residue 271 as compared with the 542 aa
sequence submitted by Cha et al. (2000) as analyzed by peptide alignment using
the Web-based sequence analysis software program Accelrys SeqWeb version 2 .
A fifth isoform of hOAT1 was found through the National Center for
Biotechnology Information (NCBI) protein database, http://www.ncbi.nlm.nih.gov/.
This 529 aa isoform is listed as isoform e. A complete listing of the proteins and
mRNA listed under human OAT1 and/or solute carrier family 22 (organic anion
transporter), member 6 (SLC22A6) in the NCBI database is provided in Table 3.
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Table 1. hOAT1 Isoforms Listed by the
European Molecular Biology Laboratory (EMBL)
EMBL Accession No. Amino acid residues

Predicted MW
(kD)

O95742

563

61.816

Q8N192

550

60.317

Q9NQC2

506

55.858

Q9NQA6

519

57.357

Table 2. hOAT3 Isoforms Listed by the
European Molecular Biology Laboratory (EMBL)
Predicted MW

EMBL Accession No.

Amino acid residues

O95820

568

62.070

Q96TC1

542

59.857

*Q8TCC7

542

59.856

* listed as a hypothetical protein
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(kD)

Table 3. National Center for Biotechnology Information (NCBI)
GenBank Entries for Human OAT1, SLC22A6
Nucleotide
Accession
Number

mRNA
bp
(variant)

Protein
Accession
Number

Isoform
Name

#
Amino
acids

Date of
Entry

Submitted by

NM_004790

2196
(1)

NP_004781

SLC22A6-a

563

04/2003

Curated by
staff

NM_153276

2194
(2)

NP_695008

SLC22A6-b

550

04/2003

Curated by
staff

NM_153277

2025
(3)

NP_695009

SLC22A6-c

506

04/2003

Curated by
staff

NM_153278

2064
(4)

NP_695010

SLC22A6-d

519

04/2003

Curated by
staff

NM_153279

2131
(5)

NP_695011

SLC22A6-e

529

04/2003

Curated by
staff

AF057039

2090

AAC70004

hROAT1

550

04/1998

Reid et al.

AF097490

1653

AAD19356

hOAT1

550

10/1999

Race et al.

AF104038

2088

AAD10052

hPAHT

550

10/1998

Lu et al.

AF124373

2118

AAD55356

OAT1

550

09/1999

Cihlar et al.

AB009697

2151

BAA75072

hOAT1-1

563

12/1997

Hosoyamada
et al.

AB009698

2113

BAA75073

hOAT1-2

550

12/1997

Hosoyamada
et al.

AJ249369
exons1-10

8635
(DNA)

CAB77184

OAT of
OAT1 gene

563

09/1999

Bahn et al.

AJ251529

1521

CAB94830

OAT1-3

506

12/1999

Bahn et al.

AJ271205

1560

CAB94830

OAT1-4

519

01/2000

Bahn et al.

BC033682

2180

AAH33682

SLC22A6

550

07/2002

Strausberg R

AK055764

2180

--

--

--

10/2001

Isogai T et al
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Western Analysis
Currently, the only known commercial supplier of antibodies for the OATs is
Alpha Diagnostics International.

However, several investigators have raised

antibodies and conducted immunohistochemical and/or Western analysis.

All

antibodies were raised against synthetic peptides of sequences at or near the
carboxy terminus. Table 4 summarizes their findings for OAT1 and OAT3 by
Western analysis. The table also includes the predicted molecular weight of the
OAT clones. These predicted values are indicated by an asterisk.
Due to the vast differences in molecular weight for the OATs reported, the study
of Bergwerk et al (1996) is worthy of mention.

In this study, Bergwerk and

colleagues performed a Western analysis of a cloned organic anion transport
protein from rat. The transporter had not been identified, but it was reported to
function in a sodium-independent manner and Northern analysis had identified
RNA in liver and kidney only. Protein for the liver revealed an 80 kD protein that
migrated to 65 kD after deglycosylation.

In the kidney, under non-reducing

conditions, the protein migrated to 83 kD but on reduction, it resolved into peptides
of 33 and 37 kD. Molecular weights marked with a double asterisk in Table 4
indicate deglycosylated protein. Additionally, a column is included in the table to
indicate if the preparation included a reducing agent.
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Table 4. Molecular Weight of OAT1 and OAT3 Proteins
Based on Western Analysis or Predicted Gene Products
* indicates predicted MW
** indicates the bands recognized after deglycosylation

Investigator

Species/Organ/Model Reduced OAT1 (kD)

Cihlar et al., 1999

Human kidney cortex

no

80-90; 60**

--

Hosoyamada et al., 1999

Human renal clone

--

61.8*

--

Race et al., 1999

Human renal clone

--

60.3*

62.1*

Reid, 1999

Human renal clone

--

60*

--

Motohashi et al., 2002

Human kidney tissue

no

84

80

Hasegawa et al., 2002

Rat kidney tissue

yes

--

65

Hasegawa et al., 2002

rOAT3 expressing
LLC-PK1 cells

yes

--

54

Ji et al., 2002

Rat kidney

yes

77

72

Kojima et al., 2002

Rat kidney

no

--

130

Kikuchi et al., 2003

Rat kidney

?

--

65; ~40**

Kikuchi et al., 2003

Rat brain capillaries

?

--

75; ~40**

Nagata et al., 2002

Rat kidney

yes

69

Slightly > 63

Nagata et al., 2002

rOAT1 and rOAT3
expressing LLC-PK1

yes

69

50, 63

Nagata et al., 2002

Rat kidney / brain

yes

69

50, 63 / 63

Tojo et al., 1999

Rat renal cortex

yes

57

--
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OAT3 (kD)

Models for Transport Studies
Traditional models for organic anion transport include renal slices, freshly
isolated cells or tubules (Visarius et al., 1996; Groves et al., 1998; Lash, 1998),
isolated perfused tubules (Newton et al., 1982), membrane vesicles (Pritchard,
1995; Sweet et al., 1997; Van Aubel et al., 2000; Burckhardt et al., 2001) and
primary culture (Groves et al, 1999a; Lash, 1998). With the recent cloning of many
of the transporters, the most common models utilized in organic anion transport
studies currently are cell lines or oocytes expressing one or multiple transporters.
These expression systems are commonly referred to as transfectants (Sugiyama
et al., 2001). Human organic anion transporter transfectants include HeLa cells
(Lu et al., 1999), Xenopus laevis oocytes (referred to hereafter as oocytes) (Cha et
al., 2001), transformed mouse S2 PT cells (Takeda et al, 2000) and Chinese
hamster ovary (CHO) cells (Cihlar and Ho, 2002).

A list of the human OAT

transfectants referenced in this document is provided in Table 5. Transfectants of
some of the apical transporters and rOATs include LLC-PK1 cells (Sugiyama et
al., 2001; Nagata et al., 2002), MDCK cells (Ilias et al., 2002, Sasaki et al., 2002)
and HEK293 cells (Uchino et al., 2000). Inside-out membrane vesicles of Sf9
insect cell transfectants are utilized for the study of the multidrug resistance
associated protein (MRP) efflux transporters (Van Aubel et al., 2002; Reid et al.,
2003; Bodo et al., 2003; Zelcer et al., 2003).
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Table 5. Human Organic Anion Transporter Expression Systems
Transporter

Expression System

Reference

hOAT1

Oocytes

Cihlar et al., 1999
Hosoyamada et al.,
1999
Race et al., 1999

CHO cells

Cihlar and Ho, 2000

Mouse S2 PTCs

Babu et al., 2002
Jung et al., 2001
Takeda et al., 2000,
2001

HeLa cells

Lu et al., 1999

Mouse S2 PTCs

Babu et al., 2002
Enomoto et al., 2002
Takeda et al., 2000,
2001

EcR293 cells

Sun et al., 2001

Oocytes

Cha et al., 2001

Mouse S2 PTCs

Babu et al., 2002
Jung et al., 2001
Takeda et al., 2000,
2001, 2002

Oocytes

Cha et al., 2000

Mouse S2 PTCs

Enomoto et al., 2002

hOAT2

hOAT3

hOAT4
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The Basolateral Transporters
Immunohistochemical staining performed by Motohashi et al. (2002)
demonstrated a wide distribution of hOAT1 in the proximal tubule. In contrast, no
staining of the S1 or S3 segment was seen in rat, suggesting rOAT1 confinement
to the S2 portion (Tojo et al., 1999). By confocal microscopy, however, Kojima et
al., (2002) found rOAT1 in S2>>S1, S3; rOAT3 in S1, S2, S3 >> other sites along
the nephron; and rOAT2 in apical membrane of the thick ascending loop (TAL) and
the collecting duct (CD), but not in the proximal tubule (PT). For structure of the
nephron, refer to Figure 2.4. Motohashi et al. (2002) also found the highest mRNA
expression levels among the transporters (hOAT1, hOAT2, hOAT3, hOAT4 and
five organic cation transporters) to be that of hOAT3 at approximately 3 x hOAT1
levels with hOAT1 levels the second highest and hOAT2 levels very low (nearly
1/20 x hOAT3). Staining for hOAT3 in renal slices was concentrated in the cortical
proximal tubules with some cortical proximal tubules negative for hOAT3. No
staining was seen in the proximal tubules of the medullary rays.
Bowman’s Capsule
Distal Tubules

S1

Proximal Tubule

Proximal Tubule

S1

S2

S2

Cortex
S3

Thick ascending limb

S3

Collecting Duct

Outer Medulla

Inner Medulla
Loop of Henle

Loop of Henle

Figure 2.4. Structure of the Nephron.
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Several immunohistochemical studies have demonstrated that hOAT1, rOAT1,
hOAT3 and rOAT3 are localized to the BLM of the proximal tubule (Hosoyamada
et al., 1999; Motohashi et al., 2002; Tojo et al.,1999; Cha et al., 2001; Hasegawa
et al., 2002; Kojima et al., 2002). (Although traditionally, discussions on the OATs
of the BLM have been restricted to OAT1 and OAT3 (Hosoyamada et al, 1999;
Cha et al., 2001), it has recently been reported that OAT2 is also localized to the
BLM of the human proximal tubule (Enomoto et al., 2002)). hOAT2 mRNA levels
in the human kidney cortex are about 1/20 the levels of hOAT3 (Motohashi et al.,
2002). In rat, rOAT2 has been localized to the luminal membrane of other sections
of the nephron (Kojima et al., 2002) and was found by Northern blot analysis to be
expressed only weakly in kidney and at much higher concentrations in the liver
(Sekine et al., 1998). hOAT4 has been localized to the apical membrane (Babu et
al., 2002). Therefore, discussions of the BL transporters will focus predominately
on OAT1 and OAT3, but will include information on OAT2 and to a lesser extent on
OAT4 where pertinent.
Two additional BL transporters of the human proximal tubule are the sulfate
exchanger, SAT1, which has been shown to mediate uptake of organic anions
(Burckhardt and Burckhardt, 2003) and the multidrug resistance associated protein
MPR6 (Russel et al., 2002). Other possibilities include other members of the MRP
family and the OATP family of transporters. MRP5, OATPA, OATPB, OATPD and
OATPE are expressed in the human kidney, but distribution along the nephron has
not been determined (Russel et al., 2002; Tamai et al., 2001).
OAT1 vs. OAT3
OAT1 is thought to be the classic sodium-dependent organic anion
transporter also known as the PAH transporter (Van Aubel et al., 2000). It
is a multispecific transporter mediating uptake of substrates against an
electrochemical gradient in exchange for a dicarboxylate, such as

α−ketoglutarate (αKG) (Pritchard and Miller, 1996). Organic anion
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exchange for dicarboxylate (most commonly αKG or glutarate) has been
demonstrated in several OAT1 clone expression models (Appiwattanakul et
al., 1999; Lu et al., 1999; Cihlar and Ho, 2000). The mechanism of
exchange is explained in the next section. Typical substrates of OAT1 are
amphiphilic exhibiting a negative or partial negative charge and a domain of
hydrophobicity, although some neutral hydrophobic substrates such as
steroid hormones and aniline derivative analgesics are also transported by
OAT1. Interaction with the transporter increases with the strength of the
ionic charge and the number of hydrogen bond acceptors.

Thus, in

general, amphiphilic compounds with a low pKa tend to display a highaffinity for OAT1 (Ullrich et al., 1997; Burckhardt et al., 2001).
Studying the effects of biotransformation, Ullrich and coworkers (1990)
found that glucuronidation reduces or abolishes the interaction with the PAH
transporter.

They suggested that this might be due to the reduced

hydrophobicity of the conjugates.
The prototypical substrates for OAT1 are PAH and fluorescein (FL) (Miller
and Pritchard, 1997; Dantzler, 2002), with a mean Km of 11.9 µM for PAH
(Burckhardt et al., 2003b). No Km has been reported for FL. Substrates
transported by OAT1 include cAMP, cGMP, folate, indoxyl sulfate, PGE2,
many antiviral agents (acyclovir, cidofovir, zidovudine), many antibiotics
(benzylpenicillin, cephaloridine, tetracycline), methotrexate, many diuretics
(acetazolamide, bumetanide, ethacrynic acid, furosemide), heavy metal
chelators

(DMPS),

nonsteroidal

anti-inflammatory

drugs

(NSAIDs:

acetylsalicylate, indomethacin, salicylate) and ochratoxin A (Burckhardt et
al., 2003b).
Unlike OAT1, OAT3 demonstrates the ability to transport sulfate and
glucuronide steroid conjugates.

Estrone sulfate (ES) is the prototypical

substrate for OAT3 with a Km of 3.1 µM (Cha et al., 2001). OAT3 (human
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and rat) also transports estradiol glucuronide (E217βG) with a Km of 8.3 µM
in rat (Sugiyama et al., 2001) and dehydroepiandrosterone sulfate (DHEAS)
with high-affinity. Overlap of substrate specificity between OAT1 and OAT3
is, however, common.

PAH, the prototypical substrate for OAT1, is

transported by OAT3 with a Km of 87 µM (Cha et al., 2001).

The

characterization of OAT3 has not been as extensive as that of OAT1.
However, transport of cAMP, glutarate, methotrexate, PGE2, PGF2α,
salicylate,

taurocholate,

urate,

zidovudine,

valacyclovir

has

been

demonstrated for OAT3 (Burckhardt et al., 2003b). In contrast to OAT1,
which can be trans-stimulated by preloading with PAH, OAT3 (rat and
human) could not be trans-stimulated with preloaded ES (or PAH in rat)
(human - Cha et al., 2001; rat - Kusuhara et al., 1999). Sweet et al. (2003),
however, have demonstrated rOAT3-mediated trans-stimulated uptake of
ES and PAH by glutarate in rOAT3 expressing oocytes. Finally, OAT3 is
thought to mediate the BL step of the reabsorption of urate in humans
(Koepsell and Endou, 2003).
Probenecid is the prototypical inhibitor of both OAT3 and OAT1 with slightly
lower inhibition constant for OAT3-mediated ES transport than OAT1mediated PAH transport (Ki = 9 µM and 12 µM, respectively) (Takeda et al.,
2001). Sensitivity to the inhibitory effects of probenecid, however, may be
determined equally by the substrate. Takeda and colleagues (2002) found
that hOAT1-mediated transport of acyclovir (ACV) was only weakly inhibited
by probenecid (~20% inhibition) vs. strong inhibition (~80-90%) of hOAT1mediated PAH transport by probenecid reported in earlier studies (Takeda
et al., 2001). They speculate that this difference may be attributed to the
difference in substrate affinity. In the 2001 study, Takeda et al. determined
the Km for PAH vs. ACV to be 20.1 and 342.3 µM, respectively. Other
inhibitors include substrates for both OAT1 as well as OAT3, thereby
making it difficult to distinguish OAT1 vs. OAT3 transport solely based on
inhibition studies. The literature reports for inhibitors are often conflicting.
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For example, cimetidine has been considered a substrate and specific
inhibitor of OAT3 (Cha et al., 2001; Nagata et al., 2002).

However,

cimetidine inhibited hOAT1-mediated uptake in a mouse PTC transfectant
model (Jung et al., 2001) and was found to be transported with low-affinity
by hOAT1 and flounder fOAT1 (Burckhardt et al, 2003a).

In contrast,

cimetidine was found to have no effect on PAH transport by rOAT1 in LLCPK1 cells (Nagata et al, 2002).

Likewise, reports of the effects of

indomethacin as a specific inhibitor of OAT1 are at odds. In contrast to the
studies by Kusuhara et al. (1999) and Deguchi et al. (2002), who found
indomethacin had no effect on uptake of ES or indoxyl sulfate by OAT3,
Feng et al. (2001) reported indomethacin caused inhibition of OAT3mediated cimetidine uptake.

Thus, inhibition of substrate transport is

determined by both the inhibitor and the substrate for each transporter.
OAT2
PAH and αKG transport by hOAT2 has been reported by Sun et al. (2001).
In this study, however, they were unable to demonstrate inhibition of
hOAT2-mediated uptake of PAH by αKG. They found no hOAT2-mediated
transport of DHEAS or salicylate.

Interestingly, in studies of rOAT2

expressing oocytes, salicylate has been used as the model substrate
(Sekine et al., 1998). A lower affinity of probenecid for hOAT2 vs. hOAT1
or hOAT3 has been demonstrated (Ki = 766 µM) (Enomoto et al., 2002).
SAT1
The sulfate-anion antiporter 1 (SAT1) is responsible for the sodiumdependent uptake of sulfate from the BLM into the PTC. Substrates include
sulfated steroid hormones and some bile acids (Ullrich et al., 1990).
Probenecid, several antibiotics, diuretics and NSAIDs were inhibitory. PAH
did not inhibit SAT1-mediated sulfate uptake (Ullrich et al., 1990).
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MRP6
Little is known regarding substrates for MRP6. Initial studies demonstrated
a lack of transport of the typical substrates of the MRP family, such as
E217βG and LTC4 (Russel et al., 2002). Subsequent studies, however,
showed transport of LTC4, the glutathione conjugate of N-ethylmaleimide
and at a very low rate, E217βG (Ilias et al., 2002). Mutation of MRP6 has
been associated with pseudoxanthoma elasticum, a connective tissue
disorder (Ilias et al., 2002). MRP6 is a primary active transporter in that it is
ATP-dependent (Ilias et al., 2002).
Transport Mechanisms at the Basolateral Membrane
Uptake of organic anions across the BLM is an uphill process, requiring the
translocation of a negatively charged molecule into a negatively charged
environment with the ability to create an intracellular > extracellular
concentration gradient.

Therefore, the process cannot involve a simple

facilitator mechanism without some component of energy input, thereby
being dependent upon an active process or an exchange with a solute
moving down its electrochemical gradient. It has been demonstrated that
OAT1 is an organic anion/dicarboxylate exchanger and is indirectly coupled
to the basolaterally-distributed Na+/K+ ATP-ase (Shimada et al., 1987;
Pritchard, 1988). Uptake by OAT1 is thus a tertiary active process,
dependent on a dicarboxylate-gradient established by co-transport of Na+
and dicarboxylate, a secondary active process, which is in-turn, dependent
upon the Na+-gradient established by the primary active Na+/K+ ATP-ase
(see Figure 2.5, page 33.)
Recently, OAT3 has also been shown to function in like manner to OAT1 in
oocytes coexpressed with rOAT3 and the Na+-dicarboxylate co-transporter,
rb-NaDC-1 (Sweet et al., 2003). Past studies however, have indicated that
OAT3 function is independent of the Na+ gradient, and the authors (Sweet
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et al., 2003) have stressed the importance of a reevaluation of the
respective roles of OAT1 vs. OAT3. The authors additionally speculate that
since OAT2 is known to transport dicarboxylates, it too may utilize the same
mechanism, thereby rendering the BLM OATs indistinguishable based
solely on energetics.
SAT1 functions as an antiporter and is sodium-dependent (Russel et al.,
2002). MRP6 is likely a primary active transporter utilizing the energy of
ATP hydrolysis (Ilias et al., 2002).
The Apical Transporters
Because transepithelial transport and net intracellular accumulation are
dependent upon both BL uptake and A efflux, the apical transporters will be
included in this discussion where appropriate.
The only member of the OAT family to be localized to the apical/brush border
membrane (BBM) in human is OAT4 (Babu et al., 2002). However, there are other
important organic anion transporters not belonging to the OAT family that are
resident in the BBM. Apical transporters known to mediate transport of organic
anions in the human PTC include MRP2, MRP4, NPT1 and URAT1. It is also
possible that a member of the OATP family is located in the BBM.
OAT4
When expressed in Xenopus laevis oocytes, hOAT4-mediated high-affinity
transport of ES (Km = 1.01 µM) and DHEAS (Km = 0.63 µM) and
prostaglandins PGE2 and PGF2α in a sodium independent manner (Cha et
al., 2000). In the study, no inhibitory effects on hOAT4-mediated transport
of ES were seen with glucuronide conjugates, including both AG and
E217βG. As a class, glucuronide conjugates showed little or no inhibitory
effect on hOAT4 (Cha et al., 2000). OAT4 transport is bidirectional and is
thought to physiologically function in the reabsorption of prostaglandins and
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organic anions and in the secretion of organic anions (Koepsell et al.,
2003). Probenecid was demonstrated to strongly inhibit hOAT4-mediated
translocation of ochratoxin A with a Ki of 44.4 µM (Babu et al., 2002). PAH
and glutarate showed no inhibitory effect on hOAT4-mediated transport
(Cha et al., 2000).
MRP2
Multidrug resistance associated protein 2 (MRP2) has been termed the
apical conjugate export pump (Keppler et al., 2000). MRP2 is a primary
active pump utilizing the energy derived from the hydrolysis of ATP to
mediate efflux of substrates into the glomerular filtrate. It is localized to the
BBM in PTCs and to the canalicular membrane of hepatocytes. Substrates
of MRP2 include conjugated and unconjugated organic anions such as
glutathione conjugates, glucuronide conjugates, leukotrienes, methotrexate,
ochratoxin A and PAH (Konig et al., 1999). The Km for E217βG is 7.2 µM
(Konig et al., 1999) vs. 880 µM for PAH (Leier et al., 2000). Van Aubel and
colleagues reported a Km of 1.9 mM and a Vmax of 187 pmol·mg-1·min-1 for
rabbit MRP2 PAH transport and a stimulatory rather than inhibitory effect of

α-naphthyl-β-D-glucuronide on PAH transport. DHEAS and ES were
determined not to be substrates for MRP2 (Sasaki et al., 2002). Rather,
Sasaki and coworkers found that ES stimulated MRP2-mediated transport.
The hepatobiliary disposition of AG and acetaminophen sulfate (AS) were
studied in isolated perfused livers of MRP2-deficient rats (Xiong et al.,
2000). Xiong and colleagues found that AG and AS biliary excretion was
decreased to 0.3% and 20% of control, respectively, with overall bile flow
decreased to 25% of control, in MRP2-deficient rats. They also found a 7fold increase in the BL efflux of AG, consistent with an upregulation in BL
transporters to compensate for the deficiency of MRP2.

Probenecid,

furosemide, indomethacin, and several conjugated bile acids stimulated
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MRP2-mediated transport of E217βG in inside-out membrane vesicles
expressing human MRP2 (Bodo et al., 2003b). Bodo et al. determined that
there is an allosteric stimulation by bile acids of MRP2 co-transport of bile
acids and glucuronide conjugates. In contrast, Ilias et al. (2002)
demonstrated 78% inhibition of MRP2-mediated transport of the glutathione
conjugate of N-ethylmaleimide by probenecid in the insect membranevesicle transfectant model.
MRP4
MRP4 is a novel multidrug resistant protein reported by Van Aubel and
colleagues (2002) to be localized to the BBM of human PTCs.

This

probenecid sensitive, ATP-dependent efflux pump has been shown to
transport cAMP, cGMP, antiviral nucleoside analogues (Van Aubel et al.,
2002), PGE1 and PGE2 with high-affinity (Reid et al., 2003). Furthermore,
Thromboxane B2, several other prostaglandins and several NSAIDs were
potent inhibitors (and possibly substrates) of MRP4-mediated transport
(Reid et al., 2003). Van Aubel and coworkers (2002) found that E217βG is
a low-affinity substrate for MRP4 and based on inhibition studies, propose
that the other glucuronides tested (α-naphthyl-β-D-glucuronide and p-nitrophenyl-β-D-glucuronide) are also substrates. The MRP4 transporter has
since been identified in several other tissues including liver where it is
localized to the sinusoidal membrane (BL) and has been shown to mediate
high-affinity transport of DHEAS (Zelcer et al., 2003).
NPT1
The human type I sodium-dependent inorganic phosphate transporter,
NPT1, originally thought to function primarily in the reabsorption of
phosphate from the glomerular filtrate, has since been determined to
transport organic anions. Uchino et al. (2000) have determined that NPT1
transports organic anions such as PAH and E217βG in a Cl--sensitive
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manner, demonstrating decreased uptake (influx) of PAH with increasing
extracellular Cl- levels. In the same study, increasing concentrations of
extracellular Cl- had no effect on efflux of preloaded PAH via NPT1. NPT1
is thought, therefore, to function in the efflux of organic anions into the
glomerular filtrate (Uchino et al., 2000). The NPT1 Km for PAH is 2.66 mM
and NPT1-mediated transport is strongly inhibited by probenecid (Uchino et
al., 2000). It is thought that NPT1 may represent the voltage-dependent
PAH transporter or anion exchange mechanism for PAH at the apical
membrane (Russel et al., 2002).
URAT1
URAT1 is the apical transporter responsible for the reabsorption of urate in
the human kidney. It functions as a sodium-independent exchanger with Clor with organic anions (Koepsell and Endou, 2003).

Urate uptake by

URAT1 (Km = 371 µM) is trans-stimulated to a higher degree by organic
anions than by Cl- and was determined not to be driven by membrane
potential (Enomoto et al., 2002b). PAH, however, showed no cis-inhibitory
or trans-stimulatory effect on urate uptake. ES caused a cis-stimulatory
effect on 1-hour urate uptake, but no data were given for the trans effect of
ES on URAT1-mediated uptake. No trans-stimulation was demonstrated by
αKG.

Agents known to cause in vivo uricosuric effects, i.e., reduce

hyperuricemia, such as probenecid, NSAIDs (salicylate and indomethacin)
and diuretic drugs, showed cis-inhibition but no trans-stimulation of urate
uptake.

Agents known to cause hyperuricemia, such as the anti-

tuberculosis agent, pyrazinamide and to a greater extent, its aromatic
monocarboxylate metabolite pyrazinecarboxylic acid (PZA), both cisinhibited and trans-stimulated uptake of urate by URAT1.

Aliphatic

monocarboxylates, such as lactate, also cis-inhibited/trans-stimulated urate
uptake, but to a lesser extent (Enomoto et al., 2002b).
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OATP
Unlike the OATs, there appears to be no one-to-one orthology of the
OATPs between rodents and human. In rat, Oatp1 is resident in the BBM
of the pars recta (Bergwerk et al., 1996) and Oatp2, an isoform of human
OATPA, is localized to the BLM (Gao et al., 2000) and to the apical
membrane (Sugiyama et al., 2002) of brain capillary endothelial cells. The
OATPs in the human liver are localized to the BLM. In the human kidney,
mRNA for OATPA, OATPB, OATPD and OATPE has been detected
(Hagenbuch and Meier, 2003).

OATPD and OATPE both contain a

carboxy-terminus consensus sequence that is typically associated with
localization to the apical membrane (Russel et al., 2002).

Thus, the

possibility of OATP(s) present in human PTCs exists and localization could
be apical, BL or both. In rat, Oatp2 is thought to be responsible for the
efflux transport of glucuronides across the blood-brain barrier (BBB)
(Sugiyama et al., 2001). Sugiyama and coworkers (2001) found Oatp2 to
be responsible for 40% of the efflux of E217βG across the BBB. In a later
study, it was determined that Oatp2 has at least two substrate recognition
sites and that E217βG stimulated the Oatp2-mediated transport of
taurocholate but inhibited transport of digoxin (Sugiyama et al., 2002).
OATP substrates are mainly high molecular weight amphipathic molecules
that are normally bound to protein (albumin) and the transporters are
thought to be organic anion exchangers (Hagenbuch and Meier, 2003). Of
the 7 human OATP transporters listed in a substrate specificity table by Van
Montfoort et al. (2003), 4 of 5 tested transported DHEAS, 5 of 7 transported
E217βG and all 7 transported ES. The affinities for these substrates were
very high. PAH was only tested for one transporter (OATPA) and was
found not to be a substrate.
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Mechanisms of the Apical Transporters
Mechanisms of the apical transporters are discussed above, beginning on
page 27, under the sections for each transporter. Briefly, the mechanism of
OAT4-mediated efflux is unknown; MRP2 and MRP4 function as primary
active transporters, utilizing the energy of ATP; the mechanism for NPT1
function is uncertain, but is thought to function in the secretion of organic
anion (OA-) in a Cl--sensitive manner; and URAT1 functions as an OA(urate and others) exchanger with Cl- or organic anions (Figure 2.5).
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Figure 2.5. Basolateral and Apical Organic Anion Transporters of the Human
Proximal Tubule. The BL organic anion transporters known to be present in the
human PTC are OAT1, OAT3 and SAT1. OAT1, and possibly OAT3, functions as
a tertiary active protein, mediating exchange of dicarboxylate for OA- in a Na+dependent manner. SAT1 is a SO4- exchanger, responsible for efflux of OA- and
uptake of SO4- and several SO4- conjugates. The apical transporters, responsible
for efflux or organic anions, include OAT4, URAT1, MRP2, MRP4 and NPT1.
URAT1 functions as an exchanger, mediating reabsorption of uric acid (or OA-)
with efflux of OA-.

MRP2 and MRP4 are primary active proteins utilizing the

energy of ATP for efflux of OA-. The mechanism of NPT1 is uncertain, however, it
is known to mediate efflux or OA- in a Cl--sensitive manner. The mechanism of
OAT4 is unknown. Other possible transporters resident in both the BBM and BLM
include both OATP and MRP proteins.
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Organic Anion Transporter Substrates and Regulation
According to Dantzler (2002), during the secretory process as studied in
perfused tubules (both mammalian and non-mammalian), the steady-state
concentration of organic anion inside the cells is greater than that in the tubule
lumen, which is greater than that in the peritubular fluid (bathing medium). This is
consistent with the observation that the BBM (luminal) has a higher apparent
permeability to PAH than does the BLM and that transport into the cell across the
BLM is the rate limiting step (Dantzler, 2002). This is, however, not always the
case. According to Terlouw et al. (2003), efflux of anions at the BBM, in general, is
less efficient than BL uptake, resulting in intracellular accumulation. This has been
demonstrated for many of the antiviral drugs for which efflux at the BBM is rate
limiting resulting in intracellular accumulation (Russel et al., 2002). Thus, relative
membrane contributions to the rate of secretion vary depending on the substrate.
Very little is known about the renal transport of glucuronides. Efficient tubular
secretion of glucuronides is well established. Apical transporters that have been
identified as transporters of glucuronides include MRP2, MRP4 and NPT1. OAT4
does not transport glucuronides and no data exist regarding URAT1 affinity for
glucuronides. In hepatocytes, Sallustio et al. (2000) report that concentration
gradients of 1:50:5,000 in the circulation, hepatocytes and bile, respectively are
found for acyl-glucuronides. MRP2 is considered to be the major conjugate efflux
pump in the liver responsible for excretion of glucuronides into the bile. Transport
of E217βG in oocytes expressing human renal OAT3 (Cha et al., 2001) is the only
report of glucuronide uptake by a BLM transporter. As a class, glucuronides have
not been investigated in carrier specific uptake at the BLM.
A list of the BL and A transporters in the kidney and their substrate specificity
are given in Table 6. The properties and substrate specificities listed are not
intended to be all inclusive, but to cover the basic characteristics and prototypical
substrates for the transporters and/or those substrates utilized for this project.
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Table 6. Substrates and Inhibitors of Renal Organic Anion Transporters
Transporter Species

Substrate (Km)

Inhibitors (Ki)

Reference

OAT1 (BL)

Human

PAH (11.9µM), FL
αKG, Glutarate

Probenecid (12µM)

Oat1 (BL)

Rat

PAH (14µM, 70 µM)

Probenecid

Russel, 2002

Oat1 (BL)

Mouse

Probenecid

Sweet et al., 2002

OAT2 (BL)

Human

OAT3 (BL)

Human

OAT3 (BL)

Rat

Oat3 (BL)

Mouse

OAT4 (A)

Human

DHEAS (0.63µM)
ES (1.3 µM)

NPT1 (A)

Human

PAH (2.66 mM)
E217βG urate

Probenecid

Uchino et al., 2000

MRP2 (A)

Human

E217βG2 (7 µM)
PAH3 (880 µM)
ES4 DHEAS4

(Probenecid1,
and ES4 stimulate
transport)

Bodo et al.1, 2003b
Konig et al.2, 1999
Leier et al.3, 2000
Sasaki et al.4, 2002

MRP2 (A)

Rat
(hepatic)

AG1

PAH, ES
Taurocholate
PAH, αKG
DHEAS
PAH (87µM), FL
ES (3µM), E217βG
DHEAS
PAH, ES
E217βG (8.43µM)
PAH, ES
Taurocholate

Probenecid2 (766µM)
Probenecid (9µM)
Ouabain1

Burckhardt et al., 2003b

Sun et al., 2000
Enomoto2 et al, 2002
Cha et al.1, 2001

Probenecid

Sugiyama et al, 2001

Probenecid

Sweet et al., 2002

BSP, Probenecid
Glucuronide Conj Cha et al., 2000
E217βG, AG, PAH

Xiong et al. 1 ., 2000
Probenecid1
Glucuronides2
NSAIDs2

Reid et al.1, 2003
Van Aubel2 et al.,
2002
Zelcer3 et al., 2003
Sugiyama et al.,
2001
Sugiyama et al.,
2001
Hagenbuch et al., 2003
Tirona et al., 2002
V Montfoort et al, 2003
Tamai et al.2, 2001
Tirona et al., 2002

MRP4 (A in
PTC, BL in
hepatocytes)

Human

DHEAS (2µM)
E217βG2,3

Oatp1

Rat

E217βG (2.58 µM)

Oatp2

Rat

E217βG (17 µM)

OATP-A
(BL in brain)

mRNA in
human
kidney

OATP-B
(BL in liver)

"

E217βG, PAH
ES (59 µM)
DHEAS (7 µM)
ES (6 µM) DHEAS
Glucuronides

OATP-D

"

ES

Hagenbuch et al, 2003

OATP-E

"

ES
E217βG

SAT1(BL)

human

sulfates

Hagenbuch et al., 2003
Tirona et al., 2002
Burckhardt and
Burckhardt (2003)

3

Probenecid
PAH
Probenecid
PAH

Probenecid

This table is not designed to be all-inclusive, but to list those substances utilized in transport studies for this
project. Strikethrough (e.g. PAH) indicates the agent was not transported by or did not inhibit the transporter.

35

AG Transport

O

Acetaminophen glucuronide
MW = 349.3

HO

OH
H
N

O

HO

O

CH3
O

OH

Acetaminophen glucuronide (AG) binding to plasma proteins in human is
low (<10%) such that AG is freely filtered at the glomerulus (Morris and
Levy, 1984).

In early studies of acetaminophen (APAP) metabolism in

humans, Prescott (1980) demonstrated that at therapeutic doses of APAP,
renal clearances of AG and acetaminophen sulfate (AS) often exceeded the
rate of glomerular filtration and that the respective percentage of APAP
metabolite excretion in the urine was 55 and 40%. In contrast, the renal
clearance of AG on average was found not to exceed that of creatinine 1-3
hours after an oral dose of APAP in human as determined by Morris and
Levy (1984).

In a study of renal tubular transport of APAP and its

conjugates in the dog, Duggin and Mudge (1975) found that at low plasma
concentrations, AG is secreted by an active transport process, whereas at
high concentrations, it is reabsorbed. They also found that net renal tubular
secretion of AS but not AG was inhibited by probenecid. The hepatobiliary
disposition of AG and AS was studied in isolated perfused livers of MRP2deficient rats (Xiong et al., 2000). In the MRP2-deficient rats, Xiong and
colleagues found that biliary excretion of AG and AS was decreased to
0.3% and 20% of control, respectively, with an overall decrease in bile flow
by 25% of control. They also found a 7-fold increase in the BL efflux of AG
which they hypothesized may be attributed to upregulation of MRP3 as
demonstrated in multiple studies of MRP2-deficient models as well as the
work of Hirohashi et al. (1999) that demonstrated transport of multiple
glucuronide conjugates by MRP3.
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DHEAS Transport

O
CH3
CH3

Dehydroepiandrosterone sulfate
MW = 390.5

O O
S
O
HO

H

H

H

Dehydroepiandrosterone sulfate (DHEAS) is the most abundant steroid
hormone in the human circulation. It is synthesized by the adrenal gland.
DHEAS is a high-affinity substrate for hOAT4 (Km = 0.63 µM, Cha et al.,
2000). Transport by hOAT3 was also demonstrated. Although the Km was
not reported for hOAT3, high uptake by hOAT3-expressing oocytes was
indicated (Cha et al., 2001). No data were given as to the affinity of DHEAS
for OAT1. DHEAS is not a substrate for MRP2 (Sasaki et al., 2002) but is a
high-affinity substrate for MRP4 (Km = 2 µM, Zelcer et al., 2003). Four of 5
human OATPs tested transported DHEAS (Van Montfoort et al., 2003).
E217βG Transport

O

H

Estradiol 17β-glucuronide
MW = 470.5

O
CH3

OH
OH

O

OH
OH

H

Estradiol

glucuronide

(E217βG)

hOAT3-

mediated transport in oocytes was reported by

H

H

HO

Cha et al. (2001). In earlier studies, (2000), Cha and coworkers found no
inhibitory effects on hOAT4-mediated transport by E217βG. Sugiyama et al.
(2001) found that E217βG efflux from the brain was mediated by Oatp2
(40%) and by OAT3 (20%). MPR2 (Km = 7 µM; Konig et al., 1999) , MPR3
(Bodo et al., 2003b) and MRP4 ( low-affinity; Van Aubel et al., 2002) all
transport E217βG. Transport of E217βG by MRP3 in LLC-PK1 cells was
inhibited by methylumbelliferone glucuronide but stimulated by methylumbelliferone sulfate (Hirohashi et al., 1999).

Stimulation rather than

inhibition of transport of E217βG also resulted from coincubation with
probenecid, indomethacin, furosemide and several conjugated bile acids
mediated by human MRP2 expressed in insect cell line inside-out
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membrane vesicles (Bodo et al., 2003b). In contrast, Bodo and colleagues
found inhibition of MRP3-mediated transport by these same substances. In
hepatocytes, E217βG causes a rapid inhibition of bile flow (85% inhibition
within 10 min) coinciding with retrieval of MRP2 into intracellular sites
(Mottino et al., 2002, 2003). E217βG is also a substrate for NPT1 (Uchino
et al., 2000). Five of 7 human OATPs tested transported E217βG (Van
Montfoort et al., 2003).

Thus, E217βG is a substrate for multiple

transporters including OAT3 (BL) and MRP2, MRP4 and NPT1 (A) present
in human renal PTCs and has been shown to affect regulation of MRP2.
ES Transport

CH3

Estrone-3-sulfate
MW = 372.4

O

O

O
S
HO

O

Estrone sulfate (ES) is the prototypical substrate for OAT3 and OAT4 (Cha
et al., 2001, 2000). Cha and colleagues demonstrated a Km of 3.1 µM and
1.01 µM for ES transport mediated by hOAT3 and hOAT4, respectively.
Unlike the ability of PAH to trans-stimulate transport of PAH by hOAT1
(Sweet and Pritchard, 1997), neither hOAT3 nor hOAT4 transport of ES
was trans-stimulated by ES (Cha et al., 2000, 2001).

Experiments in

mouse renal cortical slices indicate that OAT3 is not the only BL transporter
responsible for ES uptake (Sweet et al., 2002).

In URAT1-expressing

oocytes, ES cis-stimulated uptake of urate in exchange for Cl- by URAT1
(Enomoto et al., 2002b).

ES and DHEAS were determined not to be

substrates for MRP2 (Sasaki et al., 2002). Rather, Sasaki and coworkers
found that ES stimulated transport of substrate mediated by MRP2. ES
was found to have no inhibitory effect on rOAT1-mediated transport of PAH
(Sweet et al, 2002.) Finally, all 7 of the human OATPs tested transported ES
(Van Montfoort et al., 2003).

Thus, ES is transported into the cell by

multiple transporters at the BLM, is effluxed at the BBM by OAT4 and
stimulates efflux at the BBM mediated by URAT1 and MRP2.
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MUG

OH
HO

Methylumbelliferyl glucuronide
MW = 352.3

O

HO

Methylumbelliferyl glucuronide (MUG) is a

O

O

O

O

CH3

OH

low molecular weight glucuronide. Little is found in the literature as to its
transport properties, however, it has been used to investigate the inhibitory
properties of glucuronide transport. Transport of E217βG by MRP3 in LLCPK1 cells was inhibited by methylumbelliferoneƒ glucuronide but stimulated
by methyumbelliferone sulfate (Hirohashi et al., 1999). MUG showed no
inhibitory effect on hOAT4-mediated transport (Cha et al., 2000).
PAH Transport

O
H2N

p-aminohippurate
MW = 194.2
pKa = 3.2

OH
NH
O

PAH is the prototypical substrate for OAT1 (Km = 11.9 µM; Burckhardt et al.,
2003b). It is also transported on the BLM of the PTC by OAT3 (Km =
87 µM; Cha et al., 2001). The apparent permeabilities of the BLM and the
BBM to PAH have been measured in several species with the BBM (apical)
permeability always greater than the BLM (Dantzler, 2002).

Pritchard

(1988) determined that PAH uptake is coupled to dicarboxylate (αKG)
efflux, and later studies demonstrated trans-stimulation can also be
achieved with PAH itself. Trans-stimulation of PAH with αKG results from
an increase in the Vmax with little change in the Km (Dantzler, 2002). In
human BBM vesicles, voltage-driven PAH transport and αKG/PAH
exchange were demonstrated (Burckhardt et al., 2001). PAH had no cisinhibitory or trans-stimulatory effect on the uptake of urate by URAT1ƒ

Methylumbelliferone glucuronide could not be found in any chemical databanks as is thus thought to be methylumbelliferyl
glucuronide (MUG). MUG is the conjugate of 4-methylumbelliferone and glucuronic acid.
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expressing oocytes (Enomoto et al., 2002b) and was found to have no
effect on hOAT4-mediated transport (Cha et al., 2000). PAH is a lowaffinity substrate for both MRP2 (Km = 880 µM, Leier et al., 2000) and NPT1
(Km = 2.66 mM, Uchino et al., 2000). PAH affinity for the OATPs has only
been reported for one human OATP transporter: PAH was found not to be a
substrate for OATPA (Van Montfoort et al., 2003). PAH is not transported
by rOATP1 nor rOATP2 (Sugiyama et al., 2001).
Probenecid, the Transport Inhibitor
Probenecid
MW = 285.4
pKa 3.4
Probenecid is a highly lipid-soluble derivative

H3C

O

OH

N S
O

O

H3C

of benzoic acid. It was originally discovered during the search for a drug to
depress the renal excretion of penicillin (Goodman and Gillman, 1990).
Probenecid is secreted by the proximal tubule but is almost completely
reabsorbed by back diffusion along the nephron unless the urine is alkaline
(Goodman and Gillman, 1990). Probenecid inhibits, but is not a substrate
for OAT1. It is also an inhibitor of OAT3, URAT1, NPT1, MRP4 and the
OATP transporters. Refer to Table 6 for Ki values for the specific inhibitors.
Probenecid acts as a uricosuric agent by inhibiting the reabsorption of urate
by URAT1 (Enomoto et al., 2000b). In stop-flow studies of isolated canine
proximal tubules, probenecid had no effect on AG net tubular secretion
(Duggin and Mudge,1975). In the liver, probenecid and ouabain stimulate
bile flow (Dickinson et al., 1979). Consistent with this finding, Bodo et al.
(2003b) demonstrated that, in transport of E217βG, probenecid inhibits
MRP3, the BL export transporter in hepatocytes, whereas probenecid
stimulates MRP2, the canalicular (apical) export transporter in hepatocytes.
Finally, probenecid also inhibits the formation of glucuronide conjugates
(Savina et al., 1992).
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Regulation
Both OAT1 and OAT3-mediated uptake are inversely proportional to protein
kinase C (PKC) activity (Terlouw et al., 2003; Lu et al, 1999) and directly
proportional to cAMP signaling. Transporter activity has also been shown to be
acutely stimulated by epidermal growth factor (EGF) and the mitogen activated
protein kinase (MEK/ERK) pathway (Sauvant et al., 2001).

EGF can acutely

upregulate OAT3 activity via the extracellular MEK signaling pathway. Induction of
transporter expression (OAT1) can be affected by a 24 hour pretreatment with
5 mM sodium butyrate (Nagata et al., 2002; Sugiyama et al., 2001).
Regulation for MRP2 is more thoroughly characterized than are the OATs.
MRP2 activity and expression are regulated at three levels: 1. endocytic
retrieval/exocytic insertion (occurs within min); 2. translational regulation (within
several hours); 3. transcriptional regulation (within days) (Gerk and Vore, 2002).
Rapid retrieval and retargeting of MRP2 to the BLM in hepatocytes in response to
activation by PKC was reported to occur within 30 min as detected by
immunoreactive MRP2 (Kubitz et al., 2001). Insertion of MRP2 into the canalicular
membrane of rat hepatocytes has been demonstrated by stimulation with cAMP,
resulting in a 3-fold increase in MRP2 within min (Kipp et al., 2001). Insertion and
retrieval of MRP2 also occurs in response to hypo- and hyperosmolarity,
respectively (Kubitz et al., 1997; Schmitt et al., 2001).

Also in hepatocytes,

E217βG causes a rapid inhibition of bile flow (85% inhibition within 10 min)
coinciding with retrieval of MRP2 into intracellular sites (Mottino et al., 2002, 2003).
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HK-2 Cell Model
HK-2 Cells
The HK-2 cells used for this project were purchased from American Type
Culture Collection (ATCC). The literature provided with the cells recommended
culturing the cells in Keratinocyte Serum Free Media (KSFM) supplemented with
5 ng/ml epidermal growth factor (EGF) and 40 µg/ml bovine pituitary extract.
Normal adult male proximal tubule cells were immortalized by transfection with
human papilloma virus 16 (HPV-16) E6/E7 proteins and were reported to retain
phenotypic and functional characteristics of well differentiated proximal tubule cells
(Ryan et al., 1994). Cells retain Na+-dependent glucose transport and parathyroid
responsive, antidiuretic hormone unresponsive hormone sensitivities.

Several

investigators report successful use of different types of media used for the culture
of HK-2 cells, including Dulbecco's Modified Eagle Medium (DMEM)/Ham's F12
with supplements, and Roswell Park Memorial Institute (RPMI) Defined Media.
Additionally, many investigators supplement culture media with 2 to 10% fetal
bovine serum (FBS).
HK-2 Cells and Transport
HK-2 cells have been used in transport studies of riboflavin (Kumar et al., 1998)
and to study the function of the P-glycoprotein pump, MDR1, which is expressed in
the BBM of HK-2 cells (Romiti et al., 2002). Studies of extracellular glutathione
peroxidase have demonstrated polarization of HK-2 cells on permeable
membranes (Whitin et al., 2002). In this study, the membrane resistance was
measured and determined to be 100 Ohms.

Whitin and colleagues plated

Transwell membranes coated with human placental collagen Type IV at a seeding
density of 3.0 x 105 cells/cm2 and used fluorescein-labeled dextran to determine
paracelluar diffusion.
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CHAPTER III. Methods
Methods
Cell Culture

Materials
HK-2 human kidney, proximal tubule cells, transformed (ATCC, CRL-2190)
Keratinocyte Serum Free Media (KSFM, Invitrogen Lifetechnologies, 17005-042)
Fetal Bovine Serum, 100 ml, heat inactivated (Invitrogen Lifetechnologies, 10082139)
Trypsin-EDTA (0.25% Trypsin, 1mM EDTA.4Na) (Invitrogen Lifetechnologies, 25200)
Collagen Type IV from human placenta (Sigma, C-5533)
Collagen Type I from rat tail (Sigma, C-7661)
Costar Brand Transwell-Clear Inserts, No. 3450 (Fisher Scientific,07-200-170)
Millipore Millicell Culture plate inserts (Fisher Scientific, PIHP 030-50)
Corning Brand Culture Flasks, T25 (Fisher Scientific, 10-126-28)
Corning Brand Culture Flasks, T75 (Fisher Scientific, 10-126-37)
Falcon polystyrene 35 mm dishes (Fisher Scientific, 08-722A)
Wheaton Cryule Vial (Cryovials) (Fisher Scientific, 03-341-18N)
Nalgene Cryogenic Controlled-Rate Freezing Container (Fisher Scientific, 15-350-50)
Equipment
IEC PR-7000M centrifuge, rotor 966, International Equipment Company
Steril®GARD II Class II Type A/B3 Biosafety Cabinet, The Baker Company
Nuaire US Autoflow CO2 water-jacketed incubator
Zeiss Axiovert25 phase contrast microscope
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Cultureware and Media
HK-2 cells purchased from American Type Culture Collection (ATCC, Manassas,
VA), were cultured in T25 and T75 tissue culture flasks or on 35 mm culture plates.
Cells used for transport studies were grown on 30 mm Millicell-PCF Millipore
Millicell© Culture Plate Inserts (early studies) or 24 mm Costar® Transwell-Clear
polyester tissue culture-treated, microporous membranes.

Culture media

consisted of keratinocyte serum-free media (GIBCO/Invitrogen) containing 5 ng/ml
human epidermal growth factor and 40 µg/ml bovine pituitary extract as
recommended by ATCC and supplemented with 2% fetal bovine serum.
Antibiotics (50 µg/ml streptomycin and 48 U penicillin) were added to the culture
media during subculturing only. For transport studies and when indicated, inserts
were treated with 0.025 mg/insert Type IV human placental collagen (Sigma C5533) prepared in 0.5 M glacial acetic acid.
Subculture and Feeding
All conditions were under Biosafety Level 2 containment, performed in a Class II
Biosafety Hood using sterile pipets and plastic/glassware, wearing a laboratory
coat and double-gloved.

Subculture was performed weekly or when the

monolayers reached 80% confluence as assessed by phase-contrast microscopy.
Media from flask-grown cells were poured into a waste flask. The monolayers
were rinsed with 1.5 ml/T25, 3 ml/T75 HEPES Buffered Saline Solution (HBSS)
then trypsinized for 10 min to lift cells from flasks. Trypsinization was performed
by adding 1.5 ml/T25 or 3 ml/T75 0.25% trypsin, 0.05% EDTA (Invitrogen),
decanting after 30 seconds and incubating the monolayer in the residual trypsin
solution. When cells were released from the flasks (10 min), culture medium was
added to each flask (5 ml/T25, 8 ml/T75) and swirled over the cells. The cell
suspension was transferred to a 15 ml or 50 ml centrifuge tube and centrifuged at
270 x g for 5 min at 4oC (IEC PR-7000M centrifuge, rotor 966). The supernatant
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was discarded and the pellet resuspended in culture medium.

Using a

hemacytometer, the cell suspension was enumerated and the cells seeded into
new flasks, plates or inserts. Cells grown in T75 flasks were seeded at a density
of 4.0x106cells in 25 ml or split at a one to four ratio and fed twice weekly. Cells
grown in T25 flasks were seeded at a density of 1 to 1.5x106 cells in 12 ml or at a
one to four ratio and were fed every other day. Millicell inserts were seeded at
4.0x105 cells in 2.0 ml culture medium in the basolateral compartment with 1.5 ml
culture medium added to the apical compartment. Cells were fed every other day.
Transwells were seeded at 4.0x105 cells or superseeded at 1.41x106 cells in 2.6 ml
culture medium in the basolateral compartment with 1.5 ml culture medium added
to the apical compartment. Cells were fed every other day or daily. Cells were
maintained in an incubator at 37oC and 5% CO2.
Cryopreservation of Cell Line
Cells from intermittent passages were cryopreserved in a solution of 85% culture
medium prepared without fetal bovine serum (FBS), 10% FBS and 5% dimethyl
sulfoxide (DMSO) at a cell suspension of 1-1.5 x 106 cells/ml. The cryosuspension
was prepared as a double-strength cryomedium (0.35 ml culture medium, 0.10 ml
FBS, 0.05 ml DMSO per vial) to which a cell suspension (0.5 ml x 2.0 to 3.0x105
cells/ml culture medium) was added dropwise to the cryovial for a final volume of 1
ml cryosuspension.

The cryovials were placed in a Nalgene cryofreezer

temperature control unit and placed in a -20oC freezer overnight, transferred to a 80oC freezer for 4 hours then placed in liquid nitrogen or in a -135oC freezer for
long-term storage.
Cell Pellets for Assays or Western Blot Analysis
Cells grown in 35 mm plates, T25 or T75 flasks were rinsed X 2 with 1-3 ml HBSS,
then scraped with a Teflon scraper, transfered into 15 ml or 50 ml centrifuge tubes
and centrifuged at 270 x g for 5 min at 4oC (IEC PR-7000M centrifuge, rotor 966).
Supernantant was discarded. Cells were stored at -80oC if not used immediately.
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Cell Line Characterization
Materials
Adenosine 5’-triphosphate (Sigma, A-2383)
Alkaline phosphatase staining kit (Sigma, 85L-3R)
Phosphatase substrate (Sigma, 104)
Glucose-6-phosphate deydrogenase Type VII (Sigma, G-7877)

γ-Glutamyltransferase Kit (Sigma, 545-A)
Protein assay kit, dye reagent (Bio-Rad Laboratories, 500-0006)
Bovine Serum Albumin, (Sigma, A-6003)
Equipment
Perkin-Elmer HTS 7000 bioassay reader
Gillford III spectrophotometer
Beckman UV/Vis spectrophotometer
Growth
Ideal growing conditions were determined by comparing growth of cells with
variations in culture medium, culture plate type or plate preparation. These growth
comparisons were performed on a minimum of n=4 per culture plate and were
evaluated based on cell count and/or protein content per flask/plate. Cell count
was performed using a hemacytometer and was expressed as number of cells per
plate or flask type.
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Protein Determination
Protein determination by the method of Bradford (1976) was measured
spectrophotometrically at 595 nm using bovine serum albumin as standard and
Biorad® protein assay dye reagent.

Utilizing 5 µl aliquots of cell lysate,

measurements were performed in duplicate for each flask, plate or membrane.
Protein content was expressed as mg protein per plate or flask type or as a
measurement of the amount of cellular protein (mg) used in a specific assay.
Proximal Tubule Cell Markers
Characterization of HK-2 cells by known proximal tubule cell markers was
performed using cells from subculture cell suspensions and from cells scraped with
a Teflon cell lifter from 35 mm plates, T25 and T75 flasks. Alkaline phosphatase
(AP) levels were measured using Diagnostic Kit 104 purchased from Sigma
Chemical Company measured as nmol p-nitrophenol liberated/min/mg protein by
spectrophotometric absorbance at 410 nm or by a staining procedure using Sigma
Diagnostics Alkaline Phosphatase kit, procedure number 85, as a semiquantitative demonstration of AP activity using α-naphthyl phosphate as a
substrate and fast blue RR as the diazonium salt to stain cells expressing AP. The
stained monolayers were evaluated as positive or negative for AP based on
visibility of stain on cell membranes under light microscopy. Hexokinase (HK)
levels were determined by the method of Joshi and Jagannathan (1966) as a
measure of nmol NADP+ reduced/min/mg protein spectrophotometrically at 340
nm. Gamma-glutamyltransferase (GGT) levels were determined by colorimetric
absorbance at 540 nm with the use of Sigma kit 545, based on the formation of a
colored product in a secondary reaction after a GGT catalyzed reaction liberating
p-nitroaniline. GGT levels were expressed as GGT units/mg protein.
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Toxicity Studies
Materials
Acetaminophen (APAP) (Aldrich, A730-2)
Acetaminophen glucuronide (AG) (Sigma, A-4438)
Diclofenac sodium (Sigma, D-6899)
Lactate dehydrogenase kit (Sigma, 228)
Gilford Stasar III spectrophotometer (Fisher Scientific)
Lactate Dehydrogenase Release
Five to seven day old monolayers of HK-2 cells grown on 35 mm plates were
incubated in 0, 200 µM or 500 µM acetaminophen or acetaminophen glucuronide
(AG) for 30, 60 and 120 min in incubation medium (phosphate buffered saline
solution (PBS) with 5 mM glucose) on an orbital shaker at 60 cycles per min in an
environment of 95% air/5% CO2 at 37oC. Incubation medium was removed from
the culture well and cells were scraped from the plate and solubilized in 1 ml
PBS/0.1% Triton-X100.

Cell suspensions were transferred to microcentrifuge

tubes, vortexed for 1 min, then centrifuged at 7200 x g for 3 min. Using Diagnostic
Kit LDL-20 from Sigma Chemical Company, LDH activity was calculated as the
change in spectrophotometric absorbance at 340 nm over time corresponding to
LDH-catalyzed reduction of NADP+ to NADPH. Cell viability was determined by
measuring release of lactate dehydrogenase (LDH) into the incubation media as
compared with the total LDH and expressed as % LDH release according to the
following equation.

% LDH release =

LDH released in the medium x 100%
LDH retained in cells + LDH released in the medium

LDH release in control vs. treated data per each incubation period was statistically
analyzed by One-Way ANOVA at 95% probability with a statistically significant
increase in LDH release indicative of toxicity.
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Transport Characterization and Experimentation
Materials
4-Acetamidophenyl-ring-UL-14C glucuronide sodium ([14C]AG) (Sigma, A-1329)
Dehydroepiandrosterone

sulfate

sodium

salt,

[1,2,6,7-3H(N)]

([3H]DHEAS)

(PerkinElmer LS, NET-860)
p-[Glycyl-1-14C]-Aminohippuric Acid ([14C]PAH) (PerkinElmer LS, NEC-563)
Estrone sulfate, ammonium salt, [6,7-3H(N)] ([3H]ES) (PerkinElmer LS, NET-203)
Acetaminophen (APAP) (Aldrich, A730-2)
Acetaminophen glucuronide (AG) (Sigma, A-4438)
Dehydroepiandrosterone sulfate sodium salt (Sigma, D-5297)

β−Estradiol 17β-D-glucuronide (Sigma, E-1127)
Estrone sulfate sodium salt (ES) (Sigma, E-0251)
Fluorescein isothiocyanate dextran (FLD) (Sigma, FD-4)
Fluorescein sodium salt (FL) (Sigma, F-6377)
p-Aminohippuric acid (PAH) (Sigma, A-1422)
Probenecid (Sigma, P-8761)
Ouabain (Sigma, O-3125)
ScintiVerse II, universal liquid scintillation cocktail (Fisher Scientific, SX12-4)
Equipment
Wallac 1409 liquid scintillation counter
Perkin-Elmer HTS 7000 bioassay reader
Dubnoff Incu-Shaker Model 3575
Innova 2000 Platform Shaker

Semipermeable membranes used for transport studies were purchased from
Fisher Scientific: 30 mm Millicell-PCF Millipore Millicell© Culture Plate Inserts
(early studies) or 24 mm Costar® Transwell-Clear polyester tissue culture treated
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microporous membranes. Transport media (TM) consisted of PBS with 5 mM
glucose or Waymouth's Buffered Transport Media (WBTM). Ingredients are listed
in the appendix. All reagents were purchased from Sigma Chemical Company
unless otherwise stated. When indicated, inserts were treated with 25 µg/insert
Type IV human placental collagen (Sigma, C-5533) prepared in 0.5 M glacial
acetic acid.

Transepithelial Transport
Four to nine day old monolayers of HK-2 cells grown on membranes were rinsed
with a transport media of phosphate buffered saline solution containing 5 mM
glucose (TM), pH 7.4. TM was added to both compartments of the insert: 1.5 ml
apical (A) and 2.6 ml basolateral (BL) (Figure 3.1). Monolayers were incubated for
10 min in TM to equilibrate. At time 0, substrate was added to the BL or the A
compartment (≤ 1% compartment volume) with gentle swirling to ensure even
concentration throughout media. In experiments studying both uptake and
clearance, incubation medium was prepared as a batch rather than per insert and
medium was aspirated from the outside of the plate before placing the insert into
the TM containing the substrate. Plates were incubated at 37oC, 5% CO2, 95% air
on an orbital shaker at 60 cycles per min. Upon expiration of the incubation
period, 1.0 ml aliquots were removed from each compartment and transferred to
microcentrifuge tubes.

Aliquots (100 µl) were then assayed in triplicate for

fluorescence with a Perkin-Elmer HTS 7000 bioassay reader (485/535 nm
excitation/emission). For radiolabeled substrates, 120 µl aliquots were removed
from each compartment and transferred to microcentrifuge tubes. Aliquots (30 50 µl) were transferred to scintillation vials to which 5 ml RIA-Solve II or Scintiverse
II Cocktail scintillant was added.

Samples were vortexed then assayed for

radioactivity using a Wallac 1409 liquid scintillation counter. For each experiment,
parallel plates were incubated with 100 µM FLD to determine paracellular diffusion
and/or non-specific uptake and efflux across the monolayer. To quantify transport,
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clearance of substrate was calculated as the volume of treated media totally
cleared of substrate and received into the trans compartment, normalized to the
surface area (SA) of the membrane. For BL to A transport,

Clearance

=

[ substrate ] A * Volume A
= [ µ l / cm
[ substrate ] BL * SA * time

2

/ min]

Clearance was corrected for diffusion by subtracting the clearance of FLD.
Diffusion Studies
Diffusion studies were conducted as transport studies (above) using fluorescein
isothiocyanate dextran (FLD) as the diffusing agent and expressed as µl/cm2 or

µl/cm2/min. To determine relative confluence of monolayers, diffusion rates of 3-7
day old monolayers were compared to diffusion rates of blank plates (no cells) at
time 5, 15, 30 and 60 min.

Figure 3.1. Microporous Membrane

Luminal (Apical)
Compartment

HK-2 Cells

Microporous
Membrane

Basolateral
Compartment

Secretion

Reabsorption
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Uptake Studies
Four to eleven day old monolayers seeded on Transwell membranes were used
for uptake studies.

Culture media from HK-2 monolayers was aspirated and

monolayers were then rinsed with transport media (TM or WBTM) warmed in a
37oC water bath. After thorough aspiration, 1.5 ml transport media was added to
the A compartment and at time 0, the insert was placed in the BL compartment
(one well of a 6-well plate) containing 2.6 ml transport media containing substrate
with or without inhibitors. For apical uptake studies, the insert was placed into the
BL compartment and transport media containing substrate was placed in the A
compartment at time 0. The monolayers were placed in an incubator at 37oC, 5%
CO2, 95% air or were placed in a 37oC water bath for the shorter incubation
periods (5 min or less). Upon expiration of the incubation period, the insert was
transferred to a well containing 2.6 ml ice-cold transport media and rinsed x 2 in a
total volume of 5 ml ice-cold transport media. The inserts were aspirated and the
bottom of each insert was blotted with a Kim® wipe unless otherwise indicated.
Various methods were used to collect and lyse the cells. Cells were either A)
solubilized overnight in 1 ml 0.1 N NaOH after removal of the membrane from the
insert housing; B) solubilized by the addition of 400 µl 1% SDS/0.1 N NaOH
directly to the intact membrane, placed on an orbital shaker at 120 cycles/min for
30 min, then neutralized with 200 µl 0.2 N HCl; or C) cells were scraped from the
membranes with a Teflon cell lifter and solubilized in 500 µl 1 N NaOH overnight,
neutralized by adding 250 µl 2 N HCl. Aliquots or entire lysates were assayed for
radioactivity using a Wallac 1409 liquid scintillation counter.

Uptake was

expressed as fmol/cm2/min or pmol/mg protein/min and was calculated by one of
the two the formulas:

Uptake ( fmol / cm 2 ) = DPM *

1uCi
1
umol 10^9 fmol 1
*
*
*
2.22 x10^6 DPM Activity uCi
umol
SA

Uptake ( pmol / mg ) = DPM *

1uCi
1
umol 10^ 6 pmol
1
*
*
*
2.22 x10^ 6 DPM Activity uCi
umol
mg protein
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in which DPM is the disintegrations per min as measured by the scintillation
counter, Activity is that indicated per isotope from the manufacturer and SA is the
surface area of the membrane. For those data expressed per mg protein, parallel
plates were used to determine protein by removing membranes from the housing
and lysing the cells in 1 ml 0.1 N NaOH overnight. Aliquots (5 µl) were used for
protein determination using a Biorad protein assay kit as described above on page
47.
Dynamic Model Uptake Studies
For the dynamic model, the uptake experiments were conducted as described
above but with the medium in the apical compartment replaced with fresh WBTM
by continuous simultaneous removal and replacement of medium over the
incubation period utilizing two disposable 1 ml pipettes. Medium was slowly added
with one pipette while removed at the same rate with the other pipette for a total
volume exchange of 9 ml.
Statistics
Each Millicell insert or Transwell membrane represents an N of 1. The data are
represented as means ± standard error of the mean (SEM) of N = 2 to 7
experiments. Statistical analysis between two groups was performed using the
Student's t-Test assuming equal variances or for multiple groups using One Way
ANOVA or Repeated Measures One Way ANOVA followed by a Dunnett's post
test for comparison back to control or by Tukey's method for multiple comparisons.
Significance was reported at p < 0.05.
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Western Blot Analysis
Materials
HK-2 human kidney, PTCs, transformed (ATCC, CRL-2190)
Fisher 344 rat PTCs (kindly provided by Sarah Miles, graduate student)
Human (56 year old Caucasian female) PTCs (kindly provided by Dr. LH Lash,
Wayne State USOM)
OAT1 antibodies, affinity pure (Alpha Diagnostic International, OAT11-A)
OAT2 antibodies, affinity pure (Alpha Diagnostic International, OAT21-A)
OAT3 antibodies, affinity pure (Alpha Diagnostic International, OAT31-A)
Endo H (endoglycosidase H) (New England Biolabs, P0702S)
Benchmark™ Pre-Stained Protein Ladder (Invitrogen, 10748-010) †
ECL™ Western Blotting Detection Reagents (Amersham Biosciences, RPN2106)†
Hyperfilm™ ECL high performance chemiluminescence film (Amersham Biosciences,
RPN2114K) †
Goat anti-rabbit IgG-HRP (Santa Cruz Biotechnology, SC-2004) †
Equipment
Trans-Blot Electrophoretic Transfer Cell (BioRad)†
Beckman Optimal XL-100K Ultracentrifuge, Rotor SW 60 Ti
Beckman J6 MI centrifuge, rotor 4.2
Beckman Avanti centrifuge, rotor J14
Micromax RF Centrifuge, International Equipment Company†

†

All reagents and equipment for Western blot analysis were kindly provided by Dr.

Kelley Kiningham.
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Cell Procurement
HK-2 cells were grown as described above on page 44. Human renal PTCs
were kindly provided by Dr. Lawrence Lash. F344 PTCs were isolated by Sarah
Miles according to the following procedure.
F344 PT isolation
Male Fischer 344 rats were anestisized (pentobarbital sodium, 50mg/kg,
i.p.) and renal proximal tubule (PT) fragments were isolated following the
procedure described by Gesek et al. (1987) and modified by Aleo et al. (1991).
Additional modifications were made, initiating renal retrograde perfusion by the
procedure of Jones et al. (1979).

Following perfusion, kidneys were

decapsulated, and cortical tissue dissected away from the medulla, minced, and
placed in a 50 ml plastic beaker with 25 ml of oxygenated collagenase containing
Incubation buffer (see appendix for composition). Digestion of cortical tissue was
initiated at 37ºC in a shaking waterbath (60 rpm) with continuous oxygenation.
After 15 min, solid kidney tissue was allowed to settle in the beaker and freed
PTs remaining in suspension in the incubation buffer were removed by transfer
pipette and placed in a 50 ml centrifuge tube. The suspension was centrifuged at
50 x g for 2 min at 4º C in a Beckman J6MI centrifuge (JS 4.2 rotor). The
supernatant was removed and reserved for further cortical tissue digestion and
the pellet was resuspended in oxygenated ice cold 1x Krebs-Henseleit (KH)
buffer (see appendix for composition) and kept on ice. The remaining tissue was
digested with an additional 25 ml of Incubation buffer for additional 5 min
intervals until cortical tissue was completely digested. Total incubation time was
typically 25 min.

PTs were removed at the end of each 5 min interval,

centrifuged as described and combined. The total pellet was then rinsed three
times by resuspension in 25 ml ice cold 1x KH buffer and centrifugation at 50 x g
for 2 min. The final PT pellet was then resuspended in 10 ml 1x KH buffer. This
suspension of PT tubules was then divided in half and each 5 ml resuspended in
polycarbonate round bottom centrifuge tubes each containing 30 ml oxygenated
55

45% Percoll solution (see appendix for compositon). A 5 ml 100% Percoll
cushion was then injected into the bottom of each tube using a transfer pipette
(Fig. 3.1A). PTs were then centrifuged at 17,000 x g for 10 min at 4º C in a
Beckman Avanti™ Ultracentrifuge (JA 14 rotor) stopping without brake.
Following centrifugation PTs formed a uniform layer above the cushion layer (Fig.
3.1B). This layer was removed using a transfer pipette, and rinsed three times in
1x KH buffer at 500 x g for 5 min at 4º C in a Beckman J6MI centrifuge (JS 4.2
rotor). PT pellets were stored at -80oC.

Cell Fractionation
Plasma membrane fractions and whole cell lysates of HK-2 cells were prepared
from 7 day old monolayers scraped from T75 flasks or from Transwell membranes,
pelleted at 270 x g and frozen. Cell pellets (HK-2, human PTC and F344 rat PTC)
were resuspended in 1 ml homogenization buffer (HB, appendix), homogenized
(15 slow strokes) and centrifuged (100 x g, 2 min) to remove intact cells. To
separate membrane from cytosolic fractions, 3 different methods were used. The
supernatants (whole cell lystes) were centrifuged at 100,000 x g for 1 hour at 4oC
(procedure provided by Dr. Mary Vore) to isolate crude membrane fractions or at
15,000 x g for 30 min at 4oC (Kikuchi et al., 2003) to isolate plasma membrane
fractions. Proteins from the membrane pellets were extracted in 100 - 200 µl HB
containing 1% Triton-X100 by frequent vortexing for 1 hour followed by overnight
tumbling at 4oC. The extracts were centrifuged for 30 min at 14,000 x g, 4oC and
the supernatants (membrane proteins) were assayed for protein content.
Deglycosylation
Selected samples were incubated for 2 hours at 37oC in a buffer containing 2500
units Endo H, a deglycosylating enzyme (Kit P0702S, New England BioLabs,
buffers supplied with the kit). As a control, an equal volume of water was added to
the incubating buffer instead of enzyme.
56

SDS-PAGE and Western Blot Procedure
Each sample was solubilized in loading buffer (4% sodium dodecyl sulfate,
62.6 mM Tris, 10% glycerol) with or without 5% 2-mercaptoethanol, loaded at 200250 µg HK-2 protein/lane and 100 µg F344 rat or human kidney PTC protein/lane
and separated by polyacrylamide gel electrophoresis on a 12.5% or 8% gel
overnight at 4oC (12.5% gel for 15 hours at 70 V; 8% gel for 15 hours at 74V).
Proteins were transferred onto a nitrocellulose membrane, blocked with 5% nonfat
dry milk in Tris-buffered saline containing 0.3% Tween 20 for 1 hour at 25oC and
incubated overnight at 4oC with anti-ratOAT1, OAT2 or OAT3 antibodies reported
by the manufacturer to be specific for respective OATs and cross-reactive with the
respective human orthologues (1:333, Alpha Diagnostics International).

The

bound antibody was detected on x-ray film by enhanced chemiluminescence with
horseradish peroxidase-conjugated anti-rabbit IgG antibody.
formulations are recorded in the appendix.
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Buffer and gel

CHAPTER IV. Results
Results
HK-2 Growth and Characterization
Growth of HK-2 cells was measured for cells grown in Keratinocyte Serum Free
Media (KSFM) for 4 days in the absence or presence of 2% or 5% FBS. No
significant effect was observed on proliferation in the presence of FBS (Table 7).
Protein content was numerically greater in the presence of FBS (Table 8), yet was
statistically insignificant.

Data for both studies were analyzed by One Way

ANOVA. Although no difference was demonstrated in the effect of FBS on growth,
the 2% FBS supplementation was favored and was adopted as standard
procedure for subculture and feeding. In HK-2 cells, with supplementation of 2%
FBS, the protein content per 106 cells was only half that of freshly isolated F344 rat
PTCs (550 µg protein/106 cells; Lash and Tokarz, 1989).
Table 7. Effect of FBS on Cell Proliferation
Medium

Harvest Density
Seeding Density

No. of
monolayers

KSFM

4.48 ± 0.41

3

+ 2% FBS

4.20 ± 0.35

4

+ 5% FBS

4.28 ± 0.29

11

Table 8. Effect of FBS on Protein Level
Medium

µg protein/106 cells

No. of
monolayers

KSFM

172 ± 54.2

4

+ 2% FBS

270 ± 25.2

6

+ 5% FBS

221 ± 18.0

6
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The growth rate of cells grown in T75 culture flasks in KSFM supplemented with
2% FBS was monitored over time, from passages 29 to 40. Cells were plated at a
density of 4.0 x 106 cells/T75 flask. After 7 days, cells were harvested. Table 9
summarizes the findings for harvest cell count and the harvest to seeding ratio.
Table 9. Growth Rate of HK-2 Cells
Grown in T75 Culture Flasks
Mean
SEM
Sample Size
7 Day Harvest Density
3.70
.067
Seeding Density
7 Day Harvest*
1.35 x 107 cells 3.5 x 105

10
4

* Seeded at 4.0 x 106 cells/T75

Characteristic renal tubule cell enzymes were measured for HK-2 cells grown in
35 mm culture dishes.

Gamma-glutamyltransferase (GGT) and Alkaline

Phosphatase (AP) are brush-border enzymes known to be expressed in the
proximal tubule (Lash and Tokarz, 1989).

Thus, high concentrations for both

enzymes were expected. Hexokinase (HK) is an enzyme involved in glycolytic
metabolism and is expressed at higher concentrations in the distal tubule than in
the proximal tubule (Lash and Tokarz, 1989). The results of the enzyme assays
are presented in Table 10. Typically, these enzymes are measured for freshly
isolated PTCs for comparison with the enzyme levels of freshly isolated distal
tubule cells (DTCs) to verify purity of the isolate or for comparison for levels for
primary culture PTC vs. DTC. Enzyme measurements in the case of a cell line are
more for the purpose of demonstrating presence of the enzyme in character with
the cell type. GGT levels for HK-2 cells were comparable to those found for
primary culture of F344 rat PTC (32.2 U/106 cells; Lash et al., 1995). HK-2 HK
levels were less than those of freshly isolated F344 rat PTC (111 U/106 cells; Lash
and Tokarz, 1989). AP could not be detected by a spectrophotometric assay,
however, the enzyme was positively detected with the use of a staining procedure.
This detection method is frequently employed for cell lines and has been used to
detect AP in HK-2 cells by other investigators as well (Raucusen, 1997).
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Table 10. HK-2 Cellular Enzyme Levels
Enzyme
GGT

HK

Level of Activity in HK-2 cells
32.93 ± 2.83 U/106 cells
126.67 ± 10.89 U/mg protein
57.06 ± 7.36 U/106 cells
219.46 ± 30.12 U/mg protein

AP

Stain +

GGT gamma-glutamyltransferase, HK hexokinase, AP alkaline phosphatase

Figure 4.1.1 is a photo of HK-2 cells grown in a T-75 culture flask.
Morphological characteristics of the cell line include stellate cytoplasmic processes
extending from the cell bodies. These processes are thought to be responsible for
cell migration. When cells are plated on hydrophilic porous membranes of MillicellCM inserts, fewer of these processes are present (Figure 4.1.2). For reasons
discussed in the Transport section below, these inserts were not used for transport
studies. HK-2 cells grown on Transwell-Clear inserts display shorter processes
(Figure 4.1.3), but when superseeded (1.41 x 106 cells/insert) onto the TranswellClear inserts, no migration is necessary, and very few processes are present
(Figure 4.1.4). Superseeding on Transwell-Clear inserts was selected for transport
studies and is discussed in more detail in the Transport section.
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Figure 4.1.1. HK-2 Cells plated on a T75 Culture Flask. Five day old HK-2
cells, passage 30, were seeded on a T75 culture flask at 4.0 x 106 cells. 100X
Magnification on Zeiss Axiovert Phase Contrast Microscope.

Figure 4.1.2. HK-2 Cells seeded on a Millicell-CM Microporous Membrane.
Five day old HK-2 cells, passage 29, were seeded on a Millicell-CM insert at 4.0 x
106 cells. 100X magnification on Zeiss Axiovert Phase Contrast Microscope.
61

Figure 4.1.3.

HK-2 Cells seeded on a Transwell Microporous Membrane.

Four day old HK-2 cells, passage 31, were seeded on a Transwell-Clear
membrane at 4.0 x 105 cells. 100X , Zeiss Axiovert Phase Contrast Microscope.

Figure 4.1.4.
Membrane.

HK-2 Cells superseeded on a Transwell-Clear Microporous
Three day old HK-2 cells were seeded on a Transwell-Clear

microporous membrane at 1.41 x 106 cells. 100X, Zeiss Axiovert Phase Contrast
Microscope.
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Molecular Analysis of Organic Anion Transporters
Western blot analysis of the organic anion transporters, OAT1 and OAT3, was
performed using crude membrane fractions isolated from Fisher 344 rat (F344)
PTCs and HK-2 cells (Figures 4.2.1 and 4.2.2). Figure 4.2.3 also contains a blot
for OAT2 demonstrating lack of detection of the protein in HK-2 cells. Lack of
OAT2 in HK-2 cells is not surprising since OAT2 is expressed at high levels in the
liver, but at low levels in the kidney. F344 rat PTCs were isolated in our lab by
Sarah Miles.
The blot shown in Figure 4.2.3 consists of plasma membrane fractions from
freshly isolated human PTCs isolated from renal cortical tissue of a 56 year old
caucasian female, kindly provided by Dr. Lawrence Lash, and from HK-2 cells.
Proteins were subjected to nonreducing vs. reducing homogenization buffer and
loading buffer and/or the deglycosylating enzyme EndoH as indicated in the
caption below the figure. No effects were apparent for membrane proteins treated
with reducing vs. nonreducing conditions or for those proteins incubated with
deglycosylating enzyme vs. control. Because no positive control was used for the
deglycosylating enzyme, it is possible that the enzyme was inactive.
For all blots, molecular weight is given for protein bands only above 50 kD
because the lower molecular weight proteins are thought to be due to incompletely
synthesized proteins.

Antibodies for OAT1 and OAT3, purchased from Alpha

Diagnostics International (ADI), were synthesized against peptides homologous to
the amino-terminus and would therefore bind whole and partial proteins. The
antibodies against OAT2, also from ADI, are synthesized against a peptide
homologous to the carboxy-terminus and would therefore bind completely formed
proteins only, as is evidenced by the detection of only 2 bands for F344 rat protein
(Figure 4.2.2). Additionally, bands reported by investigators as recorded in Table
4, Literature Review Section of this document are at 50 kD and greater and are the
bands to which HK-2 bands will be compared. For all entries in Table 4, antibodies
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were synthesized against peptides homologous to the carboxy-termini of the
proteins.
The only human OAT1 Western blots reported in the literature were those of
Cihlar et al. (1999) and Motohashi et al. (2002) who found bands at 80-90 kD and
84 kD, respectively. HK-2 blots performed for this study demonstrated bands at 80
(Figure 4.2.3) and 90 kD (Figures 4.2.1 and 4.2.2). Bands at 64 kD (Figure 4.2.1),
62 kD (Figure 4.2.2) and 65 kD (Figure 4.2.3) for HK-2 cells likely represent the
nonglycosylated OAT1 proteins with MW near the predicted value of 61.8 kD
(http://harvester.embl.de). Faint bands at 55.5 kD (Figure 4.2.1) and 54 kD (Figure
4.2.2) may represent lower MW isoform(s) of OAT1 whose molecular weights are
predicted to be 55.6 and 57.4 kD (http://harvester.embl.de). The heaviest bands
found in HK-2 cells for OAT1 are the 75 kD (Figures 4.2.1 and 4.2.2) and 80 kD
bands (Figure 4.2.3) which likely represent glycosylated forms of the OAT1
isoforms. The 75 kD bands are nearest to the 77 kD bands reported by Ji et al.
(2002) for rat OAT1. Collectively, the bands demonstrated for OAT1 in HK-2 cells
are similar to those reported in the literature for both nonglycosylated and
glycosylated proteins and, as such, are evidence of OAT1 expression in the HK-2
cell line.
The OAT1 bands demonstrated for F344 rat PTCs at 75 and 76 kD bands
(Figures 4.2.1 and 4.2.2, respectively) are near the 77 kD band reported by Ji et al.
(2002) for rOAT1 whereas the 61.3 and 60.4 kD bands (Figures 4.2.1 and 4.2.2)
are likely the nonglycosylated protein forms.
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OAT1

OAT3

kD
80.9

80.9

63.8

63.8

49.5

49.5

37.4

37.4
HK2

F344

HK2

F344

Figure 4.2.1. Western Blot Analysis for OAT1 and OAT3. Crude membrane
fractions (250 µg protein/lane) isolated from HK-2 cells, passage 29, scraped from
T75 flasks and from F344 rat PTCs were separated on a 12% polyacrylamide gel,
blotted onto nitrocellulose then exposed to antibodies against OAT1 or OAT3.
Bands were detected at 64 and 75 kD (arrows) with faint bands at 55.5, 69 and
90 kD for OAT1 in HK-2 cells. For OAT3 in HK-2 cells, bands were detected at 58
and 65 kD (arrows) with a faint band at 79 kD. In freshly isolated F344 PTCs,
bands were detected at 61.3 and 75 kD for OAT1, and faint bands for OAT3 were
detected at 54 and 63 kD.
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kD
113.7
80.9

63.8
49.5

37.4

26.0

HK2

F344

HK2

F344

HK2
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Figure 4.2.2. Western Blot Analysis for OAT1, OAT2 and OAT3.

Crude

membrane fractions (200 µg protein/lane) isolated from HK-2 cells, passage 20,
scraped from T75 flasks and from freshly isolated F344 rat PTCs were separated
on a 12% polyacrylamide gel, blotted onto nitrocellulose then exposed to
antibodies against OAT1, OAT2 or OAT3. The heaviest band was detected at
75 kD with lighter bands at 62, 69, 90 and 107 kD (arrows) and a faint band at
54 kD for OAT1; and 57, 69, 77 and 80 kD (arrows) with a faint band at 63 kD for
OAT3 in HK-2 cells. No bands were detected in HK-2 cells for OAT2. A heavy
band was detected for freshly isolated F344 PTCs at 60.4 kD with a moderate
weight band at 76 kD for OAT1. Bands were detected at 39 and 44 kD for OAT2
in F344 PTCs and at 54 kD with a lighter band at 63 kD for F344 OAT3.
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Figure 4.2.3. Western Blot Analysis for OAT1 and OAT3, Human vs. HK-2.
Plasma membrane fractions isolated from freshly isolated human renal proximal
tubule cells (hPTC; 63 µg protein/lane) or from HK-2 cells, passage 50, grown in
T75 flasks (200 µg protein/lane) were separated on an 8% polyacrylamide gel,
blotted onto nitrocellulose then exposed to antibodies against OAT1 or OAT3. For
the human cells, the strongest band was detected at 148 kD with a medium
density band at 62 kD and a lighter band at 81 kD for OAT1. Bands were detected
in HK-2 cells at 80 kD, a medium density band at 65 kD and faint bands at 111 and
148 kD for OAT1. For OAT3, bands for the HK-2 fractions were detected at 50,
59, 63, 73 and 79 kD. Because the quality of the blot was poor, lanes containing
human proteins are not displayed above, but bands were detected at 54 and 62 kD
for OAT3. For the OAT1 blot, lane 1 protein was denatured but not reduced; lane
2 was reduced; lane 3 proteins were incubated with a reducing agent and a
deglycosylating enzyme and lane 4 proteins were denatured but not reduced or
deglycosylated. For the OAT3 blot, lane 1 proteins were incubated with a reducing
agent and a deglycosylating enzyme and lane 2 proteins were denatured but not
reduced or deglycosylated.
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Peptide alignment of the hOAT1 isoform b (550 aa) vs. isoform a (563 aa)
shows an excision of residues 522-534 to form the splice variant, isoform b. The
antibody produced by Cihlar et al. (1999) that demonstrated an 80-90 kD band
which resolved to a 60 kD band upon deglycosylation was raised against a
synthetic peptide of aa 515-528 of a 550 aa hOAT1. The antibodies likely would
not bind to isoform a or isoform d since these latter isoforms contain a 13 aa
sequence between residues 521 and 522 of isoform b, see Figure 4.2.4. It is also
possible that the very broad band at 80-90 kD and also at 60 kD (deglycosylated)
(Cihlar et al., 1999) are immunoreactive bands to multiple isoforms of hOAT1.
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Figure 4.2.4. Alignment of hOAT1 isoforms. Alignment of hOAT1 isoform b
(550 aa) with (1) isoform a (563 aa) and (2) isoform d (519 aa) demonstrates the
existence of an sequence of 13 aa excised from isoform b between residues 521
and 522. Analyzed by accelrys SeqWeb version 2 web-based software.
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The only known human Western blot for OAT 3 was performed by Motohashi et
al. (2002) demonstrating a very broad band at 80 kD. The strongest most well
defined band for the HK-2 plasma membrane proteins was at 80 kD (Figure 4.2.3).
HK-2 crude membrane fractions demonstrated 79 kD bands (Figures 4.2.1 and
4.2.2). Each HK-2 blot had a band near the predicted MW for OAT3 (62 kD;
http://harvester.embl.de) with bands at 65 kD (Figure 4.2.1) and 63 kD (Figures
4.2.2 and 4.2.3). Other bands found for OAT3, such as 58 kD (Figure 4.2.1),
57 kD (Figure 4.2.2) and 59 kD (Figure 4.2.3) may represent the lower MW isoform
of OAT3 estimated to be at 59.9 kD (http://harvester.embl.de). The 69, 77 kD
(Figure 4.2.2), 50 and 73 kD (Figure 4.2.3) bands demonstrated for HK-2 cells are
similar to those reported for rat OAT3 (Table 4, Literature Review). Collectively,
the bands demonstrated in HK-2 cells are similar to the bands reported in the
literature or are near the predicted MW for OAT3 and, as such, are evidence of the
expression of OAT3 in the HK-2 cell line.
The 54 and 63 kD OAT3 bands demonstrated for F344 rat PTCs (Figures 4.2.1
and 4.2.2) are identical to those reported in the literature (Table 4, Literature
Review).
Again, as with OAT1, the OAT3 Western blot by Motohashi et al. (2002) may not
detect all isoforms of OAT3. Alignment at the sequence used by Motohashi et al.
(2002) to raise antibodies against the 568 aa hOAT3 reveals a 3 aa sequence at
the beginning of the synthetic peptide that is absent from the shorter version of the
protein (see Figure 4.2.5). It is possible then, that the Western analysis performed
by Motohashi et al. (2002), which demonstrated a very broad band at 80 kD would
not have demonstrated a band for the shorter isoform. It is also possible that the
width of the band would encompass multiple isoforms.
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495 TLNQP................LPETIEDLE............NWSLRAKK 516
||| |
| :
|
. |||||
493 TLNSPCQRRSKTWKTGQSLPLAPSVLLPGEAGLGPGLFLSSLSLGLRAKK 542
.
.
517 PKQEPEVEKASQRIPLQPHGPGLGSS 542
||||||||||||||||||||||||||
543 PKQEPEVEKASQRIPLQPHGPGLGSS 568

Figure 4.2.5.

Alignment of 568 aa vs. 542 aa hOAT3 sequences at the

carboxy- termini.

The highlighted sequence represents the synthetic peptide

sequence used by Motohashi et al. (2002) to raise antibodies against OAT3. The
3 aa residues at 509-511 of the 542 aa hOAT3 protein (upper sequence)
represents an area of non-homology to the peptide sequence for the shorter
isoform of OAT3. Analyzed by accelrys SeqWeb version 2 web-based software.
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Toxicity Studies

Before transport studies were conducted, it was necessary to ensure that the
model compound for transport studies, AG, was not toxic to the HK-2 cells.
Toxicity studies were performed for AG and the parent compound acetaminophen
(APAP) by measuring LDH release from the cells after incubating the cells in
medium containing 200 µM and 500 µM AG (Figure 4.3.1) or APAP (Figure 4.3.2).
It was determined that neither AG nor APAP caused an increase in the release of
LDH, indicating no cytotoxicity from either compound for incubations up to 120
min. Parallel studies were conducted in our lab for freshly isolated PTCs from
F344 rats with similar findings (unpublished data, Sarah Miles). Additionally, ATP
studies were performed with freshly isolated F344 PTCs and no decrease in ATP
levels was found at 200 or 500 µM AG or APAP incubation (unpublished data,
Sarah Miles). It was, therefore, concluded that at 200 and 500 µM, neither APAP
nor AG were cytotoxic to HK-2 or F344 PTCs for up to 120 min exposure.
Transport of organic anions is considered to be an energy consuming process.
Toxicity to cells would, therefore, result in altered transport capability.

Higher

concentrations of AG (2.5 mM) were used in transport studies with no effect on the
ability of the HK-2 cells to transport AG (uptake or transepithelial), thus, AG
appears not to be cytotoxic at concentrations up to 2.5 mM for 5 min. Ninety min
incubation with 20 µM resulted in an intracellular AG concentration much higher
than that at 250 or 500 µM AG for 5 min and caused no alteration in the ability to
transport. Therefore, there is additional evidence that AG is not cytotoxic to HK-2
cells when used for the time periods of this study.
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Figure 4.3.1. Percent LDH Release for AG Treated HK-2 Cells. To determine if
AG is cytotoxic to HK-2 cells, 5-7 day old HK-2 monolayers grown on 35 mm
plates were rinsed with incubation medium (phosphate buffered saline solution
(PBS) with 5 mM glucose), then placed in incubation medium in the absence or
presence of 200 µM or 500 µM AG for 30, 60 or 120 min. Separate plates were
used for each incubation period. Upon expiration of the incubation period, medium
from each plate was sampled and assayed for LDH activity. Cells were scraped
from the plates, and solubilized in a 1% Triton-X100 solution and assayed for LDH.
Each bar represents the LDH released from the cells into the medium expressed
as a percent of the total LDH (remaining in the cells + released into the medium)
+/- SEM for 4 HK-2 monolayers. There was no statistical difference for control vs.
treated in LDH release at 30 or 60 min. *Percent LDH release for the 500 µM AG
treatment at 120 min was significantly lower than control as analyzed by One Way
ANOVA with Dunnett's Post Test, p < 0.05.
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Figure 4.3.2. Percent LDH Release for APAP Treated HK-2 Cells. To
determine if APAP is toxic to HK-2 cells, HK-2 monolayers grown on 35 mm
plates were rinsed with incubation medium (phosphate buffered saline solution
(PBS) with 5 mM glucose), then placed in incubation medium in the absence or
presence of 200 µM or 500 µM APAP for 30, 60 or 120 min. Separate plates
were used for each incubation period. Upon expiration of the incubation period,
medium from each plate was sampled and assayed for LDH activity. Cells were
scraped from the plates, and solubilized in a 1% Triton-X100 solution and
assayed for LDH. Each bar represents the LDH released from the cells into the
medium expressed as a percent of the total LDH (remaining in the cells +
released into the medium) +/- SEM for 4 HK-2 monolayers. There was no
statistical difference in LDH release for control vs. treated at 30 or 60 min.
*Percent LDH release for the 200 µM AG treatment at 120 min was significantly
lower than control as analyzed by One Way ANOVA with Dunnett's Post Test,
p < 0.05.
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Transport Studies
HK-2 Monolayer Confluence and FL Transport
HK-2 cells were first characterized for transport by determining their ability to
form confluent monolayers such that transport processes were distinguishable from
diffusion. Two different types of inserts were studied and several growth conditions
were examined to determine optimal confluence and transport function. Transport
models were selected based on the ability to form the most confluent monolayers as
demonstrated by the lowest rate of FLD diffusion while also demonstrating
polarization on the monolayer via vectorial transport of FL.
In the initial studies, HK-2 monolayers were seeded onto Millicell-PCF inserts for
transport studies. These membranes were opaque and thus, visualization of the
monolayer under microscopy was not possible.

To study confluence of the

monolayers, experiments were performed to determine FLD diffusion across the
monolayers in comparison to diffusion on blank inserts (Figure 4.4.1). The FLD rate
of diffusion for 5-10 day old monolayers was consistently lower than the diffusion
rate on blank inserts from 15 to 120 mins. However, the rate of FLD diffusion across
the monolayers was still high.
In an attempt to improve confluence (decrease diffusion), the Millicell-CM inserts
were tested. These inserts are clear and permit visualization of the monolayer by
phase contrast microscopy (Figure 4.1.2). It was noted that there was an acellular
margin around the perimeter of the monolayer when the cells were grown on
Millicell-CM inserts. Moreover, the Millicell-CM and the Millicell-PCF membranes
appeared to be slightly concave which may have caused cells to drift to the center of
the membrane before attaching, resulting in the high rate of diffusion. The cell
morphology on the Millicell-CM inserts appeared more compact, round and with
fewer cytoplasmic processes as compared to cells grown on culture flasks.
As an alternative to the Millicell inserts, the Transwell-Clear inserts were tested.
Monolayers (Figure 4.1.3.) appeared to be uniformly distributed across the
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membrane with cells extending to the insert housing, indicating improved confluence
on the Transwell-Clear vs. the Millicell-CM inserts. A confluence study by FLD
diffusion was conducted for the Transwell-Clear inserts (Figure 4.4.2.), indicating
improved confluence relative to the Millicell-PCF inserts.
Clearance studies with the OAT1/OAT3 substrate FL demonstrated vectorial
transport with BL-A clearance greater than A-BL for both monolayers grown on
Millicell-PCF and Transwell-Clear inserts (Figure 4.4.3). The BL-A/A-BL clearance
ratio was greater for the Millicell-PCF inserts.

However, due to the improved

confluence and the ability to visualize the cells under microscopy, it was decided
that the Transwell-Clear inserts were a better choice for this study. For all studies
involving the transport of FL, clearance rates are corrected for FLD diffusion.
To understand the differences in vectorial transport for the 2 models, directional
diffusion of FL on blank Millicell-PCF vs. Transwell-Clear inserts was studied. It was
demonstrated that on Transwell-Clear inserts, FL diffuses at nearly twice the rate in
the A-BL direction than the BL-A direction vs. nearly the same rate in each direction
on Millicell-PCF inserts (Figure 4.4.4). For both models, FL diffusion was greater
than FLD diffusion. When corrected for FLD diffusion on the blank inserts, the ratio
of A-BL/BL-A diffusion of FL was greater than unity (A-BL > BL-A) for TranswellClear inserts and less than unity (A-BL < BL-A) for Millicell-PCF inserts (Figure
4.4.5). These ratios suggest that the differences in diffusion rates of FL and FLD on
Transwell-Clear vs. Millicell-PCF inserts may contribute to the difference in vectorial
transport of FL for HK-2 monolayers on the respective inserts (Figure 4.4.3).
A time-dependent clearance study of FL by cells grown on Transwell-Clear
inserts demonstrated a nearly linear clearance for FL with time. Kinetic analysis of
the clearance of FL was best described by a rectangular hyperbolic regression with
a first order term for diffusion (Figure 4.4.6). This analysis revealed that diffusion of
FL across the monolayers increased with time to a greater extent than did transport
of FL. A table is included in the figure listing the percent of FL clearance due to
diffusion. As in all clearance studies, the FL clearance for the time-dependent
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uptake was corrected for FLD diffusion. Thus, the rate of FL diffusion is greater than
that of FLD across HK-2 monolayers seeded on Transwell-Clear inserts.

High

substrate diffusion has the effect of diminishing differences in clearance rates for
control vs. treated experiments, such that, as diffusion increases, differences in
protein-mediated processes are less evident and the clearance rate for treated cells
when expressed as a percent of control approaches 100%.
To determine if increased oxygenation would improve confluence of the
monolayers (Groves et al., 1999b), beginning the day after seeding, growth of
monolayers placed on an orbital shaker vs. a stationary shelf were compared for
diffusion of FLD and transport of FL (Figure 4.4.7). There was a slight increase in
the diffusion of FLD on the shaker-grown monolayers suggestive of decreased
confluence. There was no difference in the clearance of FL. Because ascorbic acid
has been shown to improve monolayer confluence under shaking conditions (Nowak
et al., 1996), the addition of ascorbate phosphate (AscP) to shaking monolayers was
tested (Figure 4.4.8). No improvement in confluence was demonstrated by the
addition of 100 µM AscP to shaking monolayers.
For studies on the Millicell-PCF inserts and early studies on the Transwell-Clear
inserts, the seeding density was 4.0 x 105 cells/insert. The seeding density was
increased to a superconfluent density of 1.41 x 106 cells/insert for later studies on
the Transwell-Clear inserts and is indicated herein as superseeded (Whitin et al.,
2002).

When viewed under phase contrast microscopy, the superseeded

monolayers appeared to form a much tighter monolayer as compared with the lower
seeding density monolayers in which growth was required to attain confluence
(Figure 4.1.4). The cells also displayed fewer cytoplasmic processes, which are
thought to be responsible for cell migration. Diffusion of FLD also decreased for
superseeded monolayers (Figure 4.4.9).
With cells seeded at superconfluence, growth of cells to form the monolayer is
unnecessary. Thus, the absence of epidermal growth factor (EGF) in the culture
medium was tested to determine the effect on transport (Figure 4.4.10). There was
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no statistical difference in the clearance of FL for cells grown with vs. without EGF.
It was, therefore, decided that EGF was not a necessary component of the media for
superseeded cells and EGF was excluded from the culture media for superseeded
monolayers.
To summarize the model-selection criteria: Initial studies were performed on
Millicell-PCF inserts. Although FLD diffusion rates were determined to be higher for
blank inserts than those with HK-2 monolayers, concern of incomplete confluence
across the insert leading to high diffusion and inability to visualize the monolayers
led to the search for another insert. Comparison of diffusion for monolayers seeded
on Millicell-PCF inserts vs. those seeded on Transwell-Clear inserts prompted
selection of the latter for future studies even though vectorial transport of FL by
monolayers seeded on the Millicell-PCF was higher than that of the Transwell-Clear
inserts. Differences in directional diffusion of FL for Transwell-Clear inserts (A-BL >
BL-A) but similar directional diffusion of FL on the Millicell-PCF inserts as well as
differences in FL vs. FLD diffusion on the 2 insert types may contribute to the
differences in vectorial FL transport between the insert types. Regression analysis
of a time-course study of FL transport for monolayers seeded on Transwell-Clear
inserts revealed that the rate of FL diffusion was greater than FLD diffusion and,
over time, exceeded the rate of FL transport. This finding could also be explained
by an increased rate of apical efflux of FL over time. Addition of AscP to the
medium and/or use of an orbital shaker to increase aeration during cell growth did
not significantly affect confluence of the monolayers.

Superseeding resulted in

slightly decreased FLD diffusion with improvement in the tightness of the monolayer
with fewer cytosolic processes as judged by phase contrast microscopy, and,
therefore, was selected as the preferred seeding density for subsequent studies.
Use of EGF as a media supplement to superseeded monolayers was determined to
be unnecessary as there was no significant difference in transport of FL with vs.
without supplementation. Therefore, subsequent studies with superseeded
monolayers were grown in medium without EGF.
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Diffusion of Fluorescein-Dextran for Millicell-PCF Inserts
Blank Inserts vs. 4-10 day old HK-2 Monolayers
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Figure 4.4.1.

HK-2 Monolayer Confluence Study on Millicell-PCF Inserts.

Confluence of 5 to 10 day old HK-2 monolayers seeded on Millicell-PCF inserts
was evaluated by comparing BL to A FLD diffusion across the monolayer vs. BL to
A FLD diffusion across blank (no cells) inserts. Monolayers were equilibrated in
TM, aspirated, placed in TM to which FLD was added basolaterally and incubated
for the respective period at 37oC, 5% CO2/95% air, as described. Parallel inserts
were used for each incubation period. Aliquots (100 µl) from each compartment
were assayed in triplicate for fluorescence. For each incubation period, the
diffusion for the blank inserts is significantly greater than that of all other groups, as
analyzed by One-Way ANOVA followed by Tukey's All-Pairwise Comparison Test,
p < 0.05. Each data point represents the mean diffusion ± SEM for 3 inserts.
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Diffusion of Fluorescein-Dextran for Transwell-Clear permeable membranes
Blank inserts vs. HK-2 cell monolayers grown for 3 to 7 days
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Figure 4.4.2. HK-2 Monolayer Confluence Study on Transwell-Clear Inserts.
Confluence of 3, 5 and 7 day old HK-2 monolayers seeded on Transwell-Clear
inserts was evaluated by comparing BL to A FLD diffusion across the monolayer
vs. BL to A FLD diffusion across blank (no cells) inserts.

Monolayers were

equilibrated in TM, aspirated, placed in TM to which FLD was added basolaterally
and incubated for the respective period at 37oC, 5% CO2/95% air, as described.
Parallel inserts were used for each incubation period; n = 3 per group. Aliquots
(100 µl) from each compartment were assayed in triplicate for fluorescence.
Diffusion is expressed in µl/cm2 for each incubation period.

The increased

diffusion for the blank inserts is significantly greater, per incubation period, than
diffusion for the corresponding groups, as analyzed by One-Way ANOVA followed
by Tukey's All-Pairwise Comparison Test within a 95% confidence interval.
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Figure 4.4.3.
Inserts.

Fluorescein Clearance
on Transwell-Clear inserts

B

BL-A

A-BL

BL-A / A-BL ratio
3.47
1.67

Vectorial Transport of FL on Millicell-PCF vs. Transwell-Clear

Directional transport of FL was determined for Millicell-PCF and

Transwell-Clear inserts. Five day old HK-2 monolayers seeded onto respective
inserts were equilibrated for 10 min in TM at 37oC, 5% CO2/ 95% air, aspirated of
media, placed in TM with 4 µM FL added basolaterally or apically, and incubated
for 15 min at 37oC, 5% CO2/ 95% air on an orbital shaker at 60 cycles/min.
Compartmental samples were collected, aliquots (100 µl) were assayed for
fluorescence and clearance rates calculated. *A-BL clearance was significantly
less than BL-A clearance for both insert types as determined by Student's t-Test
per insert type, p < 0.05, n = 3 per group. The BL-A vs. A-BL ratio of FL for
Millicell-PCF was twice that for Transwell-Clear inserts.
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Figure 4.4.4.

A-BL / BL-A ratio
FL
1.18
1.88

FLD
2.65
4.87

Diffusion of FL on Blank Inserts: Transwell vs. Millicell.

Directional diffusion of FL across blank (no cells) Transwell-Clear inserts and
Millicell-PCF inserts was determined by incubating inserts in TM with 4 µM FL in
the A vs. BL compartment for 15 min on an orbital shaker at 60 cycles/min at 37oC,
5% CO2/95% air. *BL-A diffusion of FL is significantly less than A-BL FL diffusion
on Transwell-Clear inserts and than BL-A or A-BL FL diffusion on Millicell-PCF
inserts. There is no significant difference in the directional diffusion of FL on
Millicell-PCF inserts.

Statistics: One Way ANOVA with Tukey All Pairwise

Comparison for Multiple Groups, p < 0.05; n = 2 per group. Additionally, the ratio
of A-BL vs. BL-A FL diffusion for each insert type was calculated with A-BL
diffusion nearly double that of BL-A for the Transwell-Clear inserts vs. nearly equal
directional diffusion for the Millicell-PCF inserts.
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FL - FLD Diffusion on Blank Inserts
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Figure 4.4.5. Comparison of Directional FL Diffusion Corrected for FLD Diffusion on
Blank Millicell-PCF vs. Transwell-Clear Inserts. To compare the directional rates of
diffusion of FL minus FLD, blank Millicell-PCF and Transwell-Clear inserts were incubated
for 15 min in TM containing 100 µM FLD or 4 µM FL on an orbital shaker at 60 cycles per
min at 37oC, 5% CO2, 95% air. Samples were taken from both compartments per insert,
100 µl aliquots were assayed for fluorescence and diffusion rates were calculated. FL
diffusion rates were corrected for FLD diffusion by calculating their difference, FL - FLD
diffusion. The A-BL/BL-A ratios of the diffusion rates of FL corrected for FLD were then
calculated for both insert types.

There was no statistical difference in the FL - FLD

diffusion in the A-BL direction than BL-A direction for Transwell-Clear or Millicell-PCF
blank inserts as determined by Student's t-Test, p < 0.05. Each bar represents mean
diffusion +/- SEM of 2 inserts (3 for Transwell-Clear FL diffusion).
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Figure 4.4.6.

Time-Course of Clearance of 4 µM FL.

The time-course

clearance for 4µM FL was performed on parallel five day-old HK-2 monolayers
grown of Transwell-Clear inserts. HK-2 monolayers were equilibrated in TM for 10
min.

FL (4 µM final concentration) was added to the BL compartments and

monolayers were incubated on an orbital shaker at 60 cycles/min at 37oC, 5%
CO2/95% air. Samples were withdrawn from the BL and A compartments at time
2, 5, 15, 30, 45 and 60 min. Aliquots (100 µl) were assayed for fluorescence and
clearance rates determined. Each data point represents the mean clearance for 3
monolayers +/- SEM. Linear regression yields R2 = 0.987 whereas a rectangular
hyperbolic regression yields an R2 of 0.996 such that the clearance (Cl) at any time
(t) can be calculated by the equation: Cl = (10.62 * t)/(11.4 min + t) + 0.55 * t.
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Figure 4.4.7. The Effects of Shaker-Grown vs. Stationary-Grown Monolayers
on Confluence and Transport. HK-2 monolayers seeded on Transwell-Clear
inserts were grown in an incubator at 37oC, 5% CO2/95% air. Beginning on the
day after seeding, 6 monolayers were grown on an orbital shaker at 60 cycles/min
and 6 monolayers remained on a stationary shelf. Five day old monolayers were
equilibrated in TM for 10 min on the shaker at 60 cycles per min, aspirated, placed
in TM with 100 µM FLD or 4 µM FL added to the BL compartment. All monolayers
were incubated at 37oC, 5% CO2/95% air for 60 min on an orbital shaker at 60
cycles/min. Samples were collected from both compartments of the inserts and
100 µl aliquots were assayed for fluorescence. (A) No significant difference was
demonstrated in FLD diffusion for control vs. shaker-grown cells (Student's t-Test,
p < 0.05, n = 3 per group). (B) No difference was seen for control vs. shakergrown cells for the clearance of FL when corrected for diffusion (n = 3 per group).
Each bar represents mean clearance +/- SEM.
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Figure 4.4.8.

+ Asc-P

The Effects of Ascorbate Phosphate in Shaker-Grown

Monolayers on Confluence.

HK-2 monolayers seeded on Transwell-Clear

inserts were grown in an incubator at 37oC, 5% CO2/95% air. Beginning on the
day after seeding, 6 monolayers were grown on an orbital shaker at 60 cycles/min,
3 of which received 100 µM AscP daily.

Five day old monolayers were

equilibrated in TM for 10 min on the shaker at 60 cycles per min, aspirated, placed
in TM with 100 µM FLD added to the BL compartment.

Monolayers were

incubated at 37oC, 5% CO2/95% air for 15 min on an orbital shaker at 60
cycles/min. Samples were collected from both compartments of the inserts and
100 µl aliquots were assayed for fluorescence. There is no statistical difference in
the diffusion of FLD for the 2 groups. Each bar represents the mean diffusion +/SEM for 3 monolayers.
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Figure 4.4.9. FLD Diffusion for Normal vs. Superseeded Monolayers. The
FLD diffusion rates calculated for various transport studies by 5 to 7 day old HK-2
monolayers seeded at 4.0 X 105 cells/insert or superseeded at 1.41 X 106
cells/insert on Transwell-Clear inserts were compared. The diffusion rates were
determined by incubation of monolayers for 5 or 15 min in 100 µM FLD. The
media from each compartment per insert was sampled, aliquots (100 µl) were
assayed for fluorescence and diffusion rates calculated.

*For 5 and 15 min

incubation periods, the rate of FLD diffusion for the superseeded monolayers was
statistically lower than that of the normally seeded monolayers.

Data was

analyzed by Student's t-Test per incubation period, p < 0.01; n = 3 for normally
seeded; n = 2 for superseeded monolayers. Each bar represents mean diffusion
+/- SEM.
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The Effect of Epidermal Growth Factor (EGF) in Culture

Medium on FLD Diffusion and FL Clearance. To compare the effects of cells
grown in culture medium with or without EGF supplementation, cells superseeded
on Transwell-Clear inserts were cultured and maintained in standard culture
medium with (standard) or without EGF (5 ng/ml) supplementation. Five day old
monolayers were equilibrated for 10 min in TM, aspirated, then placed in TM with
100 µM FLD (A) or 4 µM FL (B) added to the BL compartment and incubated at
37oC, 5% CO2/95% air for 15 min on an orbital shaker at 60 cycles/min. Samples
were taken from both compartments and diffusion or clearance rates determined
as described. A) EGF in the culture medium had no effect on the rate of FLD
diffusion. B) There was a 22% increase in the clearance of FL for the cells grown
without EGF supplementation that was statistically insignificant by Student's t-Test
at a 95% confidence interval. Each bar represents the mean clearance +/- SEM
for 2 monolayers for the FLD diffusion study and 3 monolayers for the FL
clearance study.

87

Characterization of FL Transport
HK-2 monolayers seeded or superseeded on Transwell-Clear inserts, as
indicated per study, were used to study FL transport and those factors that affect
FL transport. To determine if the transport of FL across the HK-2 monolayer was a
protein-mediated process, temperature-dependent transport was evaluated by
comparing FL clearance at 37oC vs. 4oC (Figure 4.5.1). The significant reduction
in transport at 4oC is consistent with transport mediated by a protein such as an
organic anion transporter.
To demonstrate that the cells are polarized on the membranes of the TranswellClear inserts, uptake of FL from the BL vs. A compartment was performed (Figure
4.5.2). Uptake is significantly higher from the A compartment than from the BL.
This demonstrates polarization of the monolayer and is consistent with higher
permeability of the BBM to FL (Dantzler, 2002).
Because sodium butyrate has been demonstrated to upregulate expression of
the organic anion transporters (Sugiyama et al., 2001), 24 hour pretreatment of
HK-2 cells with sodium butyrate was tested.

Although the addition of 5 mM

sodium butyrate to the culture medium 24 hours prior to experimentation caused a
significant increase in FL clearance at 15 and 30 min (Figure 4.5.3), the difference
was only minor in this model and, therefore, was not adapted as a standard
procedure.
The cardiac glycoside ouabain, which inhibits the Na/K-ATPase, and thus, Na+dependent OAT1-mediated transport, was used to study OAT1-mediated FL
transport. Differing effects on the transport of FL were observed for monolayers
that were preincubated with ouabain compared to monolayers with no
pretreatment.

For monolayers coincubated only, the effect of ouabain on FL

transport was determined for 2, 5 and 15 min (Figure 4.5.4, A). For the 2 and 5
min incubation periods, the trend was a decreasing inhibitory effect of ouabain on
FL clearance with time. By 15 min, there was no difference in FL clearance for
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treated vs. control. To determine long term effects of ouabain on FL transport,
monolayers were first preincubated with or without ouabain prior to the addition of
FL. For these monolayers, preincubated for 30 min with 100 µM ouabain, then
coincubated with 4 µM FL, the 15 min clearance of FL increased compared to
control (Figure 4.5.4, B). Thus, the acute effect of ouabain on FL clearance is
inhibitory, diminishing with time, whereas, the long term effect appears to be
stimulatory. The acute, inhibitory effect of ouabain is consistent with FL transport
by OAT1, but the long term effect suggests that there are compensatory effects
that increase FL transport. For subsequent studies, a shorter incubation period
may be favorable to minimize compensatory effects.
The OAT1/OAT3 exchange substrate αKG and the OAT1/OAT3 inhibitor
probenecid were found to effect transport of FL (Figure 4.5.5). Cells preloaded
with the dicarboxylate showed increased FL clearance suggestive of transstimulation of FL uptake. Coincubation of FL with probenecid resulted in inhibition
of FL clearance. Both results are consistent with transport of FL by an organic
anion exchanger such as OAT1 and possibly OAT3.
Inhibition studies of FL transport by the OAT1/OAT3 substrate PAH and the
OAT3 substrate DHEAS demonstrated no statistical difference in the 15 min
clearance of FL by PAH (Figure 4.5.6) and a 10% decrease in the 15 min
clearance of FL by DHEAS (Figure 4.5.7).
To summarize characterization of FL transport by HK-2 monolayers seeded or
superseeded on Transwell-Clear inserts: Temperature-dependent clearance of FL
indicated that transport of FL is protein-mediated. Greater uptake of FL from the A
vs. BL compartment is consistent with a polarized monolayer exhibiting higher
permeability of FL at the BBM. Preincubation of HK-2 monolayers with sodium
butyrate for 24 hours slightly increased FL transport, but not enough to warrant
incorporation of this step into standard procedure. Consistent with transport by
OAT1 and/or OAT3, FL clearance was increased by preincubation with αKG and
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decreased by coincubation with probenecid, DHEAS and ouabain.

Possible

distortion of modulatory effects due to the high rate of diffusion and the potential
for compensatory effects as shown in the ouabain study led to the decision to
conduct subsequent studies for substrate uptake rather than clearance and over a
shorter incubation period.
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Figure 4.5.1. Temperature-Dependent Clearance of FL. A comparison of FL
clearance at 4oC vs. 37oC was performed. Three day old HK-2 monolayers were
equilibrated for 10 min in TM at 37oC, 5% CO2/ 95% air, aspirated, placed in icecold TM or in 37oC TM, both with 4 µM FL in the BL compartment. Monolayers
were incubated for 5 min at 4oC on an orbital shaker at 60 cycles/min or in a 37oC
shaking water bath. Samples were taken from both compartments and 100 µl
aliquots were assayed for fluorescence. A parallel procedure was conducted for
FLD diffusion and FL clearance was corrected for diffusion as described.
Clearance of 4 µM fluorescein was significantly lower at 4oC vs. 37oC.

The

difference in clearance was statistically analyzed by Student's t-Test, p < 0.05;
n = 3 and 4 for 37oC and 4oC treatments, respectively.
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Figure 4.5.2. BL vs. A Uptake of FL. The rate of FL uptake from the BL vs. the
A compartment was studied by incubating five day old HK-2 monolayers seeded
onto Transwell-Clear inserts in TM containing 4 µM FL in the BL vs. the A
compartment.

Monolayers were equilibrated in TM for 10 min, aspirated and

placed in TM containing 4 µM FL in the BL or in the A compartments. Monolayers
were incubated for 15 min on an orbital shaker at 60 cycles per min, 37oC, 5%
CO2, 95% air. After 15 min, monolayers were rinsed twice in ice-cold TM, lysed in
0.1 N NaOH and assayed for fluorescence. There is a 4.5-fold greater uptake of
FL from the A vs. the BL compartment. *The difference is statisically significant by
Student's t-Test, p = 0.0001. Each bar represents the mean uptake +/- SEM for 3
monolayers.
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Figure 4.5.3. The Effects of Sodium Butyrate on FL Transport. To determine
the effect of sodium butyrate on FL clearance, 5 mM sodium butyrate was added
to the culture media of 3 HK-2 monolayers per incubation period 24 hours before
transport studies were conducted. Monolayers grown on Transwell-Clear inserts
were equilibrated for 10 min in TM, aspirated and placed in TM containing 4 µM FL
for 15, 30 or 45 min. Upon expiration of the incubation period, media was sampled
from both compartments per insert, 100 µl aliquots were assayed for radioactivity
and clearance rates were calculated. *The differences in clearance are statistically
significant as determined by Student's t-Test, p < 0.05. Each bar represents the
mean clearance +/- SEM for 3 monolayers.
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Figure 4.5.4. The Effect of Ouabain on FL Clearance. A) To determine the
acute effects of ouabain on FL transport, 8 day old HK-2 monolayers were
equilibrated for 10 min TM, aspirated, then incubated for 2, 5 or 15 min in 4 µM FL
± 100 µM ouabain on an orbital shaker at 37oC, 5% CO2/95% air. Coincubation
vs. control resulted in inhibition of FL clearance that diminished with time. There
was no significant difference in FL clearance at 15 min; n = 3 treated, n = 2 for
control. *At 5 min, ouabain significantly inhibited the clearance of FL; Student's tTest, p < 0.05, n = 3 per group. The 2 min data was not statistically analyzed (n =
3 for treated, n = 1 for control); however, the control value was within range of prior
2 min clearance rates for FL. B) To determine the long term effects of ouabain on
FL clearance, 7 day old HK-2 monolayers were preincubated for 30 min in TM with
or without 100 µM ouabain. FL was then added to the BL compartment of each
insert and monolayers were incubated for 15 min on an orbital shaker at 37oC, 5%
CO2/95% air.

Aliquots from both compartments per insert were analyzed for

fluorescence and the clearance, corrected for FLD diffusion, was determined.
Preincubation with ouabain significantly increased the 15 min clearance of FL as
analyzed by Student's t-Test, p = 0.021, n = 4 per group.
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Figure 4.5.5. Effects of αKG Preincubation and Probenecid Coincubation on
the Clearance of FL.

A comparison of the FL clearance rates for HK-2

monolayers preincubated in αKG or coincubated in probenecid vs. control was
performed on 5 day old HK-2 monolayers superseeded on Transwell-Clear inserts.
All monolayers (3 per group) were aspirated and equilibrated in TM with or without
αKG (1 mM) for 15 min. Monolayers were rinsed twice in TM and placed in TM

with 4 µM FL with or without 1 mM probenecid in the BL compartments. After
15 min on an orbital shaker at 60 cycles/min, 37oC, 5% CO2/95% air, samples
were taken from both compartments per insert and 100 µl aliquots were assayed
for fluorescence. Clearance of FL was corrected for FLD diffusion on parallel
inserts. Preincubation with αKG resulted in a 47% increase and coincubation with
probenecid resulted in 35% decrease in clearance of FL.

*Differences in

clearance were significantly different for treated vs. control as analyzed by OneWay ANOVA followed by a Dunnett's Test for Multiple Comparison vs. Control,
p < 0.05.
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Figure 4.5.6. The Effect of PAH on the Clearance of FL. The effect of 500 µM
PAH on the clearance of 4 µM FL was determined.

Seven day old HK-2

monolayers grown on Transwell-Clear inserts (3 per group) were equilibrated for
10 min in TM, aspirated then placed in TM with 4 µM FL in the absence or
presence of 500 µM PAH in the BL compartment. After 15 min on an orbital
shaker at 60 cycles/min, 37oC, 5% CO2/95% air, samples were taken from both
compartments per insert and 100 µl aliquots were assayed for fluorescence.
Clearance rates were corrected for FLD diffusion on parallel inserts. PAH did not
significantly decrease the clearance of FL at 15 min. The data were analyzed by
Student's t-Test.
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Figure 4.5.7. The Effect of DHEAS on the Clearance of FL. The effect of 1 mM
DHEAS on the clearance of 4 µM FL was determined.

Five day old HK-2

monolayers grown on Transwell-Clear inserts were equilibrated for 10 min in TM,
aspirated then placed in TM with 4 µM FL in the absence or presence of 1 µM
DHEAS in the BL compartment.

After 15 min on an orbital shaker at 60

cycles/min, 37oC, 5% CO2/95% air, samples were taken from both compartments
per insert and 100 µl aliquots were assayed for fluorescence. Clearance rates
were corrected for FLD diffusion on parallel inserts. DHEAS caused a slight (10%)
but significant decrease in the clearance of FL at 15 min as indicated by the
asterisk (*). The data were analyzed by Student's t-Test, p < 0.05, n = 2 per
group.
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Transport of OAT1 and OAT3 Substrates
The uptake and/or clearance of PAH as the model OAT1 substrate and DHEAS
and ES as the model OAT3 substrates were studied. The ability of a substrate to
inhibit its own uptake (labeled vs. addition of unlabeled), demonstrates a
competitive, protein-mediated, uptake process.

This was demonstrated for all

three substrates, PAH, ES and DHEAS.
PAH
To determine if PAH transport is protein-mediated, unlabeled PAH was
coincubated with labeled PAH and the uptake determined. The addition of 1 mM
PAH to 4.2 µM [14C]PAH inhibited the uptake of [14C]PAH by 50% (Figure 4.6.1).
The OAT1 trans-stimulatory substrate αKG showed inhibitory rather than
stimulatory effects on the uptake and clearance of 70 µM PAH when preloaded
into HK-2 monolayers (Figure 4.6.2). The αKG effects on PAH clearance were not
as great as the effects on uptake (59% decrease in uptake vs. 22% decrease for
clearance). Although the preloaded monolayers were rinsed twice with TM before
incubating in PAH, the results are consistent with inhibitory uptake by αKG and
may be due to residual dicarboxylate on the BLM of the cells. In the same figure,
1 mM probenecid was shown to inhibit the uptake of 70 µM PAH by 73% and the
clearance of PAH by 15%. Diminished differences in clearance than uptake are
likely due to paracellular diffusion of substrate across the monolayer.
Because the αKG results were inhibitory rather than stimulatory, as expected, a
subsequent experiment was performed with another dicarboxylate, glutarate, in a
shorter incubation period. Similar inhibitory effects were seen for 5 min uptake of
4 µM PAH by monolayers preloaded with glutarate or coincubated with 1 mM
probenecid (Figure 4.6.3). As with the αKG experiment, the preloaded monolayers
were rinsed twice before the incubation. However, these results also suggest
inhibition of uptake by residual dicarboxylate.
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In summary for PAH transport: Transport of PAH demonstrates self-inhibition in
the HK-2 model, consistent with protein-mediated transport. PAH transport was
inhibited by probenecid and by preloaded dicarboxylates.
ES
Uptake of the prototypical OAT3 substrate [3H]ES (3.6 nM) in the presence of
unlabeled ES (100 µM) was inhibited by 50% compared to control (Figure 4.6.4 A)
whereas the OAT3 substrate E217βG (100 µM) had no effect on ES uptake (Figure
4.6.4B). The inability of E217βG to inhibit uptake of ES is not surprising in that the
affinity of ES for OAT3 is reported to be very high (Km = 3 µM; Cha et al., 2001).
Low solubility of E217βG prohibited experimentation with a high concentration,
such as 1 mM E217βG.
Probenecid caused a greater inhibitory effect on the clearance of ES than on
the uptake of ES (Figure 4.6.5). This finding suggests a decreased permeability of
the BBM to ES relative to control, such that probenecid inhibits both the uptake
and efflux of ES. The inhibitory effect of probenecid at the BBM would create an
increased steady state concentration of ES intracellularly, such that the true
inhibitory effect at the BLM is not reflected in net accumulation of ES. This is a
confounding problem inherent in systems with both BLM and BBM transporters,
unlike the single transporter transfectant models.
In summary for ES: Transport of ES exhibits self-inhibition consistent with a
protein-mediated process. E217βG (100 µM) shows no inhibitory effect on uptake
of ES whereas probenecid inhibits both uptake and, to a greater extent, clearance
of ES.
DHEAS
Transport of the OAT3 substrate DHEAS (2.2 nM) was inhibited to a greater
extent by unlabeled DHEAS (100 µM) than by equimolar ES (Figure 4.6.6; 45%
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inhibition for DHEAS vs. no significant inhibition for ES). This experiment suggests
that DHEAS has a higher affinity for the transporter than does ES and/or that the
substrates are transported by multiple transporters that do not transport the other
substrate or that display noncompetitive transport of both substrates.

Higher

affinity of DHEAS than ES for OAT3 is consistent with the findings of Cha et al.
(2001).
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Figure 4.6.1. The Effect of Unlabeled PAH on the Uptake of [14C]PAH. The
effect of unlabeled PAH on the uptake of radiolabeled PAH was determined. Six 9 day old HK-2 monolayers superseeded on Transwell-Clear inserts were rinsed
with WBTM then placed in WBTM containing 4.2 µM [14C]PAH with or without
1 mM unlabeled PAH in the BL compartments. Monolayers were incubated in a
shaking water bath at 37oC. After 10 min, uptake was terminated by immersing
the inserts into ice-cold WBTM. Inserts were rinsed with ice-cold WBTM and
aspirated. Cells were lysed and assayed for radioactivity to determine uptake.
The 50% decrease in the uptake of [14C]PAH in the presence of unlabeled PAH
was statistically significant as determined by One-Way ANOVA for Repeated
Measures, p < 0.05, n = 5 per group.
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The Effects of αKG Preincubation and Probenecid

Coincubation on PAH Transport.

To determine the effects of αKG

preincubation and probenecid coincubation on the uptake and clearance of
PAH, nine day old HK-2 monolayers superseeded on Transwell-Clear inserts
were equilibrated in TM with or without 1 mM αKG for 15 min. Monolayers
were then rinsed 2 x with TM and placed in TM containing 70 µM PAH (~ 4 µM
[14C]PAH) with or without 1 mM probenecid in the BL compartments. After
15 min on an orbital shaker at 60 cycles/min, 37oC, 5% CO2/95% air, samples
were taken from the A and BL compartments, the inserts were placed into icecold TM and rinsed 2 x with ice-cold TM. Cells were lysed with 0.1 N NaOH,
assayed for radioactivity and uptake was calculated. Aliquots (30 µl) of the BL
and A media were assayed for radioactivity and clearance rates were
determined. Both treatments resulted in a significant decrease in uptake and
clearance of PAH as indicated by the asterisk (*).

For both uptake and

clearance the data were analyzed by One-Way ANOVA followed by Dunnett's
Test for Multiple Comparisons vs. Control, p < 0.05, n = 3 per treatment. The
αKG and probenecid treatments resulted in 59% and 73% decreases in the

uptake and 22% and 15% decreases in the clearance of PAH, respectively.
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The Effects of Glutarate Preincubation and Probenecid

Coincubation on PAH Transport.

To determine the effects of glutarate

preincubation and probenecid coincubation on the uptake of PAH, glutarate (final
concentration, 1 mM) or an equivolume of WBTM was added to the culture media
of both BL and A compartments of 5 day old HK-2 monolayers superseeded on
Transwell-Clear inserts. After a 30 min preincubation period on an orbital shaker
at 60 cycles/min, 37oC, 5% CO2/95% air, inserts were rinsed X 2 with WBTM then
placed in WBTM containing 4 µM [14C]PAH with or without 1 mM probenecid in the
BL compartments. Monolayers were incubated in a shaking water bath at 37oC.
After 5 min, uptake was terminated by immersing the inserts in ice-cold WBTM.
Inserts were rinsed with ice-cold WBTM, aspirated, and cells were lysed in
1% SDS/0.1N NaOH then assayed for radioactivity to determine uptake.
*A significant decrease in mean uptake of PAH was found for both treated groups
by One-Way ANOVA with Dunnett's Post Test for Multiple Comparison vs. Control,
p < 0.05. n = 3 per treatment.
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Figure 4.6.4. The Effects of Unlabeled ES and E217βG on the Uptake of ES.
In separate studies, the uptake of [3H]ES was determined in the presence or
absence of unlabeled ES and E217βG.

HK-2 monolayers superseeded on

Transwell-Clear inserts were rinsed with WBTM then placed in WBTM containing
3.6 nM [3H]ES with or without 50 µM unlabeled ES (A) in the BL compartments; or
4 nM [3H]ES with or without 100 µM E217βG (B), in the BL compartments.
Monolayers were incubated in a shaking water bath at 37oC. After 5 min, uptake
was terminated by immersing the inserts into ice-cold WBTM. Monolayers were
rinsed with ice-cold WBTM and aspirated. Cells were lysed in 1% SDS, 0.1 N
NaOH and assayed for radioactivity to determine uptake. The 50% decrease in
the uptake of [3H]ES in the presence of unlabeled ES by 8 day old monolayers
was statistically significant as determined by Student's t-Test, p < 0.05; n = 3 per
group. E217βG had no effect on the uptake of [3H]ES by 5 day old monolayers,
n = 3 per group.
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Figure 4.6.5. The Effect of Probenecid on the Transport of Estrone Sulfate.
To study the uptake and clearance of ES in the absence or presence of
probenecid, 4 day old HK-2 monolayers superseeded on Transwell-Clear inserts
were rinsed with WBTM then placed in WBTM containing 3.6 nM [3H]ES with or
without 1 mM probenecid in the BL compartments. Monolayers were incubated in
a shaking water bath at 37oC. After 5 min, uptake was terminated by transferring
the inserts into ice-cold WBTM. Monolayers were rinsed with ice-cold WBTM and
aspirated. Cells were lysed in 1% SDS, 0.1 N NaOH and assayed for radioactivity
to determine uptake. The uptake of ES was inhibited only 13%, whereas, the
clearance was decreased by 44% in the presence of probenecid. *Both decreases
were significant as determined by Student's t-Test, p < 0.05. Each bar represents
the mean uptake ± SEM (A) or the mean clearance ± SEM (B); n = 2 for uptake
control; n = 3 for uptake treated, clearance control and treated.
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Figure 4.6.6. The Effects of Unlabeled DHEAS and ES on the Uptake of
[3H]DHEAS.

To determine the effects of DHEAS and ES on the uptake of

DHEAS, 8 day old HK-2 monolayers superseeded on Transwell-Clear inserts were
rinsed in WBTM then placed in WBTM with 2.2 nM [3H]DHEAS +/- 100 µM DHEAS
or 100 µM ES added to the BL compartments. Monolayers were incubated for 5
min at 37oC in a shaking water bath, transferred to wells containing ice-cold TM,
rinsed in ice-cold TM, lysed with 1% SDS/0.1 N NaOH and assayed for
radioactivity. [3H]DHEAS uptake was statistically inhibited by 46% in the presence
of 100 µM unlabeled DHEAS. The 14 percent inhibition demonstrated by 100 µM
ES was not significant.

Each bar represents the mean uptake + SEM for 3

monolayers. Statistics were analyzed by One-Way ANOVA with Dunnett's Test for
Multiple Comparisons vs. Control, p< 0.05.
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AG Transport by HK-2 Cells
Initial AG transport studies were conducted at 15 min. After performing the
time-course uptake study, it was decided to decrease the incubation period to 5
min to minimize compensatory effects in the system and work within the linear
phase of uptake. Initial AG transport studies were also conducted with relatively
high concentrations of AG (50-100 µM). Later studies were conducted with tracer
AG only (4-9 µM) to maximize modulatory effects on AG transport. The results
presented below are grouped by modulator rather than chronologically such that
sections may contain data with varying incubation periods or AG concentration
levels.
The time-course uptake of AG exhibited slightly biphasic uptake with nearly
linear uptake from 2 to 10 min then rapid decline in rate of uptake between 10 to
15 min (Figure 4.7.1). The uptake was best fit to a single rectangular hyperbolic
regression without a zero or first order term for nonspecific binding and/or
diffusion.

When a nonspecific term was included in the regression, the term

constant was negative suggesting a reabsorptive process or an increase in the
rate of apical efflux with time.

A correlation coefficient, R2 = 0.99, for the

regression without the nonspecific term was greater than that for the regression
with the nonspecific term (0.95, first order; 0.94, zero order); thus, the regression
excluding a nonspecific term as shown in Figure 4.7.1 is the best fit.
Because uptake was nearly linear from 2 to 10 min, an intermediate time, 5 min
was selected for the concentration-dependent study. Concentration-dependent
uptake of AG also displayed biphasic kinetics (Figure 4.7.2).

At high

concentrations (> 1 mM), net intracellular accumulation of labeled AG no longer
decreased, but rapidly increased.

This finding is consistent with that of AG

disposition in the dog with net reabsorption at high concentrations of AG (Duggin
and Mudge, 1975). Analysis of the concentration-dependent uptake of AG for
concentrations up to 1 mM unlabeled AG fit a Michaelis-Menten regression with
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R2 = 0.959, Km = 260 µM and Vmax = 27.2 pmol/cm2/5 min. These data, however,
would not fit to a Berteloot regression.
Because the activity measured for the uptake of AG in the previous study was
so close to background and the data failed to fit a Berteloot regression analysis,
additional concentration-dependent studies were performed using a higher
concentration of [14C]AG with unlabeled concentrations of AG up to 1 mM. Figure
4.7.3 represents the combined data from 2 experiments. These data fit both a
Berteloot (R2 = 0.863) and a Michaelis-Menten (R2 = 0.995) regression analysis
(Figure 4.7.3, graph A and B, respectively). The Berteloot regression yields a Km
of 326 µM, Vmax of 6.1 pmol/cm2/5 min vs. a Km of 1.44 mM, Vmax of 16.4
pmol/cm2/5 min for the Michaelis-Menten regression. Together, the regression
analyses indicate low affinity transport of AG.
To determine if the increase in intracellular [14C]AG accumulation when
challenged with high concentrations of unlabeled AG occurred by reabsorption at
the BBM, a dynamic study was performed in which the apical medium was
continuously exchanged for fresh medium (Figure 4.7.4). It was found that AG
effluxed into the apical medium had no effect on the net accumulation of
intracellular AG, supporting mechanisms other than reuptake at the BBM to
explain the increasing intracellular accumulation of AG at higher concentrations of
AG in the BL medium.
To determine the effect of intracellular AG on AG uptake and clearance,
HK-2 monolayers were preloaded with unlabeled AG or [14C]AG by incubation in
equimolar AG or [14C]AG medium for 90 min. Each group was then rinsed and
placed in equimolar labeled AG for the unlabeled preloaded cells or unlabeled AG
for the preloaded [14C]AG cells, such that each group was the exact complement
to the other. A control group with no preloading was run on parallel monolayers
(Figure 4.7.5). Neither uptake nor clearance of [14C]AG were significantly altered
for the preloaded AG group compared to control. Because these effects were not
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significant, no conclusions can be made, however, had there been a significant
increase in transport, it could be explained by a trans-stimulation of AG uptake at
the BLM with or without an upregulation of efflux and/or uptake transporters. What
can be concluded is that intracellular AG does not inhibit the uptake or the efflux of
AG. Comparison of A vs. BL efflux of the [14C]AG preloaded cells reveals that A
efflux was 1.46 times greater than BL efflux suggestive of net secretion of AG.
Comparison of A vs. BL uptake demonstrates greater uptake from the A vs. the BL
compartment (Figure 4.7.6).

Higher efflux and greater uptake from the BBM

indicate polarization of the monolayers and suggest greater permeability of the
BBM vs. BLM to AG such that transport at the BLM is the rate limiting step in
transepithelial transport of AG.
Temperature-dependent transport was demonstrated by total inhibition of AG
clearance at 4oC, yet only a tendency toward lower net AG accumulation was
suggested (Figure 4.7.7). Net accumulation at low temperature could be explained
by nonspecific binding or by uptake processes (gradient-dependent) that are less
sensitive than are efflux processes (ATP-dependent) to temperature. A greater
effect on efflux than on uptake would increase the net intracellular accumulation of
AG, thus, masking the effect of decreased uptake. This study indicates that AG
transport is protein-mediated.
To study the effects of OAT1 and/or OAT3 modulation on the transport of AG,
studies with ouabain, probenecid and the prototypical substrates were conducted.
AG/ouabain coincubation resulted in a 2.5-fold increase in the 15 min AG BL-A
clearance vs. no significant effect in A-BL clearance compared to the AG
treatments (Figure 4.7.8 A). Since the expected ouabain effect for OAT1-mediated
transport would be decreased BL-A clearance, this experiment suggests AG
uptake at the BLM mediated by transporter(s) other than OAT1 with a possible
upregulation of transporters at the BLM or BBM rather than inhibition by ouabain.
The effect of preincubation and coincubation with ouabain had no significant effect
on AG transport (Figure 4.7.8 B).
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To determine the effect of OAT1/OAT3 inhibition on AG transport, 15 min
probenecid and AG coincubation experiments were performed.

Probenecid

(1 mM) was found to cause a significant decrease in the net accumulation of tracer
AG (4 µM) while it tended to cause an increase in AG clearance (Figure 4.7.9).
Although there was no significant effect of probenecid on AG clearance, that the
efflux did not instead decrease in proportion to the net accumulation implies that
the permeability of the BBM was increased. An increase in permeability at the
BBM is quantitatively demonstrated by a permeability-surface area product (PSa)
2.4 times greater than control. The effect of probenecid, then, may be at the BBM
with little or no effect at the BLM.
To determine if probenecid had similar effects from the A vs. BL compartment,
1 mM probenecid was added to the A or to the BL compartment with 50 µM AG in
the BL compartment (Figure 4.7.10 A). Probenecid in the BL compartment caused
a decrease in net accumulation of AG. However, when probenecid was added to
the A compartment, there was no significant effect on net AG accumulation from
the BLM compared to control.

AG uptake from the BBM (Figure 4.7.10 B)

demonstrates that probenecid plays no inhibitory role on BBM uptake transporters
when coincubated with AG in the A compartment.
At higher concentrations of AG (100 µM), 1 mM probenecid had no significant
effect on 5 min BL-A AG clearance (Figure 4.7.11).
To determine if a dicarboxylate exchange mechanism is involved in the
transport of AG, glutarate preloading experiments were run. Glutarate (90 min
preincubation) caused no significant increase in either uptake or clearance of 8 µM
AG compared to control (Figure 4.7.12).
PAH and FL were coincubated with AG to demonstrate OAT1 and/or OAT3
interactions. AG (200 µM) was found to have a stimulatory effect on the 15 min
clearance of 4 µM FL (Figure 4.7.13) whereas no effect was found for AG on the
5 min clearance of 4 µM PAH (Figure 4.7.14 B). The differences in effect may be
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due to differences in transport of FL vs. PAH or it may be due to an upregulation in
transporters with time. Interestingly, the net intracellular accumulation of PAH was
decreased by AG suggesting possible inhibitory effects at OAT1 or OAT3, or
stimulatory effects of PAH efflux at the BBM (Figure 4.7.14 A).
ES was used to explore inhibitory effects at OAT3. AG (1 mM) had no effect on
the uptake of 4 nM ES (Figure 4.7.15), whereas 100 µM ES caused a 32%
decrease in the net accumulation of AG (Figure 4.7.16) and tended to decrease
AG clearance. ES is the prototypical substrate for OAT3 and, therefore, would
likely inhibit the BL uptake of AG, if AG is an OAT3 substrate. If AG and ES are
competitive for the same sites on the transporter and OAT3 is the sole transporter
available to both substances, one would expect mutual inhibition of transport.
Recalling that 100 µM ES inhibited low concentration uptake of ES by 50% in this
model and the Km for AG is approximately 300-1000 µM, inhibition of 9 µM AG
much greater than 50% would be expected with the addition of 100 µM ES and
tracer ES uptake should be inhibited by about 50% by 1 mM AG.

Assuming

transport of ES by OAT3 in this model, unless the substrates bind at different sites
on the transporter or multiple transporters are responsible for ES and AG uptake,
OAT3 transport of AG is likely very low in HK-2 cells. ES uptake mediated by
multiple transporters is supported by the study of Sweet et al. (2002) which
demonstrated that uptake of ES in mouse renal cortical slices was inhibited 56%
by probenecid and was transported at 53% of rates of wild-type control in renal
cortical slices of Oat3-knockout mouse.
The effects of the OAT3 substrate DHEAS on the transport of AG are AG
concentration- and/or time-dependent. At 5 min, 1 mM DHEAS caused a 42%
decrease in the clearance of 100 µM AG (Figure 4.7.17). To minimize possible
upregulation of BLM or BBM transporters, the DHEAS (1 mM) and PAH (1 mM)
study was conducted at 2 min. The AG concentration was increased to 20 µM to
ensure readings were well above background. At 2 min, neither 1 mM PAH nor
1 mM DHEAS had an effect on the uptake or the clearance of 20 µM AG (Figure
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4.7.18). This study indicates that primary uptake of AG is not likely mediated by
OAT1 nor OAT3 unless AG binds at different sites on the transporters than do
PAH and DHEAS.
To assess the long term effects of DHEAS on AG transport, monolayers were
treated for 24 hours with 1 mM DHEAS (Figure 4.7.19).

A 76% significant

increase in AG transport was shown for DHEAS preincubated monolayers,
implying upregulation of BLM and possibly BBM transporters. This effect could
also be explained by trans-stimulation from preloaded DHEAS.
The effects of the glucuronide conjugates, MUG and E217βG, on the transport
of AG were studied as presented in Figure 4.7.20. No significant effect in net
accumulation or transepithelial transport was demonstrated for either glucuronide.
Lack of inhibition of AG uptake by E217βG, a substrate for OAT3, is consistent with
the results of the ES and DHEAS studies indicating that AG is likely not a good
substrate for OAT3, multiple transporters are involved, or that AG binds at a
different site on the transporter than does E217βG.
In summary for AG transport: HK-2 cells exhibit biphasic transport for both
time- and concentration-dependent uptake. The increasing rate of intracellular
accumulation of AG at concentrations above 1 mM is consistent with reabsorption
of AG as reported by Duggin and Mudge (1975). Temperature-dependent studies
indicate that AG movement across the HK-2 monolayer is transporter-mediated.
The BBM of HK-2 cells is more permeable to AG than is the BLM as evidenced by
higher uptake from the A vs. BL compartment and higher BBM vs. BLM efflux from
preloaded cells. Lack of inhibition of AG uptake by intracellular AG and greater AG
efflux across the BBM than the BLM were demonstrated in cells preloaded with
AG. A tendency for increased AG clearance when coincubated with ouabain or
probenecid suggests possible upregulation of transporters whereas decreased
clearance rates at high concentrations of AG suggest that probenecid may inhibit
BLM uptake and/or BBM efflux.

ES results suggest possible low affinity AG
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transport by OAT3; however, PAH and DHEAS studies suggest uptake of AG
primarily by transporters other than OAT1 or OAT3. Furthermore, DHEAS studies
also indicate modulatory effects over time with decreased transepithelial transport
of AG at higher concentrations of AG and DHEAS. The glucuronides, MUG and
E217βG, caused no significant effect on net AG accumulation or clearance. No
inhibition at the BLM by E217βG also suggests a noncompetitive process or little to
no transport of AG by OAT3.
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Figure 4.7.1. Time Course Uptake of 50 µM AG. The uptake of 50 µM AG was
performed by incubating 6-7 day old HK-2 monolayers superseeded on TranswellClear inserts for 2, 5, 15, 30 and 60 min in WBTM containing 50 µM AG in the BL
compartments.

After 5 min in a shaking water bath at 37oC, inserts were

transferred to ice-cold TM, rinsed with ice-cold TM, lysed in 0.1 N NaOH and
assayed for radioactivity. Parallel monolayers were used for protein determination.
Each data point represents the mean AG uptake +/- SEM for 3 monolayers. The
plot includes a single rectangular hyperbolic regression of the data that can be
expressed by the equation: Uptake = (3.131 pmol/mg protein x time)/(1.11 + time);
R2 = 0.99.
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Figure 4.7.2. Biphasic Concentration-Dependent AG Uptake - Study I. A
concentration-dependent study was conducted using 4 µM [14C]AG (tracer) in the
presence of 0, 0.046, 0.05, 0.25, 0.5, 1, 2.5 and 5 mM unlabeled AG. Seven day
old HK-2 monolayers superseeded on Transwell-Clear inserts were rinsed in
WBTM then placed in WBTM containing tracer and unlabeled AG in a 37oC
shaking water bath. After 5 min, inserts were transferred to ice-cold TM, rinsed
with ice-cold TM, lysed in 0.1 N NaOH, assayed for radioactivity and uptake was
calculated. Parallel inserts were used for protein determination. Each data point
represents the mean total AG uptake +/- SEM for 3 monolayers. The plot depicts
total AG uptake vs. total AG concentration indicating a biphasic accumulation of
intracellular AG which first plateaus with increasing concentration of AG in the
incubation medium, then rapidly rises at the highest concentrations tested. The
inset depicts the first 6 data points and includes a Michaelis-Menten regression
curve.

The regression analysis yields Vmax = 27.2 pmol/cm2/5 min or 381.6

pmol/mg/5 min and Km = 260 µM with an R2 = 0.959.
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Concentration Dependent Uptake of AG - Study II.

The

concentration-dependent uptake for AG was evaluated using 8.5 µM [14C]AG
(tracer) in the presence of 0, 0.05, 0.1, 0.25, 0.5, and 1 mM unlabeled AG. Five
to 7 day old HK-2 monolayers superseeded on Transwell-Clear inserts were
rinsed in WBTM then placed in WBTM containing tracer and unlabeled AG in a
37oC shaking water bath. After 5 min, inserts were transferred to ice-cold TM,
rinsed with ice-cold TM, lysed in 1%SDS/0.1 N NaOH and assayed for
radioactivity from which uptake was calculated. Both graphs represent the same
data, but expressed as tracer and unlabeled AG (A) or total AG (B). Each data
point represents the mean AG uptake +/- SEM for 7 monolayers. Graph A is a
plot of the uptake of tracer AG vs. unlabeled AG concentration. A Berteloot
regression analysis for this data yields the kinetic constants, Vmax = 6.1
pmol/cm2/5 min and Km = 326.3 µM AG with an R2 = 0.863. Graph B is a plot of
total AG uptake vs. total AG concentration and includes a Michaelis-Menten
regression curve.

Michaelis-Menten regression analysis gives Vmax = 16.4

pmol/cm2/5 min) and Km = 1.44 mM with an R2 = 0.995.
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The Effects of Unlabeled AG on the Uptake of

[14C]AG -

Dynamic vs. Static Apical Compartment. The uptake of 9 µM [14C]AG (tracer)
in the presence or absence of a high concentration of unlabeled AG (2.5 mM) was
determined using 5 day old HK-2 monolayers superseeded on Transwell-Clear
inserts. Monolayers were rinsed in WBTM then placed in WBTM containing tracer
+/- unlabeled AG in the BL compartments and incubated in a 37oC shaking water
bath for 5 min. For the dynamic (dyn) group, the medium in the A compartment
was continuously exchanged for fresh WBTM. The monolayers were placed in icecold TM, rinsed with ice-cold TM, lysed in 1%SDS/0.1 N NaOH and assayed for
radioactivity. *Tracer AG uptake was significantly inhibited by the presence of
2.5 mM AG as analyzed by a Student's t-Test, p = 0.022. Data failed to achieve
significance by One-Way ANOVA for the 3 groups. Each bar represents the mean
uptake +/- SEM for 3 monolayers.
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Figure 4.7.5. The Effects of Preloaded AG on AG Transport. To determine the
effects of preloaded AG on the transport of AG, 5 day old HK-2 monolayers
superseeded on Transwell-Clear inserts were preloaded by 90 min incubation in
WBTM containing 20 µM [14C]AG or 20 µM unlabeled AG on an orbital shaker at 60
cycles/min at 37oC, 5% CO2/95% air. Monolayers were rinsed in WBTM, placed in
WBTM with the BL compartments containing either 20 µM unlabeled AG, for
monolayers preloaded with radiolabeled AG; or 20 µM [14C]AG (tracer), for control
monolayers and monolayers preloaded with unlabeled AG. After 2 min in a 37oC
shaking water bath, media was sampled from both compartments per insert and the
monolayers were placed into ice-cold TM, rinsed with ice-cold TM, lysed with
1% SDS/0.1 N NaOH and assayed for radioactivity. Uptake was then calculated.
Aliquots (50 µl) of the BL and A compartments were assayed for radioactivity and the
clearance rates and efflux were calculated. There was no significant difference in the
uptake (A) or the clearance (B) of tracer AG for control vs. preloaded monolayers. (A)
Each bar represents the mean of uptake +/- SEM for 4 control monolayers and 3
monolayers preloaded with unlabeled AG.

(B) Each bar represents the mean

clearance +/- SEM for 3 control and 4 monolayers preloaded with unlabeled AG. (C)
Their was no statistical significance for A vs. BL efflux of preloaded tracer AG. Each
bar represents the mean efflux +/- SEM for 4 monolayers.
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Figure 4.7.6. BL vs. A Uptake of AG. A) To determine the BL vs. A uptake of
AG, 5 day old HK-2 monolayers superseeded on Transwell-Clear inserts were
rinsed with WBTM, placed in WBTM containing 9 µM AG in the BL or A
compartments and incubated in a 37oC shaking water bath.

After 5 min,

monolayers were transferred to ice-cold TM, rinsed with ice-cold TM, lysed with
1%SDS, 0.1 N NaOH and assayed for radioactivity. The uptake rates were then
calculated. Uptake of AG was significantly greater from the A vs. BL compartment
as analyzed by Student's t-Test, p < 0.01. Each bar represents the mean uptake
+/- SEM for 3 monolayers. B) To determine the BL-A vs. A-BL clearance of
100 µM AG, 3 day old HK-2 monolayers grown on Transwell-Clear inserts were
equilibrated in TM at 37oC, 5% CO2, 95% air for 10 min, aspirated, placed in TM
containing 100 µM AG in the BL or A compartments and incubated in the same
atmosphere for 5 min. Samples were taken from the BL and A media, aliquots
(100 µl) were assayed for radioactivity and clearance rates were calculated. There
was no difference in the BL-A vs. A-BL clearance of AG. Each bar represents the
mean clearance +/- SEM for 2 monolayers.
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The uptake and

clearance of 9 µM AG were examined at 37oC vs. 4oC using 5 and 7 day old HK-2
monolayers superseeded on Transwell-Clear inserts. Monolayers were rinsed with
WBTM, placed in WBTM containing 9 µM AG in the BL compartments and
incubated in a 37oC or 4oC shaking water bath. After 5 min, samples were taken
from both compartments per insert and the inserts were placed in ice-cold TM,
rinsed with ice-cold TM, lysed with 1%SDS, 0.1 N NaOH and assayed for
radioactivity. The uptake rates were then calculated. Aliquots (100 µl) of BL and A
media were assayed for radioactivity and the clearance rates were calculated.
The decrease in uptake at 4oC vs. 37oC was statistically insignificant whereas the
clearance of AG was abolished at 4oC. Each bar represents the mean uptake +/SEM for 6 monolayers or the mean clearance +/- SEM for 3 monolayers. *Data
was analyzed by Student's t-Test, p < 0.001.
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Figure 4.7.8. The Effects of Ouabain on AG Clearance. To determine the
effects of (A) ouabain coincubation or (B) ouabain preincubation and coincubation
on the clearance of AG, 4-7 day old HK-2 monolayers seeded on Transwell-Clear
inserts were (A) equilibrated in TM for 10 min or (B) equilibrated in TM +/- 100 µM
ouabain for 30 min, then aspirated and placed in TM containing 200 µM AG +/100 µM ouabain in the BL or A compartments. After 15 min at 37oC, 5% CO2,
95% air on an orbital shaker at 60 cycles/min, 1 ml samples were taken from both
compartments per insert and the AG concentrations were determined by HPLC.
A) *The difference in BL-A AG clearance for control vs. ouabain cotreated
monolayers was statistically significant by Student's t-Test, p=0.011.

**The

difference in BL-A vs. A-BL AG clearance for like treatments was statistically
significant by Student's t-Test, p<0.02. Each bar represents the mean clearance
+/- SEM for 5 monolayers for control (AG-treated) and 3 monolayers for the
AG+ouabain cotreated monolayers. B)**The difference in BL-A vs. A-BL AG
clearance was statistically significant by Student's t-Test, p=0.006.

Each bar

represents the mean clearance +/- SEM for 3 monolayers, except control A-BL, 2
monolayers.
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Figure 4.7.9. The Effect of Probenecid on AG Transport. The uptake and
clearance of 4 µM AG were examined in the absence and presence of 1 mM
probenecid using 7 day old HK-2 monolayers superseeded on Transwell-Clear
inserts. Monolayers were equilibrated in TM for 10 min at 37oC, 5% CO2, 95% air,
aspirated then placed in TM containing 4 µM AG +/- 1 mM probenecid in the BL
compartments and incubated for 15 min as above. Samples were taken from both
compartments per insert and the inserts were placed in ice-cold TM, rinsed with
ice-cold TM, lysed with 0.1 N NaOH and assayed for radioactivity. Uptake was
then calculated.

Aliquots (100 µl) of BL and A media were assayed for

radioactivity and the clearance rates were calculated.

Probenecid caused a

significant decrease (52% x control) in the net accumulation of intracellular AG.
The clearance rate increased by 19%, but this difference was not statistically
significant. The PSa for the probenecid treated cells was 2.4 times that of control
indicating an increase in BBM permeability. Each bar represents the mean uptake
or clearance +/- SEM for 3 monolayers. *Data was analyzed by Student's t-Test,
p < 0.002.
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Figure 4.7.10. The Effects of BL vs. A Probenecid on the Uptake of AG. To
determine the A vs. BL effect of probenecid on the uptake of AG, 5 and 6 day old
HK-2 monolayers superseeded on Transwell-Clear inserts were rinsed with WBTM
and placed in WBTM containing 50 µM AG in the BL compartments in the absence
or presence of 1 mM probenecid in the BL or A compartments (A) or 9 µM AG in
the A or BL compartments in the absence or presence of 1 mM probenecid in the
same compartment (B). Monolayers were incubated in a 37o C shaking water
bath. After 5 min, they were transferred to ice-cold TM, rinsed with ice-cold TM,
lysed with 0.1 N NaOH and assayed for radioactivity. The uptake rates were then
calculated. Each bar represents the mean uptake +/- SEM for 3 monolayers.
*Probenecid caused a significant decrease in the uptake of AG when
coinincubated in the BL compartment. A) Probenecid in the A compartment had
no significant effect on BL AG uptake. Data analyzed by One-Way ANOVA with
Dunnett's post test, p <0.05. B) ** There is a statistical difference in like treatments
for BL vs. A uptake. Probenecid had no significant effect on the uptake of AG from
the A compartment. Data analyzed by Student's t-Test per comparison, p<0.05.
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The Effect of Probenecid on the Clearance of AG.

To

determine the effect of probenecid on the clearance AG, 3 and 4 day old HK-2
monolayers grown on Transwell-Clear inserts were equilibrated in TM at 37oC, 5%
CO2, 95% air for 10 min, aspirated, placed in TM containing 100 µM AG +/- 1 mM
probenecid in the BL compartments and incubated in the same atmosphere for 5
min.

Samples were taken from the BL and A media, aliquots (100 µl) were

assayed for radioactivity and clearance rates were calculated. The decreased
clearance of AG for the probenecid treatment was not significant by Student's tTest at a 95% confidence interval. Each bar represents the mean clearance +/SEM for 4 monolayers.
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Figure 4.7.12. The Effects of Glutarate Preincubation on AG Transport. To
determine the effects of glutarate preincubation on AG transport, 8 day old HK-2
monolayers superseeded on Transwell-Clear inserts were incubated for 90 min in
culture media containing 1 mM glutarate. Preincubated and control monolayers
were then rinsed twice with WBTM, placed in WBTM containing 7.9 µM AG in the
BL compartments and incubated at 37oC in a shaking water bath. After 5 min,
media samples were removed from each compartment per insert and monolayers
were placed into ice-cold TM, rinsed with ice-cold TM, lysed in 1% SDS, 0.1 N
NaOH and assayed for radioactivity. Uptake rates were then calculated. Aliquots
(50 µl) of the BL and A media were assayed for radioactivity and the clearance
rates determined. The glutarate preincubation caused an increase in both uptake
and clearance of AG, yet both were insignificant by Student's t-Tests. Each bar
represents the transport mean +/- SEM for 3 monolayers.
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Figure 4.7.13. The Effect of AG on the Clearance of FL. The clearance of
4 µM FL in the presence of 200 µM AG was determined using 6 day old HK-2
monolayers seeded on Transwell-Clear inserts. Monolayers were first equilibrated
for 10 min in TM at 37oC, 5% CO2, 95% air on an orbital shaker at 60 cycles/min
before a 15 min incubation period in TM containing 4µM FL +/- 200 µM AG in the
BL compartment under the same conditions. Aliquots (100 µl) of the media from
both compartments per insert were assayed for fluorescence and the clearance
rates determined.

A slight increase in FL clearance which was statistically

significant by Student's t-Test, p < 0.05, resulted from coincubation with AG when
compared to control. Each bar represents the mean clearance +/- SEM for 3
monolayers.
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Figure 4.7.14. The Effect of AG on the Transport of 4 µM PAH. To determine
the effect of AG on the uptake and clearance of PAH, 5 day old HK-2 monolayers
superseeded on Transwell-Clear inserts were rinsed with WBTM, placed in WBTM
containing 4 µM PAH +/- 1 mM AG in the BL compartments and incubated at 37oC
in a shaking water bath. After 5 min, media samples were taken from BL and A
compartments and uptake was terminated by placing the monolayers into ice-cold
TM.

Monolayers were rinsed in ice-cold TM, lysed in 1%SDS/0.1 N NaOH,

assayed for radioactivity and the uptake rates calculated. Aliquots (50 µl) of the BL
and A media were assayed for radioactivity and the clearance rates were
calculated. A) *AG coincubation with PAH resulted in a 49% inhibition of PAH
uptake compared to control as analyzed by Student's t-Test, p < 0.05. B) AG had
no effect on the clearance of PAH. Each bar represents the mean uptake +/- SEM
or the mean clearance +/- SEM for 3 monolayers.
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Figure 4.7.15. The Effect of AG on ES Uptake. To determine the effects of AG
on ES uptake 7 day old HK-2 monolayers superseeded on Transwell-Clear inserts
were rinsed in WBTM and placed in WBTM with 4 nM ES +/- 1 mM AG added to
the BL compartments. Monolayers were incubated at 37oC in a shaking water
bath. After 5 min, uptake was terminated with ice-cold TM and monolayers were
rinsed with ice-cold TM. Cells were lysed in 1% SDS/0.1 N NaOH, assayed for
radioactivity and the uptake rates were calculated. The addition of 1 mM AG to
4 nM ES had no effect on the uptake of ES; n = 3 per group. Each bar represents
the mean uptake +/- SEM.
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Figure 4.7.16. The Effect of ES the Uptake and Clearance of AG. To determine
the effects of ES on AG transport, 5 and 7 day old HK-2 monolayers superseeded
on Transwell-Clear inserts were rinsed in WBTM and placed in WBTM with 9 µM
ES +/- 100 µM ES added to the BL compartments. Monolayers were incubated at
37oC in a shaking water bath. After 5 min, media samples were taken from the BL
and A compartments. Uptake was terminated with ice-cold TM and monolayers
were rinsed with ice-cold TM. Cells were lysed in 1% SDS/0.1 N NaOH, assayed
for radioactivity and the uptake rates were calculated. Aliquots (50 µl) of media
were assayed for radioactivity and clearance rates were calculated.
(100 µM) inhibited the uptake of 9 µM AG by 32%.

A) ES

*The difference was

statistically significant as analyzed by paired T-Test; p < 0.05; n = 9 for control, n =
7 for the + 100 µM ES treatment. B) There was no statistical significance in the
clearance between groups.

n = 6 per group.

uptake or clearance +/- SEM.
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Figure 4.7.17. The Effect of DHEAS on the Clearance of AG. To determine the
effects of DHEAS on the clearance of AG, 3 and 4 day old HK-2 monolayers
superseeded on Transwell-Clear inserts were equilibrated in TM for 10 min on an
orbital shaker at 60 revolutions/min, 37oC, 5% CO2/95% air, aspirated, transferred
to TM containing 100 µM AG +/- 1 mM DHEAS in the BL compartments and
returned to the same conditions. After 5 min, media samples were taken from A
and BL compartments per insert. Aliquots (100 µl) were assayed for radioactivity
and clearance rates determined. DHEAS caused a 42% reduction in clearance of
AG. This difference was statistically significant from control as analyzed by OneWay ANOVA for Repeated Measures, p < 0.05. Each bar represents the mean
clearance +/- SEM for 6 monolayers.
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Figure 4.7.18. The Effects of PAH and DHEAS on the 2 min Transport of AG.
The uptake and clearance rates for AG in the absence or presence of PAH and
DHEAS were determined using 5 day old HK-2 monolayers superseeded on
Transwell-Clear inserts.

Monolayers were rinsed with WBTM, placed in WBTM

containing 20 µM AG +/- 1 mM PAH or 1 mM DHEAS in the BL compartments and
incubated at 37oC in a shaking water bath. After 5 min, media was sampled from both
compartments per insert and uptake was terminated by placing the inserts into icecold TM. Cells were rinsed with ice-cold TM, lysed in 1% SDS, 0.1 N NaOH, assayed
for radioactivity and the uptake rates were determined. Aliquots (50 µl) of the media
samples were assayed and the clearance rates were determined. There was no
difference in the uptake or the clearance rates for either +PAH or +DHEAS vs. control.
This is reflected in the PSa values indicating no change in the BBM permeability in
response to PAH or DHEAS. Each bar represents the mean uptake +/- SEM or the
mean clearance +/- SEM for 5 control monolayers and 4 monolayers for both PAH and
DHEAS treated.
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Figure 4.7.19.

The Effect of 24 Hour Pretreatment with DHEAS on the

Clearance of AG.

To determine the effects of DHEAS pretreatment on the

clearance of AG, 8 day old HK-2 monolayers seeded on Transwell-Clear inserts
were incubated for 24 hours in culture medium with or without 1 mM DHEAS.
Monolayers were rinsed twice with TM then equilibrated in TM for 10 min on an
orbital shaker at 60 revolutions/min, 37oC, 5% CO2/95% air, aspirated, transferred
to TM containing 100 µM AG in the BL compartments and returned to the same
conditions. After 5 min, media samples were taken from A and BL compartments
per insert. Aliquots (100 µl) were assayed for fluorescence and clearance rates
determined. DHEAS 24 hour preincubation caused a 76% increase in clearance
of AG. This difference was statistically significant from control as analyzed by
Student's t-Test, p < 0.05. Each bar represents the mean clearance +/- SEM for 3
monolayers.
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Figure 4.7.20. The Effect of MUG and E217βG on the Transport of AG. The
uptake and clearance rates for AG in the absence or presence of MUG and E217βG were
determined using 5 and 7 day old HK-2 monolayers superseeded on Transwell-Clear
inserts. Monolayers were rinsed with WBTM, placed in WBTM containing 9 µM AG +/100 µM MUG or 100 µM E217βG in the BL compartments and incubated at 37oC in a
shaking water bath. After 5 min, media was sampled from both compartments per insert
and uptake was terminated by placing the inserts into ice-cold TM. Cells were rinsed with
ice-cold TM, lysed in 1% SDS, 0.1 N NaOH, assayed for radioactivity and the uptake rates
were determined. Aliquots (50 µl) of the media samples were assayed and the clearance
rates were determined.

There was no difference in the uptake for either +MUG or

+E217βG vs. control as analyzed by One-Way Repeated Measures ANOVA.

The

difference in clearance for E217βG vs. Control is statistically significant by One-Way
ANOVA followed by Dunnett's Test for Multiple Comparisons vs. Control, p < 0.05. The
clearance for E217βG was calculated using the BL concentrations for the MUG data
because sampling problems due to viscosity of E217βG made the BL concentrations
artificially low and was apparent by media sticking to the pipet tips. Sticking did not occur
for the lower concentration of E217βG of the A compartment. MUG and E217βG medium
were prepared from the same batch of AG WBTM. Each bar represents the mean uptake
+/- SEM for 6 monolayers or the mean clearance +/- SEM for 3 control monolayers.

133

CHAPTER V

Discussion

Development of the HK-2 cell line as a Model for Transport Studies
Development of the HK-2 model utilized for organic anion transport in these
studies involved several phases including PTC marker identification, optimization
of growth conditions, OAT immunoblot analysis, and verification of cell polarization.
Because HK-2 cells are an established human renal proximal tubule cell line, little
characterization was necessary.

Assay values for GGT and hexokinase and

positive staining for AP were consistent with expected results for the enzymes in a
proximal tubule cell line.
Growth conditions were optimized for protein, rate of growth, adherence and
confluence of the monolayer. Growth of cells in flasks was optimal for protein and
rate of growth when cultured in KSFM with 40 ng/ml BPE, 5 ng/ml EGF and
supplemented with 2% FBS. This medium was initially used for cells grown on
porous membranes, but was modified when cells were superseeded.
6

Cells

2

seeded at superconfluence (superseeded = 1.41 x 10 cells/4.7 cm insert) onto
Transwell-Clear membranes demonstrated the highest level of confluence as
determined by phase contrast microscopy and FLD diffusion. Because growth of
superseeded cells was not required to achieve confluence, use of EGF in the
culture medium was not necessary and was omitted from the culture media. Cell
adhesion was superior for inserts coated with human placental Type IV collagen
(25 µg/insert).
To validate the HK-2 cell line as an appropriate model to study BL organic
anion transport, evidence of transporter expression was sought. OAT1 and OAT3,
known to be expressed in the BLM of human renal PTCs, were detected by
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Western blot analysis of HK-2 cell membrane fractions using antibodies purchased
from Alpha Diagnostics International, Inc.. An aberrant banding pattern was found
for both transporters, suggestive of varying levels of glycosylation of transporter
isoforms. The heaviest bands for OAT1 were 75 and 80 kD and for OAT3 were
79-80 kD. These bands are consistent with findings in the literature and likely
represent glycosylated proteins. Lower MW bands, 62-65 kD for OAT1 and 6365 kD for OAT3 are near the predicted MW for both transporters and thus would
likely represent the nonglycosylated proteins.

Bands found in this study are

consistent with findings in the literature, and are thus, evidence of OAT1 and OAT3
expression in the HK-2 cell line.
Polarization of the HK-2 monolayer on Transwell-Clear membranes was
demonstrated by FL and AG studies, both of which indicated higher permeability of
the BBM vs. BLM per substrate. These results represent an expected finding for
FL (Dantzler, 2002) and provide evidence of polarization for the HK-2 cell model.
With polarization of the HK-2 monolayer, one can expect transport measurements
to reflect net uptake across the BLM when substrate is added to the BL
compartment of the Transwell insert.
Despite polarization and apparent confluence of the monolayers, high FL
diffusion, greater than that of FLD diffusion, was suggested by regression analysis of
a time-course study of FL clearance. This analysis indicated that diffusion
represented an increasing percentage of total clearance of FL with time. This effect
could also be explained by upregulation of transporters with time, however, with
upregulation, one would expect to find magnified differences in clearance
corresponding to longer incubation periods for control vs. treated experiments. This
was not seen.

Instead, a high rate of diffusion would diminish differences in

clearance rates with rates for treated groups approaching 100% of control. Results
of FL clearance experiments should be interpreted with this effect of diffusion in
mind, particularly for those experiments conducted over 5 min. It was for this reason
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as well as evidence of compensatory mechanisms over time that shorter incubation
periods (5 min or less) were preferred.
OAT1 and OAT3 Studies
Time- and temperature-dependent transepithelial flux of FL demonstrated that
FL movement across the HK-2 monolayer is a transporter-mediated process.
Competitive self-inhibition of BL uptake of PAH, ES and DHEAS also supported
transporter-mediated transport.

Furthermore, because FL and PAH are the

prototypical substrates for OAT1, as is ES for OAT3, the results suggest that these
transporters are functional in the HK-2 model. Trans-stimulation of FL clearance
by the dicarboxylate αKG, ouabain inhibition of FL clearance, and probenecid
inhibition of FL, PAH and ES transport further support functionality of OAT1 and
OAT3 in this model.

However, because of substrate specificity overlap,

probenecid sensitivity and recent evidence of similar mechanisms of action for
OAT1 and OAT3, one cannot definitively state that OAT1 is functional in this
model. That is, FL and PAH are reported to be substrates of OAT3 as well as
OAT1; probenecid inhibits both OAT1- and OAT3-mediated transport; and OAT3
has been shown to act as an exchanger for dicarboxylates, as does OAT1 (Sweet
et al., 2003).
The self-inhibition studies in this project demonstrated 50% inhibition of 4 µM
[14C]PAH by 1 mM PAH, 50% inhibition of 4 µM [3H]ES by 100 µM ES and 45%
inhibition of 2.2 nM [3H]DHEAS by 100 µM DHEAS. For each of these substrates,
a higher inhibition was expected due to the high affinity of these substrates for
OAT1 and/or OAT3 as reported in the literature (Table 6, p. 35). These results
suggest considerable nonspecific binding of substrate to the membrane support.
The greatest inhibitory effect by probenecid for OAT1 and/or OAT3 substrates was
found to be 73% inhibition of PAH uptake by 1 mM probenecid. Greater inhibitory
effects were expected based on literature results. This, too, is thought to be
attributed to nonspecific binding of substrate to the membrane support. Unlike
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most renal PTC cell monolayers, HK-2 monolayers do not form domes which are
indicative of tight junction formation (Kim et al., 2002). Thus, in the HK-2 cell
model, substrates may have greater access to the membrane support resulting in
high levels of nonspecific binding and high rates of diffusion across the membrane.
AG Transport
Studies with AG strongly support transporter-mediated uptake of AG across the
BLM.

Time-, concentration- and temperature-dependent uptake of AG were

demonstrated in the HK-2 cell model. Time- and concentration-dependent studies
revealed biphasic transport. The time-course was nearly linear for 10 min, then
rapidly leveled off. This uptake was closely fit (R2=0.99) to a single rectangular
hyperbolic regression.

Concentration-dependent uptake demonstrated typical

kinetics of transporter-mediated uptake at low concentration and a nearly linear,
increased rate of uptake at high concentrations (above 1 mM AG). Although these
studies are referred to as uptake studies, the measurements are of net intracellular
accumulation and are thus representative of uptake and efflux processes. Thus,
the increased rate of uptake at high concentrations of AG may be due to increased
uptake at the BLM, reuptake at the BBM, or decreased efflux at the BBM.
Reuptake at the BBM was tested and determined not to occur. Decreased efflux
at the BBM is suspected and is discussed in the next section.
Concentration-dependent uptake of AG up to 1 mM was analyzed by both
Berteloot and Michaelis-Menten regressions yielding Km values of 326 µM and
1.44 mM with correlation coefficients R2 = 0.863 and 0.995, respectively.

By

formulation, a Berteloot regression is performed on the actual tracer uptake data
as opposed to the total substrate uptake calculated from tracer and unlabeled
substrate as required for a Michaelis-Menten regression.

For this reason, a

Berteloot regression is thought to be more reflective of the system. Thus, despite
a lower correlation coefficient,

the Berteloot analysis is likely a closer

approximation of the kinetics of the system. Additionally, the initial Michaelis137

Menten analysis from earlier data yielded a Km of 260 µM, closer to the Berteloot
Km. Together, these analyses suggest low affinity BL transport of AG in the HK-2
cell line with an approximate Km of 330 µM.
Coincubations of AG with OAT1 substrates FL and PAH and OAT3 substrates
DHEAS, E217βG and ES suggest a strong noncompetitive component to uptake at
the BLM for these substrates with AG. The most convincing support for possible
OAT3-mediated AG uptake is the ES study, which demonstrated a 32% inhibition
of AG net accumulation with a decrease, although insignificant, in AG clearance
(9 µM AG, 100 µM ES). A purely competitive process would have yielded a much
greater inhibition of AG transport.

Decreased clearance of 100 µM AG when

coincubated with 1 mM DHEAS also suggests possible OAT3-mediated AG
transport.
Additional support of possible OAT3- and/or OAT1-mediated transport of AG
includes, a slight, but insignificant increase in 8 µM AG transport with preloaded
glutarate, and a decrease in clearance of 100 µM AG when coincubated with
probenecid.

However, 2 min coincubation of monolayers with 20 µM AG and

1 mM PAH or 1 mM DHEAS resulted in no change in AG uptake or clearance.
Longer incubation periods yielded varying results that are discussed in the section
below. AG (1 mM) inhibition studies of 4 µM FL and 4 µM PAH demonstrated lack
of inhibition of FL or PAH clearance across the monolayer. AG (1 mM) had no
effect on 5 min, 4 nM ES uptake. The glucuronide conjugates E217βG, an OAT3
substrate, and MUG, both at 100 µM, had no significant effect on the uptake or
clearance of 9 µM AG, but tended to cause a slight increase in intracellular
accumulation and a slight decrease in clearance suggestive of inhibition of efflux at
the BBM as opposed to uptake at the BLM.

Lack of inhibition of low

concentrations of AG clearance by probenecid also supports uptake at the BLM by
transporter(s) other than OAT1 or OAT3. However, the experiments of Takeda et
al. (2002) should be considered when evaluating the inhibitory effects of
substrates/inhibitors on low affinity substrate transport. Takeda and colleagues
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found that the low affinity (Km = 342 µM) hOAT1-mediated transport of acyclovir
was only weakly inhibited by probenecid (~20% inhibition) vs. strong inhibition
(~80-90%) of hOAT1-mediated PAH transport by probenecid found in earlier
studies (Takeda et al., 2001). Thus, the prototypical substrate/inhibitor transport
studies may not be predictive of the degree of inhibition for other low affinity
substrates such as AG.
Due to overlap in OAT1/OAT3 substrate specificity, it is difficult to evaluate
purely OAT1-mediated transport in a multiple transporter system. However, in that
ES is an OAT3 and not an OAT1 substrate, it is thought that AG transport is more
likely OAT3- rather than OAT1-mediated. OAT1-mediated AG transport is also
less likely according to the findings of Ullrich et al. (1990) that glucuronidation of
substrates reduces or abolishes the interaction with the PAH transporter.
Evidence of Transporter Regulation
Although the primary focus of this project was organic anion transport across
the BLM, results of many of the studies made it difficult to ignore BBM
transporters, some which have been shown to be highly regulated over time.
Glucuronides are known substrates of the BBM transporters MRP2, MRP4 and
NPT1. Little is known about the regulation of MRP4 or NPT1, however, MRP2 is
regulated by insertion and retrieval into the membrane, as well as at the level of
transcription and translation.

For example, rapid retrieval and retargeting of

MRP2 from the canalicular membrane to the BLM in hepatocytes in response to
activation by PKC was reported to occur within 30 min (Kubitz et al., 2001).
E217βG has been shown to affect endocytic retrieval of MRP2 (Mottino et al.,
2003), whereas cAMP has been shown to cause insertion (Gerk and Vore, 2002).
This regulation occurs within min (Gerk and Vore, 2002). Bile flow, a process
involving MRP2-mediated efflux, was inhibited by 85% in 10 min by E217βG in rat
(Mottino et al., 2002). Short incubation periods are ideal to limit these effects,
however, the amount of tracer substrate required to attain intracellular radioactivity
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levels well above background for short incubation periods was cost prohibitive in
the HK-2 cell line. Additionally, probenecid (Bodo et al., 2003b) and ES (Sasaki et
al., 2002) have been shown to cause stimulation of MRP2-mediated transport.
Therefore, it became apparent that the BBM transporters must be considered
when interpreting the results of several experiments, with concern of insertion or
retrieval of transporters for studies with incubation periods of 5 min or longer.
Studies of PAH and AG, known substrates of MRP2, suggested possible
upregulation or stimulation of apical transporters resulting in a diminished
decrease or a net increase in transepithelial transport in the presence of
decreased net intracellular accumulation of substrate when coincubated with other
compounds. For example, PAH uptake was decreased 73% vs. 15% decreased
clearance (a diminished decrease) when coincubated with probenecid.

While

diffusion of PAH likely contributed to the diminished effect of probenecid on PAH
clearance, stimulation of the MRP2 transporter in the BBM by probenecid (Bodo et
al., 2003b) may have resulted in increased apical efflux since PAH is a known
substrate of MRP2 (Leier et al., 2000).
Similar results occurred with coincubation of AG and probenecid, showing
decreased net accumulation of tracer AG, but no significant effect on the BL-A
clearance. Since inhibition at the BLM would cause decreased clearance as well
as accumulation, these results may best be explained by stimulation of BBMmediated transport (such as MRP2) by probenecid resulting in greater efflux of AG
with resultant lower intracellular AG. Because the amount of AG effluxed into the
A compartment is on the order of 400 to 900 times that accumulated intracellularly,
significant decreases in accumulation due to BBM efflux may not cause significant
increases in clearance. Lack of decreased clearance of AG when coincubated
with probenecid is also in line with the finding by Duggin and Mudge (1975) that
probenecid does not inhibit the transport of AG. Even at a higher concentration of
AG (100 µM), probenecid had no significant effect on AG clearance.
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The opposite effect was seen for probenecid inhibition of ES transport, with a
greater decrease (44%) in clearance than in net accumulation (13%). This finding
is likely attributed to probenecid inhibition of both OAT3-mediated uptake at the
BLM and OAT4-mediated efflux at the BBM (Cha et al., 2000) resulting in a net
accumulation greater than would be expected with uninhibited apical efflux. ES is
not a substrate of MRP2 (Sasaki et al., 2002).
Assuming expression of the human renal BBM transporters in the HK-2 cell
line, the effects of probenecid at the BBM would be to inhibit efflux via MRP4 and
NPT1 but to stimulate efflux via MRP2. These differing effects may also contribute
to the results found for AG/probenecid coincubation.

Results suggest the

possibility of time-dependent and possibly concentration-dependent effects. At 15
min, 1 mM probenecid caused a decrease in intracellular accumulation of AG with
no significant effect on clearance of 4 µM AG. If probenecid had inhibited uptake
at the BLM, the clearance rate should also have been decreased.

Thus,

stimulation of AG efflux at the BBM best explains these results and is suggestive of
MRP2-mediated efflux. However, at 5 min, 1 mM probenecid tended to cause a
decrease in clearance of 100 µM AG. This discrepancy between these two

experiments can be attributed to regulatory mechanisms or simply to a greater
inhibitory than stimulatory effect at the higher concentration of AG resulting in
decreased clearance.

Two alternative explanations support regulation: 1.

upregulation of MRP2 by insertion into the BBM over the longer incubation period
and, therefore, greater efflux via MRP2 than inhibition of MRP4- or NPT1-mediated
transport; 2. downregulation in MRP2 affected by the high concentration of AG
resulting in primarily inhibitory effects of probenecid at MRP4 or NPT1.
The effects of DHEAS, a high affinity substrate of MRP4, on the transport of AG
also appear to be time- and/or concentration-dependent. At 5 min, 1 mM DHEAS
caused a 42% decrease in the clearance of 100 µM AG suggestive of inhibition of
OAT3-mediated uptake and/or MRP4-mediated efflux. DHEAS is not a substrate
of MRP2, but is a high affinity substrate for MRP4. Since no effect on uptake or
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clearance was seen at 2 min for 20 µM AG coincubated with 1 mM DHEAS, a
regulatory process is supported.

Upregulation of MRP4 or NPT1 by higher

concentrations of AG or DHEAS over the 5 min incubation period would explain
these results. Alternatively, downregulation of MRP2 by the higher concentration
of AG over the longer incubation period in conjunction with inhibition of MPR4 by
DHEAS would also affect decreased clearance of AG compared to control. Thus,
BBM transporter inhibition and regulation can explain the effects of DHEAS on the
transport of AG.
Yet another study supports AG concentration-dependent efflux pump downregulation. The biphasic concentration-dependent AG uptake study demonstrated
a sharp increase in net intracellular accumulation of AG at concentrations above
1 mM. Downregulation of MRP2 by retrieval from the membrane, as affected by
E217βG, was demonstrated by Mottino et al. (2002). Downregulation of MRP2 by
high concentrations of AG would explain the biphasic results of the concentrationdependent study in HK-2 cells and the findings of Duggin and Mudge (1975) that
AG is reabsorbed at high concentrations in the dog. Thus, 3 studies with HK-2
cells suggest that AG may downregulate MRP2.
The effects of ouabain on FL and AG transport are also best explained by
regulatory mechanisms.

Dickinson et al. (1979) demonstrated that ouabain

stimulates bile flow. Because MRP2 is the primary canalicular pump responsible
for efflux of bile acid conjugates, it is likely that ouabain stimulates MRP2-mediated
transport. In the HK-2 model, ouabain affected an increase in 15 min AG BL-A
clearance vs. no significant effect on A-BL clearance. For FL, coincubation with
ouabain caused inhibition of transport at 2 and 5 min, but the effect was lost after
15 min. Reversal of the acute effects of ouabain was seen for both the FL and AG
studies when monolayers were preincubated for 30 min with or without ouabain.
In the preincubation studies, subsequent coincubation of substrate with ouabain
vs. control caused no significant effect on AG clearance, but caused increased FL
clearance.

This 30 min preincubation period is adequate to allow regulatory
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effects by retrieval or insertion as described by Kubitz et al. (2001), who found that
retrieval and retargeting of MRP2 from the canalicular to the BLM in hepatocytes
in response to activation by PKC occurred within 30 min.
Project Appraisal
Evidence of BLM transporters responsible for the initial step of renal excretion
of numerous anions as shown by Western blot analysis and functional studies of
OAT1 and OAT3 suggest the HK-2 cell line has considerable potential for organic
anion transport studies.

Determination of the presence of known renal PTC

transporters would increase the usefulness of this cell line and eliminate much of
the confusion in interpreting transport study results.
It is possible that the findings attributed to regulation of the BBM transporters
could be overcome by selectively inhibiting those transporters. Because we chose
not to focus on the apical transporters, this was not attempted. The inhibitors of
MRP2 may also affect the BL transporters making this a futile exercise. Hence,
quantitative transport kinetics and inhibition studies for AG would best be
determined in single transporter transfectant models. Some of the transfectant
models also have endogenous transporters that make kinetic and substrate
specificity studies challenging. These studies use the nontransfectant mock cells
as control cells to distinguish between endogenous vs. transfectant (transporter
expressing) cells. There are no mock cells for the HK-2 cell model.
Overall transport of AG in the HK-2 model is consistent with the Duggin and
Mudge (1975) finding that AG is secreted at low plasma concentrations and
reabsorbed at higher concentrations in the dog. Consequently, the HK-2 model
may be more useful for simulation of in vivo effects, or end-results, rather than
kinetic analysis and substrate specificity studies.
The choice of AG as the model glucuronide-substrate for renal organic anion
transporters was made due to the limited glucuronides available. Ideally, an acyl143

glucuronide associated with renal toxicity would have been studied.

These

compounds, however, are highly labile and are difficult to synthesize. Synthesis
and concern of degradation would have severely limited the progress of the
project.

E217βG, available radiolabeled, would have been the only feasible

alternative. Since more information regarding transporter handling of E217βG is
available, this would seem to have been a favorable choice over AG. However,
many of the renal transporters are recognized for their ability to transport steroids
or steroid conjugates, thus, transporter affinity for E217βG due to the steroid
moiety is a possibility. Low solubility and high viscosity of E217βG also make it an
unfavorable substrate.

Another alternative to AG would have been MUG.

However, little data exist concerning the transport of this compound.
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Summary and Conclusion

HK-2 cells grown on Transwell-Clear inserts were studied to demonstrate both
the presence and the function of transporters. OAT1 and OAT3, but not OAT2
were found to be present in the membrane fractions of HK-2 cells by Western
blot analysis. Transport and self-inhibition of PAH and ES were demonstrated,
indicating function of OAT1 and OAT3. Inhibition experiments with ouabain and
probenecid confirmed OAT1 and/or OAT3 function. Transport of AG and FL
demonstrated polarization of the monolayer on the insert membranes and a
higher permeability of the BBM to both substrates.
Time-dependent studies with FL, as well as diffusion studies with FLD,
indicate that HK-2 monolayers are leaky. Therefore, transport studies were
designed to minimize the effects of diffusion by short incubation periods and
uptake rather than or in addition to transepithelial studies. Short incubation
periods were also favored to minimize upregulation of transporters.
Uptake experiments for AG indicated transporter-mediated uptake at the BLM
as evidenced by time-, concentration- and temperature-dependent uptake.
Kinetic analysis of the concentration-dependent uptake of AG yielded a Km of
330 µM, suggesting low-affinity transport. Studies that demonstrated lack of
inhibition of AG transport by coincubation with probenecid, ouabain, PAH and
DHEAS suggest that uptake of AG is primarily mediated by a transporter other
than OAT1 or OAT3. The OAT3 substrate E217βG demonstrated no significant
inhibitory effect on AG transport. Decreased net accumulation of AG by ES was
not high enough to indicate transport of AG primarily by OAT3. Together, these
findings indicate the possibility of an unidentified transporter at the BLM
responsible for uptake of AG or noncompetitive OAT3-mediated transport of AG
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in that a purely competitive process would have yielded much greater inhibition of
AG transport.
Upregulation or stimulation of BBM transporters, most likely MRP2, by
ouabain, and probenecid offered the best explanation for the findings in this
study. Increased clearance of AG was shown when AG was coincubated with
ouabain and increased PSa (BBM permeability) was demonstrated for
probenecid. Results also suggest possible downregulation of BBM transporters,
such as MRP2, by AG. These findings are consistent with literature reports of
MRP2 upregulation by ouabain, probenecid and ES and downregulation of MRP2
by E217βG. Because upregulation of MRP2 can cause a decrease in net
accumulation of substrate, it was determined that uptake experiments for AG are
best interpreted along with parallel clearance studies.
The biphasic concentration-dependent uptake of AG with an increased rate of
cellular accumulation at high concentrations of AG (> 1 mM) are consistent with
in vivo studies that found reabsorption at high AG concentrations. Lack of
inhibition of transport by probenecid also supports in vivo studies. Together with
the difficulties attributed to upregulation, these findings indicate that the HK-2
model may be more appropriate for the study of net effects for glucuronides
rather than kinetic analysis and transporter specificity.
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Future Directions

The current study was limited to exploration of the BLM transporters
responsible for the transport of the majority of organic anions. However,
numerous findings were best explained by the presence of BBM transporters.
Further characterization of the HK-2 model regarding the expression and function
of the BBM transporters MPR2, MPR4, NPT1, and URAT1 and the BLM
transporter SAT1 would be valuable. A literature search would be required to
determine the expected MW, substrates and inhibitors of the transporters as well
as availability of antibodies. Western blot analysis would determine expression
of the transporters. Utilizing the HK-2 model developed in the current study,
combined uptake and clearance studies of the prototypical substrates and
inhibitors for each transporter would be performed.
Additionally, further characterization of transport of the prototypical OAT1 and
OAT3 substrates PAH and ES would be performed to provide combined uptake
and clearance data in time-dependent and concentration-dependent studies. To
minimize modulatory effects as demonstrated in the current study, 2 min
incubation periods with minimum tracer concentrations would be used for the
concentration-dependent studies. The minimum concentration would be
determined by pretesting in uptake experiments to achieve radioactivity levels
well above background for a 2 min incubation. From these studies, kinetic
analysis of the HK-2 transport system for PAH and ES could be determined.
Transduction of the HK-2 cell line with metallothionein isoform 3 by Kim et al.
(2002) resulted in dome formation in the cell line and increased cell density.
Domes are associated with tight junctions and vectorial transport function in renal
cells. Use of these cells for the study of organic anion transport may yield
improved confluence, increased cell density of the monolayer, decreased
147

diffusion and vectorial transport of organic anions. Initial studies would be sideby-side comparison of FLD diffusion and PAH uptake and clearance. In the
event this cell line proves superior for transport studies, the proposed
characterization studies described above should be performed in this cell line.
Further work with AG would best be performed in single and double
transfectant systems. Use of oocytes or inside-out insect membrane vesicles are
the most common models used for such systems. A feasibility study should be
performed to determine if development of these models at the current facilities is
practical. Development of this technology would open the door to a screening
program for chemicals and toxins as substrates or inhibitors of the transduced
transporters and provide a valuable complement to the transport and toxicity
studies currently performed in the HK-2 cell model and renal tissue slices in the
toxicology lab.
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Appendix

Buffer Preparation
10 X Phosphate Buffered Saline (PBS) with 5 mM glucose, 500 ml
1.38 M sodium chloride ................................................................................. 40.32 g
26.82 mM potassium chloride ...........................................................................1.00 g
23.25 mM sodium phosphate, dibasic/anhydrous ............................................1.65 g
14.70 mM potassium phosphate, monobasic/anhydrous .................................1.00 g
5.00 mM magnesium chloride ...........................................................................1.02 g
50 mM glucose ..................................................................................................4.50 g
In approximately 460 ml of deionized distilled water, the ingredients were added
while stirring. The pH was adjusted to 7.4 with HCl and NaOH. The buffer was
brought to volume (500 ml) with deionized distilled water, sterile filtered and
refrigerated. Dilute 1:10 with deionized distilled H2O and adjust pH to 7.4.
Waymouth's Buffered Transport Media (WBTM), 1 liter
135 mM sodium chloride ............................................................................... 7.889 g
13 mM HEPES ............................................................................................... 3.384 g
2.5 mM calcium chloride dehydrate ............................................................... 0.368 g
1.2 mM magnesium chloride hexahydrate ..................................................... 0.244 g
0.8 mM magnesium sulfate ............................................................................ 0.194 g
5 mM potassium chloride .............................................................................. 0.373 g
5.78 mM glucose ............................................................................................ 1.042 g
In approximately 950 ml of deionized distilled water, the ingredients were added
while stirring. The pH was adjusted to 7.4 with HCl and NaOH. The buffer was
brought to volume (1000 ml) with deionized distilled water, sterile filtered and
refrigerated.
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Compounds for Toxicity Studies

AG (200 µM and 500 µM)
A 50 mM stock of AG was prepared by adding 0.5 ml deionized water to
8.732 mg AG. A 20 mM stock was prepared from the 50 mM stock by
adding 80 ml x 50 mM AG to 120 ml deionized water. Final concentration
incubation buffers were prepared by adding 20 µl x 20 mM stock to 2 ml
transport media (PBS, 5 mM glucose) for 200 µM AG and 20 µl x 50 mM
stock to 2 ml transport media for 500 µM AG. Control transport media was
prepared with 20 ml x deionized water to 2 ml transport media.
APAP (200 µM and 500 µM)
A 50 mM stock of APAP was prepared by adding 1.0 ml deionized water to
7.56 mg APAP. A 20 mM stock was prepared from the 50 mM stock by
adding 80 ml x 50 mM APAP to 120 ml deionized water.

Final

concentration incubation buffers were prepared by adding 20 µl x 20 mM
stock to 2 ml transport media (PBS, 5 mM glucose) for 200 µM APAP and
20 µl x 50 mM stock to 2 ml transport media for 500 µM APAP. Control
transport media was prepared with 20 ml x deionized water to 2 ml
transport media.
Diclofenac (200 µM and 500 µM)
A 50 mM stock of diclofenac was prepared by adding 0.5 ml deionized
water to 7.952 mg diclofenac.

A 20 mM stock was prepared from the

50 mM stock by adding 80 ml x 50 mM diclofenac to 120 ml deionized
water. Final concentration incubation buffers were prepared by adding 20
µl x 20 mM stock to 2 ml transport media (PBS, 5 mM glucose) for 200 µM

diclofenac and 20 µl x 50 mM stock to 2 ml transport media for 500 µM
diclofenac. Control transport media was prepared with 20 ml x deionized
water to 2 ml transport media.
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Solutions for Gel Preparation and Western Blot

†

Solutions were prepared by Dr. Kelley Kiningham

Cell Fractionization
Homogenization Buffer (25 ml)
20 mM HEPES .........................................................................5 ml x 100 mM
5 mM EGTA..............................................................................1.25 ml x 0.1M
10 mM 2-mercaptoethanol (2ME)*...........................................................20 ul
1 ug/1 ml pepstatin ........................................................... 25 ul of (1 mg/1 ml)
1 ug/1 ml leupeptin ........................................................... 20 ul of (1 mg/1 ml)
1 ug/1 ml aprotinin............................................................ 20 ul of (1 mg/1 ml)
1 mM phenylmethylsufonyl fluoride (PMSF) .............................500 ul x10mM
Diluted to 25 ml with deionized water
* 2ME was not included for nonreduced protein samples.
Gel Preparation
30% Acrylamide, 0.8% Bisacrylamide† (neurotoxic)
60 g acrylamide
1.6 g bisacrylamide
dilute to 200 ml with water
Use 37oC water bath to dissolve solids if necessary; sterile filter into foil
wrapped or brown bottle and store at 4oC.
5X Separation Buffer†
56.76 g TRIS
1.25 g sodium dodecyl sulfate (SDS)
pH to 8.8
Diluted to 250 ml with DI water
165

5X Stacking Buffer†
37.85 g TRIS
2.5 g SDS
pH to 6.8
Diluted to 500 ml with DI water
10% Ammonium Persulfate (APS) (prepared fresh daily)
0.1 g APS in 1 ml deionized water
2X Sample Buffer†
0.76 g TRIS (125 mM)
2 g SDS (13.9 mM or 4%)
10 ml Glycerol (20%)
5 ml 2-mercaptoethanol (2ME)* (10%)
pH to 6.8
Diluted to 50 ml with DI water
Bromophenol blue (1-2 mg) added until deep blue color obtained
Sample Buffer was prepared without 2-ME which was added just before use
(1:10). Note: If 2X sample buffer is prepared without 2ME, it can remain at
room temperature.
* 2ME was not included for nonreduced protein samples. DI water was
substituted for 2ME.
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Separation Gel

8 % Gel (ml) 12.5% Gel (ml)

5X Separation Buffer

7.0

7.0

30% Acrylamine, 0.8% Bis

9.3

14.6

H2O

18.5

13.2

10% Ammonium Persulfate*

0.15

0.15

TEMED

0.025

0.025

Total

35.0 ml

35.0 ml

N-butanol (~2 ml)
Stacking Gel

ml

5X Separation Buffer

3.0

30% Acrylamine, 0.8% Bis

1.5

H2O

10.5

10% Ammonium Persulfate*

0.075

TEMED

0.015

After rinsing n-butanol from the set separation gel with a large volume of
water then carefully drying the mold, Stacking Gel was prepared and
poured over the separation gel then left at room temperature for one hour to
set.
10X Electrode Buffer† (Dilute 1:10 prior to use)
30.3 g TRIS (250 mM)
144 g Glycine (1.92 M)
10 g SDS (34.68 mM)
pH to 8.3
Diluted to 1 L with deionized water
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Solutions Needed for Western Analysis
Transfer Buffer†
12.12 g TRIS
57.6 g glycine
800 ml methanol
3.2 L distilled water
Solution should be precooled for high voltage transfers.
Ponceau S†
g Ponceau S
5 ml acetic acid
diute to 100 ml with deionized water
Solution is stored in a brown bottle and may be reused.
10X TBS† (Dilute 1:10 prior to use)
12.12 g TRIS
87.66 g NaCl
pH to 8.0
Dilute to 1 L with deionized water
1X TBST
Add 500 µl Tween-20 to 1 L 1X TBS
Blocking solution (Blotto A)
5% non-fat dry milk in TBST (2.5 mg to 50 ml)
Prepared fresh daily and refrigerated.
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Stock Solutions for Transport Substrates/Inhibitors
Stock solutions were prepared according to the following formula:
Mass (g) = MW (g/mol) x desired molarity (mol/L) x 1L/1000 ml
Diluted to 1 ml with appropriate solution.
Transport media was prepared at 1:100 (26 µl stock to 2.6 ml WBTM). An equal
volume (26 µl) of WBTM was added to the control treatment.
AG (MW 349.3)
A 5mM stock was prepared from 1.746 mg AG solubilized in 1 ml deionized
distilled water. Dilutions were prepared from this stock. Typically a 1:100
dilution (30 µl in 3 ml transport media) was prepared.
DHEAS (100 mM) MW 390.5
3.905 mg DHEAS was dissolved in 0.1 ml 100% methanol (solubility,
50 mg/ml methanol) and vortexed for 1 min. This 100 mM stock was used
at 1:100 for final concentration of 1 mM or diluted 1:10 (100 µl to 1 ml) with
WBTM and used 1:100 for 100 µM final concentration. Final concentration
of methanol was 1% for 1 mM DHEAS or 0.1% for 10 µM DHEAS. An
equal amount of methanol was added to control and all other treatments run
simultaneously.
E217βG (21.254 mM) MW 470.5
25 mg E217βG was dissolved in 2.5 ml 0.1 M NaOH yielding a 21.254 mM
solution; 37.6 µl x 21.254 mM E217βG was added to a volume of 8 ml
WBTM for a final concentration of 0.1 mM.
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ES (10 mM) MW 372.4
3.729 mg ES was dissolved in 200 µl ethanol and brought to 1 ml with
distilled water. This 10 mM stock was used 1:100 for a final concentration
of 100 µM ES/ 0.2% ethanol. An equal amount of ethanol was added to
control and all other treatments run simultaneously. Due to light sensitivity,
containers were wrapped in foil and experiments were conducted in a dark
environment.
FL (400 µM) MW 376.3
Stock FL (400 µM) was prepared by bringing 1.51 mg of FL to a volume of
10 ml with distilled water. The stock was prepared in a dark environment
and stored in a foil wrapped microcentrifuge tube. This stock was used at
1:100 in transport medium for a final concentration of 4 µM FL.
FLD (10 mM) MW 4300
Stock FLD (10 mM) was prepared by the addition of 2.32 ml of distilled
water to a bottle of 100 mg FLD.

The stock was prepared in a dark

environment and stored in a foil wrapped microcentrifuge tube. This stock
was used at 1:100 in transport medium for a final concentration of 100 µM
FLD.
MUG (MW 352.3)
A 5mM stock was prepared from 1.76 mg MUG solubilized in 1 ml
deionized distilled water. Dilutions were prepared from this stock. Typically
a 1:100 dilution (30 µl in 3 ml transport media) was prepared.
Ouabain (100 mM) MW 728.8
Ouabain (72.8 mg) was dissolved in 1 ml of water and heated at 95oC for 15
min. The stock was prepared in a dark environment and stored in a foil
wrapped microcentrifuge tube. The stock was used at 1:100 or 1:1000.

170

PAH (100 mM) MW 194.2 g/mol
19.42 mg PAH was dissolved in 1 ml WBTM (solubility, 50 mg/ml water ),
heated at 95oC x 5 min and vortexed (according to Sigma technical
services, PAH is reported to decompose if dissolved in HCl or NaOH). The
100 mM PAH stock was used 1:100 for 1 mM PAH or diluted 1:10 to make
a 10 mM PAH stock and used 1:100 for 100 µM PAH final concentration.
Probenecid (100 mM) 285.4
290 µl x 1.0 M NaOH was added to 28.54 mg probenecid (solubility,
100 mg/ ml 1 M NaOH, Sigma Technical) and brought to 1 ml with distilled
water or WBTM. This 100 mM stock was used 1:100 or 1:1000 for a final
concentration of 1 mM or 100 µM.
Radiolabeled Working Solutions (WS) for Transport Studies
[14C]AG Working Solution (40 µCi/ml, 820 µM)
Activity: 48.8 µCi/µmol
Prepared from 1 uCi/ml Stock
1. Transfer 0.5 ml Stock to [14C]AG WS vial.
2. Rinse stock bottle x 3 with 0.25 ml distilled H2O.
3. Using hot pipette tip, transfer each rinse to AG WS vial.
4. Use 1:100 (26 µl per 2.6 ml media) Æ 0.4 µCi/ml, 8.2 µM
5. Or use 1:200 (13 µl per 2.6 ml media) Æ 0.2 µCi/ml, 4.1 µM
[3H]DHEAS Working Solution (20 µCi/ml, 253 nM)
Activity: 79.1 Ci/mmol
Prepared from 1.0 mCi/ml Stock (250 µCi [3H]DHEAS in 0.25 ml)
1. Add 2.45 ml distilled H2O to [3H]DHEA WS vial.
2. Add 0.05 ml STOCK solution to WS vial.
3. Pipette WS in and out to ensure all STOCK is rinsed into WS.
4. Use 1:100 (26 µl per 2.6 ml media) Æ 0.2 µCi/ml, 2.53 nM
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[3H]ES Working Solution (20 µCi/ml, 435 nM)
Activity: 46.0 µCi/nmol
Prepared from 1 mCi/ml Stock in a dimly lit room due to light sensitivity
1. Add 2.45 ml distilled H2O to [3H]ES WS foil wrapped vial.
2. Add 0.05 ml STOCK solution to WS vial.
3. Pipette WS in and out to ensure all STOCK is rinsed into WS.
4. Use 1:100 (26 µl per 2.6 ml media) Æ 0.2 µCi/ml, 4.35 nM
5. Or use 1:200 (13 µl per 2.6 ml media) Æ 0.1 µCi/ml, 2.17 nM
[14C]PAH Working Solution (40 µCi/ml, 760 µM)
Activity: 52.7 µCi/µmol
Prepared from 100 µCi/ml Stock (50 µCi [14C]PAH in 0.5 ml)
1. Transfer 0.5 ml Stock to [14C]PAH WS vial.
2. Rinse stock bottle x 3 with 0.25 ml distilled H2O.
3. Using hot pipette tip, transfer each rinse to PAH WS vial.
4. Use 1:100 (26 µl per 2.6 ml media) Æ 0.4 µCi/ml, 7.6 µM
5. Or use 1:200 (13 µl per 2.6 ml media) Æ 0.2 µCi/ml, 3.80 µM
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Solutions for Isolation of F344 renal proximal tubules

Perfusion Buffer A
pH
7.36
Chemical

Concentration
115.0 mM
5.0 mM

NaCl
KCl
NaHCO3

25.0 mM

NaH2PO4

2.0 mM

MgSO4●7H2O
Alanine
Glucose
Deferoxamine
Mannatol
Lactate
Dextran
Penicillin G

1.0 mM
1.0 mM
5.0 mM
0.1 mM
25.0 mM
4.0 mM
0.6 % (w/v)
100 units/ml

CaCl2

1.0 mM

bubble with 95% O2/ 5% CO2 for 30 min

Perfusion Buffer B
Chemical
Collagenase
SBTI

Concentration
130 units/ml
0.01 % (w/v)

diluted in 25 ml Perfusion buffer A
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Incubation Buffer A
pH 7.36
Chemical
NaCl
KCl

Concentration
115.0 mM
5.0 mM

NaHCO3

25.0 mM

NaH2PO4

2.0 mM

MgSO4●7H2O
Alanine
Glucose
Deferoxamine
Malic acid
Butyric acid
Lactate

1.0 mM
1.0 mM
5.0 mM
0.1 mM
5.0 mM
2.0 mM
5.0 mM

CaCl2
Penicillin G

1.0 mM
100 units/ml

bubble with 95% O2/ 5% CO2 for 30 min

Incubation Buffer B
Chemical
Concentration
Collagenase
150 units/ml
SBTI
0.02% (w/v)
BSA
0.2% (w/v)
Dnase
70 units/ml
diluted in 50 ml Incubation buffer A
Krebs-Henseleit Buffer Concentrate (KHB 10x)

NaCl
KCl

Concentration
118.0 mM
4.8 mM

NaHCO3

0.12 mM

MgSO4●7H2O
Hepes

25.0 mM
25.0 mM

bubble with 95% O2/ 5% CO2 for 30 min
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Krebs-Henseleit Buffer (1x)
pH 7.36
Chemical
KHB 10x
dH2O

Amount
20.0 ml
180.0 ml

bubble with 95% O2/ 5% CO2 for 30 min

45% Percoll Density Gradient
pH 7.36
Chemical
KHB 10x

Amount
6.0 ml

dH2O

27.0 ml
27.0 ml

Percoll
bubble with 95% O2/ 5% CO2 for 30 min

mixed in exact order
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